anti-pd-1 antibodies and treatment methods

专利摘要:
PD-1 antigen binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions are provided here. Methods of making PD-1 antigen binding proteins and methods of treating a subject are also provided.
公开号:BR112020014121A2
申请号:R112020014121-6
申请日:2019-01-11
公开日:2020-12-01
发明作者:Khaled M.K.Z. Ali；Neeraj Jagdish Agrawal；Gunasekaran Kannan；Ian Foltz；Zhulun Wang；Daren Bates；Marissa Mock；Shunsuke Takenaka
申请人:Amgen Inc.；
IPC主号:

专利说明:

[0001] [0001] This order claims priority for United States Interim Order No. 62 / 616,733 filed on January 12, 2018 and United States Interim Order No. 62 / 770,029 filed on November 20, 2018. The contents of each order are incorporated here by reference.
[0002] [0002] A reference list of computer readable nucleotide / amino acid sequences submitted simultaneously here and identified as follows: ASCII (Text) file of 1,429,100 bytes called “53810_Seqlisting.txt”; created on January 10, 2019. BACKGROUND
[0003] [0003] The PD-1 / PD-L1 axis is involved in the suppression of T cell immune responses in cancer. Antagonists of this route have been clinically validated over a number of solid tumor indications. Nivolumab and pembrolizumab are two such inhibitors that target the PD-1 pathway, and each has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. Recently, researchers have tested the paradigm of inhibiting checkpoints in the setting of other tumor types. Although some advances have been made, checkpoint inhibition therapy still remains in the shadows of other cancer treatment options.
[0004] [0004] Studies of checkpoint inhibitors in combination with other agents are ongoing or have recently been completed. The combination of nivolumab and ipilimumab, a CTLA-4 receptor blocking antibody, for example, was tested in a Phase III clinical trial in patients with unresectable stage III or IV melanoma. In this study, the percentage of patients achieving a complete response was the highest among those who received the combination of nivolumab and ipilimumab, beating the result displayed by those in the group receiving any of the drugs alone. Other combinations are also currently being explored.
[0005] [0005] Interleukin-21 (IL-21) is a pleiotropic cytokine derived from T cells that regulates the activity of both innate and adaptive immune cells. IL-21 is able to increase T cell survival and effector function. As it plays a key role in antitumor and antiviral responses, in addition to exerting great effects on inflammatory responses that lead to the development of autoimmune and inflammatory diseases, IL-21 has been an attractive target for several therapies.
[0006] [0006] However, the development of therapies based on IL-21 has been complex. The investigation has been complicated by studies showing that the intensification or, confusingly, the inhibition of the action of IL-21 leads to a therapeutic effect. There are additional challenges due to the wide expression of the IL-21 receptor (IL-21R). IL-21R is expressed not only in T cells, but also in B cells, NK cells and myeloid cells. Accordingly, care must be taken to limit the wide activation of IL-21 in leukocytes and to avoid the potential for toxicity. The restriction of IL-21 signaling must be balanced and selective. The triggering of IL-21 effects must be designed to occur at the right time and place.
[0007] [0007] In fact, any success, especially clinical success with IL-21 fractions as a monotherapy or in combination with control point inhibitors, has been muted. Thus there remains a need for treatment modalities using IL-21, including modalities combining fractions of IL-21 with control point inhibitors. There also remains a need for IL-21 therapies combined with inhibition of immune control points. SUMMARY
[0008] [0008] The present disclosure provides IL-21 muteins comprising the amino acid sequence of SEQ ID NO: 2, where SEQ ID NO: 2 is QGQDX HMXXM XXXXX XVDXL KNXVN DLVPE FLPAP EDVET NCEWS AFSCF
[0009] [0009] Thus, in one aspect, the present disclosure also provides IL-21 muteins comprising only an amino acid substitution, relative to the wild-type IL-21 amino acid sequence, which is provided herein as SEQ ID NO: 1 In exemplary aspects, the amino acid substitution is located at an amino acid position selected from the group consisting of: 5, 8, 9, 11, 12, 13, 14,
[0010] [0010] The present disclosure additionally provides IL-21 muteins comprising only two amino acid substitutions, in relation to SEQ ID NO: 1. In exemplary aspects, the amino acid substitutions are located in two amino acid positions selected from the group consisting of: 5, 9, 15, 70, 71, 72, 73 and 76, according to the numbering of amino acid positions of SEQ ID NO: 1.
[0011] [0011] In exemplary embodiments, IL-21 muteins bind to the IL-21 receptor (IL-21R) with reduced affinity, relative to the wild-type IL-21 affinity for the IL-21 receptor. In exemplary aspects, the IL-21 mutein binds to human IL-21R with a KD that is greater than or is about 0.04 nM. In exemplary aspects, the IL-21 mutein binds to monkey-cinomologist IL-21R with a KD that is greater than or is about 0.055 nM.
[0012] [0012] The present disclosure also provides conjugates comprising an IL-21 mutein of the present disclosure linked to a heterologous moiety. In exemplary aspects, the heterologous fraction is a polypeptide, such that the conjugate is a fusion protein. Therefore, the present disclosure provides fusion proteins comprising an IL-21 mutein of the present disclosure. In exemplary aspects, the fusion protein comprises an IL-21 mutein of the present disclosure linked to an antigen-binding protein, such as an antibody, or an antigen-binding antibody fragment thereof.
[0013] [0013] In particular embodiments, the fusion protein comprises an IL-21 mutein bound to a PD-1 antigen binding protein (e.g., a PD-1 antigen binding antibody) of the present disclosure.
[0014] [0014] The present disclosure also provides PD-1 antigen binding proteins and conjugates and fusion proteins comprising a PD-1 antigen binding protein.
[0015] The present disclosure further provides nucleic acids comprising a nucleotide sequence encoding an IL-21 mutein, a PD-1 antigen binding protein (e.g., a PD-1 antigen binding antibody) or a fusion protein comprising an IL-21 mutein and a PD-1 antigen binding protein (e.g., a PD-1 antigen binding antibody) of the present disclosure. In exemplary aspects, the nucleic acid molecule comprises a sequence of nucleotides encoding a conjugate or fusion protein of the present disclosure. Vectors comprising the nucleic acids of the present disclosure and host cells comprising the nucleic acids of the present disclosure are further provided herein.
[0016] [0016] The present disclosure further provides kits comprising an IL-21 mutein, a PD-1 antigen binding protein (e.g., a PD-1 antigen binding antibody), a conjugate, fusion protein ( e.g., a fusion protein comprising an IL-21 mutein and a PD-1 antigen binding protein (eg, a PD-1 antigen binding antibody)), nucleic acid, vector, or cell host of the present disclosure or a combination thereof.
[0017] [0017] Pharmaceutical compositions comprising an IL-21 mutein, a PD-1 antigen binding protein (e.g., a PD-1 antigen binding antibody), a conjugate, fusion protein (e.g. , a fusion protein comprising an IL-21 mutein and a PD-1 antigen binding protein (e.g., a PD-1 antigen binding antibody)), nucleic acid, vector, or host cell of the present disclosure , or a combination thereof, are provided here.
[0018] [0018] Methods of preparing an IL-21 mutein, PD-1 antigen binding protein (e.g., a PD-1 antigen binding antibody) and a fusion protein comprising an IL-21 mutein and a PD-1 antigen-binding protein (e.g., a PD-1 antigen-binding antibody) are provided here. The method, in exemplary embodiments, comprises culturing a host cell of the present disclosure to express the IL-21 mutein, a PD-1 antigen binding protein (e.g., a PD-1 antigen binding antibody) or a fusion protein comprising an IL-21 mutein and a PD-1 antigen binding protein (eg, a PD-1 antigen binding antibody) and collecting IL-21 mutein, a protein binding to PD-1 antigen (eg, a PD-1 antigen binding antibody) or fusion protein comprising an IL-21 mutein and a PD-1 antigen binding protein (eg, a PD-1 antigen) binding to the expressed PD-1 antigen).
[0019] [0019] Treatment methods are additionally provided by the present disclosure. The method, in exemplary embodiments, is a method of treating a subject with his need, comprising administering to the subject with his need for a pharmaceutical composition of the present disclosure in an amount effective to treat the subject. In exemplary aspects, the subject has a tumor (e.g., a solid tumor, a hematological malignancy or a lymphoid malignancy) and the pharmaceutical composition is administered to the subject in an amount effective to treat the tumor in the subject. In other exemplary aspects, the tumor is non-small cell lung cancer (NSCLC) (eg, Stage III or IV NSCLC), small cell lung cancer (SCLC), head and neck cancer, kidney cancer , breast cancer, melanoma, ovarian cancer, liver cancer, pancreatic cancer, colon cancer, prostate cancer, gastric cancer, bladder cancer, hepatocellular carcinoma, cancers with high microsatellite instability (ie, MSI-rich cancers) , lymphoma or leukemia. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] [0020] Figure 1A represents a graph of the tumor volume (mm3) of BALB / c mice implanted with CT26 / 3E5 colon carcinoma cells as a function of time (days). On Day 12, tumors were measured and mice were given an intraperitoneal (IP) injection of 300 µg isotype control antibody (mIgG1) on days 12, 15 and 18.
[0021] [0021] Figure 1B represents a graph of the tumor volume (mm3) of BALB / c mice implanted with CT26 / 3E5 colon carcinoma cells as a function of time (days). On Day 12, tumors were measured and mice were given an IP injection of 300 µg of an anti-PD-1 antibody on days 12, 15 and 18.
[0022] [0022] Figure 1C represents a graph of the tumor volume (mm3) of BALB / c mice implanted with CT26 / 3E5 colon carcinoma cells as a function of time (days). On Day 12, tumors were measured and mice were given 50 µg of recombinant murine IL-21 (rmIL-21) three times a week for 3 weeks. Dosing ended on Day 33.
[0023] [0023] Figure 1D represents a graph of the tumor volume (mm3) of BALB / c mice implanted with CT26 / 3E5 colon carcinoma cells as a function of time (days). On Day 12, tumors were measured and mice were given 300 µg of anti-PD-1 antibody on days 12, 15 and 18 and 50 µg of rmIL-21 three times a week for 3 weeks. Dosing ended on Day 33.
[0024] [0024] Figure 2 represents a graph of the percentage of survival of the four groups of BALB / c mice implanted with CT26 / 3E5 colon carcinoma cells. Group 1 mice were given an intraperitoneal (IP) injection of 300 µg isotype control antibody (mIgG1) on days 12, 15 and 18. Group 2 mice were given a 300 µg IP injection of an anti -PD-1 on days 12, 15 and 18. Mice in group 3 were given 50 µg of rmIL-21 three times a week for 3 weeks. Mice in group 4 were given 300 µg of anti-PD-1 antibody on days 12, 15 and 18 and 50 µg of rmIL-21 three times a week for 3 weeks. Administration of a combination of anti-PD-1 and rmIL-21 significantly prolongs survival compared to rmIL-21 or anti-PD-1 monotherapy.
[0025] [0025] Figure 3 is an illustration of a hypothesis of the mechanism of action of a fusion protein comprising an antibody against PD-1 blocker fused to an IL-21 mutein (αPD-1 mutein: IL-21). Without being limited by a particular theory, fusion is believed to bind to IL-21R in CD8 + T cells while simultaneously blocking signal transduction between PD-1 and PD-L1.
[0026] [0026] Figure 4A is an illustration of a fusion protein comprising an anti-PD-1 antibody fused to an IL-21 mutein homodimer. The fusion protein does not have a linker. The antibody may comprise constant regions that reduce or eliminate binding and effector functions associated with Fc (eg, they are unable to interact with Fcγ receptors (eg, SEFL2-2)).
[0027] [0027] Figure 4B is an illustration of a fusion protein comprising an anti-PD-1 antibody fused to an IL-21 mutein homodimer. The fusion protein can comprise a GGGGS (G4S) linker between the antibody heavy chain constant region and the IL-21 mutein. The antibody can also comprise modifications of SEFL2-2.
[0028] [0028] Figure 4C is an illustration of a fusion protein comprising an anti-PD-1 antibody fused to an IL-21 mutein monomer. The fusion protein may comprise a G4S linker between the antibody heavy chain constant region and the IL-21 mutein. Heavy chains of the antibody comprise mutations of charge pairs (cpm; e.g., V1, V4, V103 or V131) to assist in preferential association of heterodimer Fc regions. The antibody can also comprise modifications of SEFL2-2.
[0029] [0029] Figure 5A is a graph of STAT3 signaling in Hut78 PD-1-vas T cells exposed to (i) recombinant human IL-21 (rhIL-21) alone (solid line with closed circles), (ii) mAb anti-PD-1 alone (solid line with closed diamonds), (iii) anti-PD-1 mAb fused to an IL-21 homodimer without ligand (solid line with closed triangles), (iv) anti-PD-1 mAb fused to an IL-21 homodimer with ligand (dashed line with open triangles), (v) anti-PD-1 mAb fused to an IL-21 monomer without ligand (solid line with closed squares) or (vi) anti mAb -PD-1 fused to an IL-21 monomer with a linker (dashed line with open squares).
[0030] [0030] Figure 5B represents a graph of STAT3 signaling in Hut78 PD-1 + T cells exposed to (i) recombinant human IL-21 (rhIL-21) alone (solid line with closed circles), (ii) mAb anti-PD-1 alone (solid line with closed diamonds), (iii) anti-PD-1 mAb fused to an IL-21 homodimer without ligand (solid line with closed triangles), (iv) anti-PD-1 mAb fused to an IL-21 homodimer with a linker (dashed line with open triangles), (v) anti-PD-1 mAb fused to an IL-21 monomer without a linker (solid line with closed squares) or (vi) anti-PD-1 mAb fused to an IL-21 monomer with a linker (dashed line with open squares).
[0031] [0031] Figure 6 is a graph of serum concentrations of a homodimer fusion protein comprising IL-21 WT fused to an anti-PD-1 mAb that was intravenously administered to 6 animals at a low dose (250 µg / kg ) or a high dose (1000 µg / kg). An IgG antibody domain (150 µg / kg) was operated as a control.
[0032] [0032] Figure 7 represents a graph of the reduction of times in IL-21 activity (in relation to rhIL-21 activity) by Hut78 PD-1-vas cells (open bars) or Hut78 PD-1 + vas cells ( closed bars) exposed to IL-21 muteins with reduced affinity for IL-21Rα.
[0033] [0033] Figure 8 represents a graph of the reduction of times in IL-21 activity (in relation to rhIL-21 activity) by Hut78 PD-1-vas cells (open bars) or Hut78 PD-1 + vas cells ( closed bars) exposed to IL-21 muteins with reduced affinity for IL-21Rγ.
[0034] [0034] Figure 9A depicts a graph of STAT3 signaling on Hut78 PD-1-vas T cells exposed to (i) recombinant human IL-21 (rhIL-21) alone (solid line with closed circles), (ii) mAb anti-PD-1 fused to an IL-21 WT homodimer (dotted line with open circles), (iii) anti-PD-1 mAb fused to an IL-21 WT monomer (dotted line with closed circles) and (iv ) anti-PD-1 mAb fused to an IL-21 mutein homodimer 51 (R65P) (dotted line with closed triangles).
[0035] [0035] Figure 9B is a graph of STAT3 signaling in Hut78 PD-1 + T cells exposed to (i) recombinant human IL-21 (rhIL-21) alone (solid line with closed circles), (ii) mAb anti-PD-1 fused to an IL-21 WT homodimer (dotted line with open circles), (iii) anti-PD-1 mAb fused to an IL-21 WT monomer (dotted line with closed circles) and (iv ) anti-PD-1 mAb fused to an IL-21 mutein homodimer 51 (R65P) (dotted line with closed triangles).
[0036] [0036] Figure 10 is a graph of serum concentrations of a fusion protein comprising (i) an anti-PD-1 mAb fused to an IL-21 R76E mutein homodimer (dotted line with closed circles), (ii ) an anti-PD-1 mAb fused to an IL-21 R76A mutein homodimer (dashed line with closed triangles), (iii) an anti-PD-1 mAb fused to an IL-21 D15N mutein homodimer (line dashed with Xs), (iv) an anti-PD-1 antibody (8.25 mg / kg; dashed line with open diamonds) and (v) an anti-PD-1 mAb fused to an IL-21 mutein homodimer WT (solid line with closed squares).
[0037] [0037] Figure 11 represents a graph of IL-2 (pg / mL) secreted by cells from a mixed lymphocyte reaction as a function of the antibody concentration of (i) an anti-PD-1 antibody (solid line with closed circles) ), (ii) a fusion protein comprising IL-21 R5Q / R76E double mutein homodimer (dashed line with open circles), (iii) a combination of anti-PD-1 mAb and rhIL-21 (dotted line with squares (iv) a fusion protein comprising IL-21 R76E mutein homodimer (closed squares), (v) IgG control (dotted line with open diamonds) and (vi) a rhIL-21 (broken line with open triangles).
[0038] [0038] Figure 12A is a graph of the change in times of the mean fluorescence intensity (MFI) of the STAT3 activity of cells exposed to (i) a fusion protein comprising an IL-21 R5E / R76A double mutein ( line with open triangles), (ii) an IgG1 control (dotted line with closed diamonds), (iii) rhIL-21 (dashed line with open squares), (iv) an anti-PD-1 mAb (solid line with ovals (v) a combination of rhIL-21 and anti-PD-1 mAb (dashed line with closed ovals) or (vi) a fusion protein comprising a simple IL-21 R76E mutein (line with open diamonds).
[0039] [0039] Figure 12B represents a graph of the change in times of MFI of STAT3 activity of cells exposed to (i) a fusion protein comprising an IL-21 R5Q / R76E double mutein (line with open triangles), (ii) an IgG1 control (dotted line with closed diamonds), (iii) rhIL-21 (dashed line with open squares), (iv) an anti-PD-1 mAb (solid line with open ovals), (v) a combination of rhIL-21 and anti-PD-1 mAb (dashed line with closed ovals) or (vi) a fusion protein comprising a single IL-21 R76E mutein (line with open diamonds).
[0040] [0040] Figure 12C is a graph of the change in times of MFI of STAT3 activity of cells exposed to (i) a fusion protein comprising an IL-21 R9E / R76A double mutein (line with open triangles), (ii) an IgG1 control (dotted line with closed diamonds), (iii) rhIL-21 (dashed line with open squares), (iv) an anti-PD-1 mAb (solid line with open ovals), (v) a combination of rhIL-21 and anti-PD-1 mAb (dashed line with closed ovals) or (vi) a fusion protein comprising a single IL-21 R76E mutein (line with open diamonds).
[0041] [0041] Figure 13A represents a graph of% specific lysis by CTLs (y-axis) vs. ratios between effector cells and target (x-axis) exposed to (i) rhIL-21 (solid line with closed circles), (ii) hIgG4 control antibody (dashed line with open circles), (iii) anti-PD- mAb 1 (dashed line with closed triangles), (iv) a combination of rhIL-21 and anti-PD-1 mAb (dotted line with open triangles) or (v) a fusion protein comprising IL-21 R5E / R76A (line broken with Xs).
[0042] [0042] Figure 13B is a graph of% specific lysis by CTLs exposed to (i) rhIL-21 (solid line with closed circles), (ii) hIgG4 control antibody (dashed line with open circles), (iii) anti-PD-1 mAb (dashed line with closed triangles), (iv) a combination of rhIL-21 and anti-PD-1 mAb (dotted line with open triangles) or (v) a fusion protein comprising R5Q / R76E of IL-21 (broken line with Xs).
[0043] [0043] Figure 13C is a graph of% specific lysis by CTLs exposed to (i) rhIL-21 (solid line with closed circles), (ii) hIgG4 control antibody (dashed line with open circles), (iii) anti-PD-1 mAb (dotted line with closed triangles), (iv) a combination of rhIL-21 and anti-PD-1 mAb (dotted line with open triangles) or (v) a fusion protein comprising R9E / R76A of IL-21 (broken line with Xs).
[0044] [0044] Figure 14 represents serum concentrations of (i) anti-PD-1 mAb (solid line with closed squares), (ii) a fusion protein comprising anti-PD-1 mAb and an R5Q / R76E homodimer of IL -21 (solid line with circles), (iii) a fusion protein comprising anti-PD-1 mAb and an IL-21 R76E homodimer (solid line), (iv) a fusion protein comprising anti-PD-1 mAb and an IL-21 R5E / R76A homodimer (dashed line with Xs), (v) a fusion protein comprising anti-PD-1 mAb and an IL-21 R76A homodimer (dashed line with closed diamonds) or (vi) a fusion protein comprising anti-PD-1 mAb and an IL-21 R76E monomer (solid line with closed triangles).
[0045] [0045] Figure 15A represents a timeline of cell sampling (open arrows) and administrations (closed arrows).
[0046] [0046] Figure 15B is a graph of the change in times in PD-1 + / CD4 + cells (relative to Day -5) as measured on Day 7 in animals given a dose of (i) a fusion protein comprising anti-PD-1 mAb and an IL-21 R76E mutein (bar with horizontal lines), (ii) a fusion protein comprising anti-PD-1 mAb and an IL-21 R76E simple mutein monomer (bar with vertical lines) or (iii) a fusion protein comprising anti-PD-1 mAb and an IL-21 R5Q / R76E double mutein homodimer (open bar) (each administered on Day 0).
[0047] [0047] Figure 15C represents a graph of the change in times in PD-1 + / CD8 + cells (relative to Day -5) as measured on Day 7 in animals given a dose of (i) a fusion protein comprising anti-PD-1 mAb and an IL-21 R76E mutein (bar with horizontal lines), (ii) a fusion protein comprising anti-PD-1 mAb and an IL-21 R76E simple mutein monomer (bar with vertical lines) or (iii) a fusion protein comprising anti-PD-1 mAb and an IL-21 R5Q / R76E double mutein homodimer (open bar) (each administered on Day 0).
[0048] [0048] Figure 15D is a graph of the change in times in PD-1 + / CD8 + cells (relative to Day -5) as measured on Day 21 in animals given a first dose of (i) a protein of fusion comprising anti-PD-1 mAb and an IL-21 R76E mutein (bar with horizontal lines), (ii) a fusion protein comprising anti-PD-1 mAb and an IL-21 R76E simple mutein monomer (bar with vertical lines) or (iii) a fusion protein comprising anti-PD-1 mAb and an IL-21 R5Q / R76E double mutein homodimer (open bar) (first dose administered on Day 0 and second dose administered on Day 8 ).
[0049] [0049] Figure 16 represents a graph of the expansion of PD-1 + / CD8 + cells (in relation to Day -5) as a function of the occupancy of the PD-1 receptor (RO) in PD-1 + / CD8 + cells. The single mutants of IL-21 (801, 802, 807 and 808) are shown inside the small circle and the double mutants of IL-21 (803, 804, 805 and
[0050] [0050] Figure 17 represents graphical representations of the flow of individual animals treated with single mutant homodimer constructs (animals 801 and 802), double mutant homodimer constructs (animals 803 - 806) or monomeric single mutant constructs (animals 807 and 808 ). PD-1 + T cells were detected by non-competing or competing detection antibody. The percentage of target coverage is calculated as a percentage of the ratio between antibody against competing and non-competing PD-1. The data show that all constructs demonstrate robust target coverage after repeated dosing on Day 21.
[0051] [0051] Figure 18A is a graph of the change in times (relative to rhIL-21 (solid line with circled Xs)) of the STAT3 activity of Hut78 PD-1-vas T cells exposed to a fusion protein comprising one of ten different anti-PD-1 mAbs and an IL-21 R5Q / R76E mutein homodimer. The ten anti-PD-1 test mAbs included 20A2.003 (line with diamonds), 20C1.006 (line with open squares), 20C1.009 (line with triangles) and 22D4.006 (line with open circles).
[0052] [0052] Figure 18B is a graph of the change in times (relative to rhIL-21 (solid line with circled Xs)) of the STAT3 activity of Hut78 PD-1 + T cells exposed to a fusion protein comprising one of ten different anti-PD-1 mAbs and an IL-21 R5Q / R76E mutein homodimer. The ten anti-PD-1 test mAbs included 20A2.003 (line with diamonds), 20C1.006 (line with open squares), 20C1.009 (line with triangles) and 22D4.006 (line with open circles). The comparison of Figure 18A with Figure 18B indicates that the PD-1 targeting required for pSTAT3 signaling and that the mutein activity is similar when fused to different anti-PD-1 mAbs.
[0053] [0053] Figure 19A is a graph of the change in times (relative to rhIL-21 (solid line with circled Xs)) of the STAT3 activity of Hut78 PD-1-vas T cells exposed to a fusion protein comprising one of seven different anti-PD-1 mAbs and one R9E / R76A mutein homodimer of IL-21. The seven anti-PD-1 test mAbs included 20A2.003 (line with open triangles), 20C1.006 (line with open squares), 20C1.009 (line with open diamonds) and 22D4.006 (line with open circles) .
[0054] [0054] Figure 19B represents a graph of the change in times (relative to rhIL-21 (solid line with circled Xs)) of the STAT3 activity of Hut78 PD-1 + T cells exposed to a fusion protein comprising one of seven different anti-PD-1 mAbs and one R9E / R76A mutein homodimer of IL-21. The comparison of Figure 19A with Figure 19B indicates that the PD-1 targeting required for pSTAT3 signaling and that the mutein activity is similar when fused to different anti-PD-1 mAbs. The seven anti-PD-1 test mAbs included 20A2.003 (line with open triangles), 20C1.006
[0055] [0055] Figures 20A-20D represent the amount of pSTAT3 signaling observed with various IL-21 monomeric or dimeric mutein anti-PD-1 mAb fusions. The solid line with closed circles (top of the graphs) is rhIL-21; the dashed line with open circles (bottom of the graphs) is IgG1 control; the line with Xs (bottom of the graphs) is IgG2 control; the dotted line with closed squares (bottom of the graphs) is the anti-PD-1 mAb 22D4.006 (present as mAb; i.e., not as a fusion) used in IL-21 mutein fusions; the dotted line with open squares and the dotted line with open diamonds (bottom of the graphs) are anti-PD-1 control mAbs; the remaining lines are anti-PD-1 mAb fusions (22D4.006) - IL-21 monomeric or dimeric double mutein (with several charge pair mutations) in which the double mutants are R5E / R76A; R9E / R76A; R5A / R76E or R5Q / R76E. rhIL-21 demonstrates activity in both PD-1-vas and PD-1 + vas cells, monomeric and homodimeric double mutein fusions are unable to demonstrate pSTAT3 activity (based on IL-21) in PD-1-vas cells , and monomeric and homodimeric double mutein fusions are able to demonstrate pSTAT3 activity (based on IL-21) in PD-1 + vas cells. Thus, monomeric fusions with double IL-21 mutants exhibit similar levels of attenuation of IL-21 activity in PD-1-vas cells and rescue of IL-21 activity in PD-1 + vas cells than their dimeric fusions In contrast. Figures 20A and 20B are duplicate operations of the pSTAT3 assay on PD-1-vas cells. The figures
[0056] [0056] Figures 21A-21D represent the results of a PD-1 reporter gene assay (RGA; Figures 21A and 21B) and MLR assay (Figures 21C and 21D) with the same anti-PD-1 mAb fusions ( 22D4.006) - IL-21 monomeric or dimeric double mutein evaluated in Figures 20A-20D. Figures 21A-21D demonstrate that the anti-PD-1 mAb (22D4.006) - double monomeric and dimeric mutein fusions of IL-21 are capable of inducing PD-1 activity. The solid line with closed circles (bottom of the graphs) is rhIL-21; the line with open circles (bottom of the graphs) is IgG1 control; the line with Xs (bottom of the graphs) is IgG2 control; the dashed line with closed squares (top of the graphs) is the anti-PD-1 mAb 22D4.006 (present as mAb; i.e., not as a fusion) used in IL-21 mutein fusions; the dashed line with open squares and the dotted line with open diamonds (top of the graphs) are anti-PD-1 control mAbs; the remaining lines are anti-PD-1 mAb fusions - IL-21 monomeric or dimeric double mutein. Figures 21A and 21B are duplicate operations of the PD-1 RGA assay. Figures 20C and 20D are duplicate operations of the MLR assay.
[0057] [0057] Figures 22A-22D represent the results of pSTAT3 assays testing the same constructs as those in Figures 20A-20D, except that a different anti-PD-1 mAb (20A2.003) is used in anti-PD mAb fusions -1 - IL-21 monomeric and dimeric double mutein. The results in Figures 22A-22D are similar to those seen in Figures 20A-20D. The solid line with closed circles (top of the graphs) is rhIL-21; the dashed line with open circles (bottom of the graphs) is IgG1 control; the line with Xs (bottom of the graphs) is IgG2 control; the dotted line with closed squares (bottom of the graphs) is the anti-PD-1 mAb 20A2.003 (present as mAb; i.e., not as a fusion) used in IL-21 mutein fusions; the dotted line with open squares and the dotted line with open diamonds (bottom of the graphs) are anti-PD-1 control mAbs; the remaining lines are anti-PD-1 mAb fusions (20A2.003) - IL-21 monomeric or dimeric double mutein (with multiple charge pair mutations) in which the double mutants are R5E / R76A; R9E / R76A; R5A / R76E or R5Q / R76E. Figures 22A and 22B are duplicate operations of the pSTAT3 assay on PD-1-vas cells. Figures 22C and 22D are duplicate operations of the pSTAT3 assay on PD-1 + vas cells.
[0058] [0058] Figures 23A-23D represent the results of PD-1 reporter gene assays (Figures 23A and 23B) and MLR assays (Figures 23C and 23D) testing the same constructs as those in Figures 21A-21D, except that a different anti-PD-1 mAb (20A2.003) is used in IL-21 monomeric and dimeric mutein anti-PD-1 mAb fusions. The results in Figures 23A-23D are similar to those seen in Figures 21A-21D. The solid line with closed circles (bottom of the graphs) is rhIL-21; the dashed line with open circles (bottom of the graphs) is IgG1 control; the line with Xs (bottom of the graphs) is IgG2 control; the dotted line (top of the graphs) is the anti-PD-1 mAb 20A2.003 (present as mAb; i.e., not as a fusion) used in IL-21 mutein fusions; the dashed line with open squares and the dotted line with open diamonds (top of the graphs) are anti-PD-1 control mAbs; the remaining lines are anti-PD-1 mAb (20A2.003) fusions - IL-21 monomeric or dimeric double mutein. Figures 23A and 23B are duplicate operations of the PD-1 RGA assay. Figures 23C and 23D are duplicate operations of the MLR assay.
[0059] [0059] Figure 24 represents a graph of the NFAT / luciferase activity of anti-PD-1 antibodies purified as a function of the mAb concentration.
[0060] [0060] Figure 25A is a graph of the change of times in the number of Ki67 + / CD3 + / CD4 + cells in relation to the baseline after exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer) or to anti-PD-1 antibody [22D4.017].
[0061] [0061] Figure 25B is a graph of the change of times in the number of Ki67 + / CD3 + / CD8 + cells in relation to the baseline after exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer) or to anti-PD-1 antibody [22D4.017].
[0062] [0062] Figure 25C is a graph of the change in times in the number of pSTAT3 + / CD3 + / CD4 + cells relative to the baseline after exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer) or to anti-PD-1 antibody [22D4.017].
[0063] [0063] Figure 25D is a graph of the change in times in the number of pSTAT3 + / CD3 + / CD8 + cells relative to the baseline after exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer) or to anti-PD-1 antibody [22D4.017].
[0064] [0064] Figure 25E is a graph of the change in times in the number of CD3 + / CD4 + cells in relation to the baseline after exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer) or anti antibody -PD-1 [22D4.017].
[0065] [0065] Figure 25F is a graph of the change in times in the number of CD3 + / CD8 + cells in relation to the baseline after exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer) or anti antibody -PD-1 [22D4.017].
[0066] [0066] Figure 25G is a graph of the change in times in the number of PD-1 + / CD3 + / CD4 + cells in relation to the baseline after exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer ) or anti-PD-1 antibody [22D4.017].
[0067] [0067] Figure 25H is a graph of the change of times in the number of PD-1 + / CD3 + / C84 + cells in relation to the baseline after exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer ) or anti-PD-1 antibody [22D4.017].
[0068] [0068] Figure 25I is a graph of the times change in the amount of perforin in the serum in relation to the baseline after 72 hours of exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer) or to anti-PD-1 antibody [22D4.017].
[0069] [0069] Figure 25J is a graph of the% of Ki67 + cells in relation to the baseline as a function of the increase in times in perforin after 72 hours of exposure to the fusion protein [22D4.017] - [R9E: R76A] (monomer ) or anti-PD-1 antibody [22D4.017].
[0070] [0070] Figure 26A is a graph of the absorbance (nm) as a function of time (sec) used to determine the indicated KD of the 22D4.017 antibody by the human PD-1 antigen.
[0071] [0071] Figure 26B is a graph of the absorbance (nm) as a function of time (sec) used to determine the indicated KD of antibody 20C1.009 by the human PD-1 antigen.
[0072] [0072] Figure 26C is a graph of absorbance (nm) as a function of time (sec) used to determine the indicated KD of antibody 20A2.003 by the human PD-1 antigen.
[0073] [0073] Figure 26D is a graph of the absorbance (nm) as a function of time (sec) used to determine the indicated KD of an anti-PD-1 IgG1 mAb, by the human PD-1 antigen.
[0074] [0074] Figure 26E is a graph of absorbance (nm) as a function of time (sec) used to determine the indicated KD of a mAb against PD-1 IgG4 by the human PD-1 antigen.
[0075] [0075] Figure 26F is a graph of the absorbance (nm) as a function of the time (sec) used to determine the indicated KD of 22D4.017 by the cino PD-1 antigen.
[0076] [0076] Figure 26G is a graph of the absorbance (nm) as a function of the time (sec) used to determine the indicated KD of the 20C1.009 antibody by the cino PD-1 antigen.
[0077] [0077] Figure 26H is a graph of the absorbance (nm) as a function of time (sec) used to determine the indicated KD of antibody 20A2.003 by the PD-1 antigen of cino.
[0078] [0078] Figure 26I is a graph of the absorbance (nm) as a function of the time (sec) used to determine the indicated KD of an anti-PD-1 IgG1 mAb by the cyan PD-1 antigen.
[0079] [0079] Figure 26J is a graph of the absorbance (nm) as a function of the time (sec) used to determine the indicated KD of an anti-PD-1 IgG4 mAb by the cyan PD-1 antigen.
[0080] [0080] Figure 27 is a graph of Cp (kcal / mol / ºC) as a function of temperature for anti-PD-1 antibodies 22D4.017 and 20C1.009.
[0081] [0081] Figure 28 is a graph of viscosity plotted against the shear rate for anti-PD-1 antibodies 22D4.017 and 20C1.009.
[0082] [0082] Figures 29A-29D are a series of graphs graphically depicting the signal as a function of antibody concentration in (Fig. 29A) a variant Hut78 T cell line that is positive for PD-1, (Fig. 29B) a variant Hut78 T cell line that is positive for TIGIT (Fig. 29C) a variant Hut78 T cell line that is positive for LAG3 and (Fig. 29D) the variant Hut78 T cell line that does not endogenously express PD- 1, TIGIT or LAG3.
[0083] [0083] Figure 30A is an illustration summarizing the experimental design of the study. Figure 30B is a graph of in vivo activity as measured by tumor volume (mm3) versus time (days). P values were calculated with one-way Anova with Turkey's post-hoc test and were as follows; Day 21: P = 0.0023 (anti-PD-1 mAb vs. anti-PD-1 mAb x R9E monomer: R76A) and P = 0.0056 (Isotype vs. anti-PD-1 mAb x R9E monomer: R76A ); Day 24: P = 0.0001 (anti-PD-1 mAb vs. anti-PD-1 mAb x R9E monomer: R76A) and P = 0.0001 (Isotype vs. anti-PD-1 mAb x R9E monomer: R76A ); Day 28: P = 0.0001 (anti-PD-1 mAb vs. anti-PD-1 mAb x R9E monomer: R76A) and P = 0.0012 (Isotype vs. anti-PD-1 mAb x R9E monomer: R76A ); Day 32: P = 0.0001 (anti-PD-1 mAb vs. anti-PD-1 mAb x R9E monomer: R76A) and P = 0.0001
[0084] [0084] Figures 30D and 30E represent a summary of tumor volume at randomization (day 17) and pre-treatment (Figure 30D) and at day 32 (Figure 30E). P values were calculated using one-way ANOVA with a Turkey post-hoc test. P = 0.0001 (anti-PD-1 mAb vs. anti-PD-1 mAb x R9E monomer: R76A) and P = 0.0001 (Isotype vs. anti-PD-1 mAb x R9E monomer: R76A).
[0085] [0085] Figure 30F is a graph of the survival of mice carrying tumors. The P-values of the log-rank test (Mantel-Cox) were as follows; P = 0.0037 (Isotype vs. anti-PD-1 mAb x R9E monomer: R76A), P = 0.0001 (anti-PD-1 mAb vs. anti-PD-1 mAb x R9E monomer: R76A) .
[0086] [0086] Figure 31 is a graph showing that the combination of single chain antibody constructs and an anti-PD-1 antibody results in significant inhibition of tumor growth versus any of the single agents.
[0087] [0087] Figure 32 is a graph showing that the combination of single chain antibody constructs and an anti-PD-1 antibody results in improved survival versus any of the single agents.
[0088] [0088] Figures 33-41 show the results of the TDCC assay described in Example 20. Shortly, different target cells overexpressing PD-L1 and human T cells (effector cells) were incubated with an anti-single chain antibody construct -CD3 x anti-TAA (tumor associated antigen) bispecific alone or with the bispecific antibody construct in combination with the anti-PD-1 antibody 20C1.009.
[0089] [0089] There remains a need for new immune enhancing approaches that can employ the immune system against cancer cells in a safe and effective manner, especially in light of the fact that current immunotherapy approaches are effective only in a minority of patients and may have significant and often unpredictable toxicities. In one aspect, the new class of bifunctional fusion molecules comprising an antibody targeting PD-1 that can block the PD-1 / PD-L1 interaction, fused to an interleukin-21 mutein with manipulated attenuated affinity, disclosed here addresses this need . The antibody / cytokine fusions described here overcome significant barriers associated with cytokine therapies, allowing, inter alia, antibody-like dosing and selective distribution of the IL-21 cytokine in a manner targeted by PD-1. When fused to an anti-PD-1 antibody, IL-21 muteins are able to selectively activate and expand T cells expressing PD-1 in vivo. Accordingly, the antibody / cytokine fusions described here can improve and prolong the usefulness of anti-PD-1 therapies currently being tested in the clinic.
[0090] [0090] The combination of cytokine and co-inhibitor receptor agonists or antagonists remains challenging due to the risks of incremental toxicity and the need for complex assay design (see, e.g., Ott et al., J Immunother Cancer 5, 16 ( 2017); and Hermel et al., Cancer Metastasis Rev 36, 43-50 (2017)). With regard to cytokines, there is also the potential for the activation of inhibitory feedback pathways that can lead to immune suppression (see, eg, Portielje et al., Clin Cancer Res 9, 76-83 (2003); Wan et al., Immunity 38, 514-527 (2013); and Mooradian et al., Oncoimmunology 7, e1423172 (2018)). Interleukin-21 (IL-21) is a type I cytokine and a member of the gamma chain (cg chain) family of common cytokine receptors that has emerged as a promising immune therapy for the treatment of cancer.
[0091] [0091] A challenging aspect of cytokine immunotherapy is that, in addition to activating immune cells to boost immune responses, the same cytokine can also activate counter-regulating pathways. For example, IL-2 and IFNγ which can activate protective immune responses as well as responses of regulatory T cells and inhibitory pathways (such as PD-L1), respectively. In dendritic cells (DCs), IL-21 can inhibit both DC maturation and activation, can induce the apoptosis of conventional DCs, can potently inhibit T cell initiation in mixed cultures and can play a role in inducing tolerance . In humans, IL-21 has been tested as a non-targeted free cytokine in several cancer indications but, despite promising pre-clinical data and early phase I clinical data, the development of this approach has not progressed beyond the phase II test. (see, e.g., Thompson et al., J Clin Oncol 26, 2034-2039 (2008); and Davis et al., Clin Cancer Res 15, 2123-2129 (2009)). In more recent preclinical models, the combination of recombinant IL-21 cytokine with co-inhibitor receptor antagonists (eg, anti-CTLA-4 and anti-PD-1) has shown that IL-21 is able to prolong the effectiveness of these treatments. Such combinations are now being tested in the clinic, although clinical efficacy has not yet been demonstrated (Lewis et al., Oncoimmunology 7, e1377873 (2017)).
[0092] [0092] Without being limited by theory, the antibody / cytokine fusions described here are designed to utilize the immune enhancing activity of IL-21 (which may be a prerequisite to deal with toxicity and immune suppression outside the target), to maximize effectiveness and improve dosage viability in the clinic. IL-21 and IL-21 muteins
[0093] [0093] Interleukin-21 (IL-21) is a cytokine expressed by T cells, B cells, NK cells and myeloid cells and regulates the activity of both innate and adaptive immune cells and improves T cell survival and effector function. Several Phase I and II clinical trials include IL-21 as the experimental product for the treatment of cancers, inflammatory diseases and autoimmune diseases, including melanoma, renal cell carcinoma, acute myeloid leukemia, non-Hodgkin's lymphoma, ovarian cancer, cancer colorectal cancer, systemic lupus erythematosus, Crohn's disease and rheumatoid arthritis.
[0094] [0094] IL-21 has a four-helix package structure and exists as a monomer. Two isoforms of IL-21 are known in humans, each of which is derived from a precursor molecule. The first isoform of IL-21 comprises 162 amino acids (aa), the first 29 of which constitute the signal peptide; and the second isoform of IL-21 comprises 153 aa, the first 29 of which constitute the signal peptide as in the first isoform. The amino acid sequences of the first and second IL-21 isoforms (including the signal peptide) are provided herein as SEQ ID NO: 258 and SEQ ID NO: 259, respectively.
[0095] [0095] IL-21 binds to the heterodimeric IL-21 (IL-21R) receptor expressed on the surface of T, B and NK cells. IL-21R is similar in structure to both the IL-2 receptor and the IL-15 receptor, in that each of these cytokine receptors comprises a common gamma (γc) chain. In addition to γc, IL-21R comprises an alpha chain that is important for binding to IL-21. There are two isoforms of the human IL-21 receptor alpha chain: isoform 1 and isoform 2. The amino acid sequences of isoform 1 and isoform 2 are provided here as SEQ ID NOs: 256 and 261, respectively. The amino acid sequence of the human common gamma chain is provided here as SEQ ID NO: 257.
[0096] [0096] When IL-21 binds to IL-21R, the Jak / STAT signaling pathway is activated to activate target genes. Although IL-21-induced signaling may be therapeutically desirable, careful consideration of the timing and location of signaling is necessary, given the broad expression profile of IL-21 and due to the fact that IL-21 has the ability to potentiate CD8 T cell responses as well as suppressing antigen presentation and T cell initiation. The data presented here support for the first time the use of IL-21 muteins carefully designed to achieve IL-21 signaling at the appropriate time and place .
[0097] [0097] The present disclosure provides IL-21 muteins comprising at least one amino acid substitution with respect to the wild-type IL-21 amino acid sequence, which is provided herein as SEQ ID NO: 1. For example, mutein IL-21 comprises at least one and no more than
[0098] [0098] In exemplary aspects, IL-21 mutein comprises the amino acid sequence of SEQ ID NO: 2, where SEQ ID NO: 2 is QGQDX HMXXM XXXXX XVDXL KNXVN DLVPE FLPAP EDVET NCEWS AFSCF QKAQL KSANT GNNEX XIXXX XXXLX XXXXX TNAGR RQKHR LTCPS CDSYE
[0099] [0099] Thus, in exemplary aspects, the IL-21 mutein comprises the sequence of SEQ ID NO: 2, in which SEQ ID NO: 2 differs from SEQ ID NO: 1 in at least one amino acid in a position designated by X in SEQ ID NO: 2. In exemplary aspects, the IL-21 mutein comprising SEQ ID NO: 2 is at least about 30%, at least about 40%, at least about 50%, at least about 60 %, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or has more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 1. In exemplary aspects, IL-21 mutein comprises an amino acid sequence that is less than about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70% at least about 80%, at least about 85%, at least about 90% or more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97 %, about 98% or about 99%) of sequence identity with SEQ ID NO: 1.
[00100] [00100] In exemplary embodiments, the IL-21 mutein comprises an amino acid sequence comprising at least one amino acid substitution with respect to the wild-type IL-21 amino acid sequence, and the amino acid substitution (s) occurs (m) within the N-terminal half of the amino acid sequence. For example, the substitution (s) occurs in a position within positions 5-25 or 8-23 (both inclusive), according to the amino acid position numbering of SEQ ID NO: 1.
[00101] [00101] In exemplary embodiments, the IL-21 mutein comprises an amino acid sequence comprising at least one amino acid substitution with respect to the wild-type IL-21 amino acid sequence, and the amino acid substitution (s) occurs (m) within the C-terminal half of the amino acid sequence. For example, the substitution (s) occurs in a position within positions 100-133 or 109-123 (both inclusive), according to the numbering of amino acid positions of SEQ ID NO: 1.
[00102] [00102] In exemplary embodiments, the IL-21 mutein comprises an amino acid sequence comprising at least one amino acid substitution with respect to the wild-type IL-21 amino acid sequence, and the amino acid substitution (s) occurs (m) in the middle third of the amino acid sequence. For example, the substitution (s) occurs in a position within positions 55-85 or 65-80 (both inclusive), according to the numbering of amino acid positions in SEQ ID NO: 1.
[00103] [00103] The present disclosure also provides IL-21 muteins comprising only an amino acid substitution, relative to the wild-type IL-21 amino acid sequence, which is provided here as SEQ ID NO: 1. In exemplary aspects, the amino acid substitution is located at an amino acid position selected from the group consisting of: 5, 8, 9, 11, 12, 13, 14, 15, 16, 19, 23, 65, 66, 68, 69, 70, 71, 72, 73, 75, 76, 77, 78, 79, 80, 109, 110, 112, 113, 116, 117, 119, 120 or 123, according to the amino acid position numbering of SEQ ID NO: 1. In other exemplary aspects, the amino acid substitution is located at an amino acid position selected from the group consisting of: 5, 8, 9, 11, 12, 13, 14, 15, 16, 19, 23, 65, 66, 68, 69, 70, 72, 73, 75, 76, 77, 78, 79, 80, 109, 110, 112, 113, 116, 117, 119, 120 or 123, according to the amino acid position numbering of SEQ ID NO: 1. In still other exemplary aspects, mutein d and IL-21 comprises any of the amino acid sequences of SEQ ID NOs: 3-21 and 23-37.
[00104] [00104] The present disclosure additionally provides IL-21 muteins comprising only two amino acid substitutions, in relation to SEQ ID NO: 1. In exemplary aspects, the amino acid substitutions are located at two amino acid positions selected from the group consisting of: 5, 8, 9, 11, 12, 13, 14, 15, 16, 19, 23, 65, 66, 68, 69, 70, 71, 72, 73, 75, 76, 77, 78, 79, 80, 109, 110, 112, 113, 116, 117, 119, 120 or 123, according to the numbering of amino acid positions of SEQ ID NO: 1. In other exemplary aspects, the amino acid substitutions are located in two amino acid positions selected from the group consisting of: 5, 9, 15, 70, 71, 72, 73 and 76, according to the numbering of amino acid positions of SEQ ID
[00105] [00105] In exemplary embodiments, IL-21 mutein comprises an amino acid sequence comprising at least one amino acid substitution with respect to the wild-type IL-21 amino acid sequence, and the amino acid substitution (s) is / are conservative amino acid substitution (s). As used herein, the term "conservative amino acid substitution" refers to the replacement of one amino acid by another amino acid having similar properties, eg, size, charge, hydrophobicity, hydrophilicity and / or aromaticity, and includes exchanges within one of the following five groups: I. Small aliphatic residues, non-polar or slightly polar: Ala, Ser, Thr, Pro, Gly; II. Negatively charged, polar residues and their amides and esters: Asp, Asn, Glu, Gln, cystic acid and homocysteic acid; III. Positively charged, polar residues: His, Arg, Lys; Ornithine (Orn)
[00106] [00106] In exemplary embodiments, the IL-21 mutein comprises an amino acid sequence comprising at least one amino acid substitution with respect to the wild-type IL-21 amino acid sequence, and the amino acid substitution (s) is / are non-conservative amino acid substitution (s). As used herein, the term "non-conservative amino acid substitution" is defined here as the substitution of one amino acid for another amino acid having different properties, eg, size, charge, hydrophobicity, hydrophilicity and / or aromaticity, and includes exchanges outside of the above five groups:
[00107] [00107] In exemplary aspects, the IL-21 mutein comprises an amino acid sequence comprising at least one amino acid substitution with respect to the wild-type IL-21 amino acid sequence, and the substitute amino acid is a naturally occurring amino acid. By "naturally occurring amino acid" or "standard amino acid" or "canonical amino acid" is meant one of the 20 alpha amino acids found in eukaryotes encoded directly by the codons of the universal genetic code (Ala, Val, Ile, Leu, Met, Phe, Tyr, Trp , Ser, Thr, Asn, Gln, Cys, Gly, Pro, Arg, His, Lys, Asp, Glu). In exemplary aspects, the IL-21 mutein comprises an amino acid sequence comprising at least one amino acid substitution with respect to the wild-type IL-21 amino acid sequence, and the substitute amino acid is a non-standard amino acid or an amino acid that is not is incorporated into proteins during translation. Non-standard amino acids include, but are not limited to: selenocysteine, pyrrolysin, ornithine, norleucine, β-amino acids (eg, β-alanine, β-aminoisobutyric acid, β-phenylalanine, β-homophenylalanine, β-glutamic acid , β-glutamine, β-homotryptophan, β-leucine, β-lysine), homo-amino acids (eg, homophenylalanine, homoserine, homoarginine, monocysteine, homocystine), N-methyl amino acids (eg, L- abrin, N-methyl-alanine, N-methyl-isoleucine, N-methyl-leucine), 2-aminocaprylic acid, 7-aminocephalosporanic acid, 4-aminocinamic acid, alpha-aminocyclohexanepropionic acid, amino- (4-hydroxyphenyl acid) ) acetic, 4-amino-nicotinic acid, 3-aminophenylacetic acid and the like.
[00108] [00108] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with at least one amino acid substitution with respect to the human IL-21 amino acid sequence (SEQ ID NO: 1), the substitution of amino acid is in one or more of the positions 5, 8, 9, 12, 14, 15, 65, 66, 69, 70, 72, 73, 75, 76, 77, 80, 116 and 119 of SEQ ID NO: 1, and the substitute amino acid (s) is / are aliphatic amino acids. In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with only one amino acid substitution in relation to SEQ ID NO: 1, the amino acid substitution is in position 5, 8, 9, 12, 14, 15, 65, 66, 69,
[00109] [00109] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with at least one amino acid substitution with respect to the human IL-21 amino acid sequence (SEQ ID NO: 1), the substitution of amino acids is in one or more of the positions 5, 8, 9, 11, 12, 13, 14, 15, 16, 19, 23, 65, 66, 69, 70, 72, 73, 75, 76, 77, 78, 79, 110, 112, 116, 117, 119, 120 or 123 of SEQ ID NO: 1, and the substitute amino acid (s) is / are acidic amino acids. In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with only one amino acid substitution in relation to SEQ ID NO: 1, the amino acid substitution is in position 5, 8, 9, 11, 12, 13, 14, 15, 16, 19, 23, 65, 66, 69, 70, 72, 73, 75, 76, 77, 78, 79, 110, 112, 116, 117, 119, 120 or 123 of SEQ ID NO: 1, and the substitute amino acid is an acidic amino acid.
[00110] [00110] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with at least one amino acid substitution with respect to the human IL-21 amino acid sequence (SEQ ID NO: 1), the substitution of amino acids is in one or more of positions 5, 9, 73, 76, 109, 113 or 116 of SEQ ID NO: 1, and the substitute amino acid (s) is / are basic amino acids. In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with only one amino acid substitution with respect to SEQ ID NO: 1, and the amino acid at position 5, 9, 73, 76, 109, 113 or 116 of SEQ ID NO: 1 is a basic amino acid.
[00111] [00111] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with at least one amino acid substitution with respect to the human IL-21 amino acid sequence (SEQ ID NO: 1), the substitution of amino acids is in one or more of positions 5, 8, 9, 70 or 76 of SEQ ID NO: 1, and the substitute amino acid (s) is / are aromatic amino acids. In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with only one amino acid substitution in relation to SEQ ID NO: 1, the amino acid substitution is in position 5, 8, 9, 70 or 76 of SEQ ID NO: 1, and the substitute amino acid is an aromatic amino acid.
[00112] [00112] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with at least one amino acid substitution with respect to the human IL-21 amino acid sequence (SEQ ID NO: 1), the substitution of amino acid is in one or more of positions 5, 8, 9, 12, 15, 73, 76, 116 or 119 of SEQ ID NO: 1, and the substitute amino acid (s) is / are amino acids comprising a side chain amide. In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with only one amino acid substitution in relation to SEQ ID NO: 1, the amino acid substitution is in position 5, 8, 9, 12, 15, 73, 76, 116 or 119 of SEQ ID NO: 1, and the substitute amino acid is an amino acid comprising a side chain amide.
[00113] [00113] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with at least one amino acid substitution with respect to the human IL-21 amino acid sequence (SEQ ID NO: 1), the substitution of amino acid is in one or more of positions 5, 8, 9, 11, 12, 14, 15, 73, 76, 116 or 119 of SEQ ID NO: 1, and the substitute amino acid (s) is / are amino acids comprising a side chain hydroxyl. In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with only one amino acid substitution in relation to SEQ ID NO: 1, the amino acid substitution is in position 5, 8, 9, 11, 12, 14, 15, 73, 76, 116 or 119 of SEQ ID NO: 1, and the substitute amino acid is an amino acid comprising a side chain hydroxyl.
[00114] [00114] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with at least one amino acid substitution with respect to the human IL-21 amino acid sequence (SEQ ID NO: 1), the substitution of amino acid is in one or more of positions 65, 66, 69, 70, 72, 73, 75, 76, 77 or 80 of SEQ ID NO: 1, and the substitute amino acid (s) is / are imino acids. In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with only one amino acid substitution in relation to SEQ ID NO: 1, the amino acid substitution is at position 65, 66, 69, 70, 72,
[00115] [00115] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with at least one amino acid substitution with respect to the human IL-21 amino acid sequence (SEQ ID NO: 1), the substitution of amino acids at one or more of positions 5, 9, 15, 76, 116 or 119 of SEQ ID NO: 1, and the substitute amino acid (s) is / are amino acids comprising a sulfur-containing side chain. In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with only one amino acid substitution in relation to SEQ ID NO: 1, the amino acid substitution is in position 5, 9, 15, 76, 116 or 119 of SEQ ID NO: 1, and the substitute amino acid is an amino acid comprising a sulfur-containing side chain.
[00116] [00116] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with at least one amino acid substitution, in relation to the human IL-21 amino acid sequence (SEQ ID NO: 1), wherein at least one amino acid substitution is shown in Table A.
[00117] [00117] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence with only one amino acid substitution with respect to SEQ ID NO: 1, and the amino acid substitution is one shown in Table A. In others embodiments, the IL-21 mutein of the present disclosure comprises an amino acid sequence with two amino acid substitutions with respect to SEQ ID NO: 1, and the amino acid substitutions are two of those shown in Table A.
[00118] [00118] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence shown in Table B.
[00119] [00119] In exemplary embodiments, the IL-21 mutein of the present disclosure comprises an amino acid sequence of any of SEQ ID NOs: 47, 48, 51, 61, 62, 64-67, 69, 71-112, 114 -198, 249-254 or 283. In exemplary aspects, IL-21 mutein comprises an amino acid sequence that is less than about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or have more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with any of SEQ ID NOs: 47, 48, 51, 61, 62, 64-67, 69, 71-112, 114-198, 249-254 or 283.
[00120] [00120] The present disclosure further provides IL-21 muteins comprising only two amino acid substitutions, in relation to SEQ ID NO: 1, and the two amino acid substitutions occur in two of the positions 5, 9, 15, 70, 71,
[00121] [00121] In exemplary aspects, the IL-21 mutein of the present disclosure comprises an amino acid sequence from any of SEQ ID NOs: shown in Table C.
[00122] [00122] In exemplary aspects, the IL-21 mutein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 213-219 and 227-248. In exemplary aspects, IL-21 comprises an amino acid sequence that is at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least at least about 80%, at least about 85%, at least about 90%, or more than about 90% (eg, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about
[00123] The IL-21 muteins described herein can comprise a peptide backbone of any number of amino acids, i.e., can be of any length of peptides. In some embodiments, the peptides described here are about the same length as SEQ ID NO: 1, ie, they are 133 (± about 1 to about 20, ± about 1 to about 15, ± about 1 to about 10 or ± about 1 to about 5) amino acids in length. In some embodiments, the currently disclosed peptide is more than 133 amino acids in length because it is fused to another polypeptide chain, e.g., an antibody heavy chain comprising about 400 to about 600 amino acids, a light chain antibody comprising about 150 to about 300 amino acids, as further described herein. Additional peptide modifications
[00124] [00124] In alternative or additional modalities of the present disclosure, the IL-21 mutein is lipidized (e.g., myritoylated, palmitoylated), glycosylated, amidated, carboxylated, phosphorylated, esterified, acylated, acetylated, cyclized or converted to a acid addition salt and / or optionally dimerized or polymerized or conjugated, as further described herein. Pharmaceutically acceptable salts
[00125] [00125] In exemplary aspects, IL-21 mutein is in the form of a salt, e.g., a pharmaceutically acceptable salt. Such salts can be prepared in situ during the final isolation and purification of IL-21 mutein or separately prepared by reacting a free base function with a suitable acid. Examples of acids that can be employed to form pharmaceutically acceptable acid addition salts include, for example, an inorganic acid, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, and an organic acid, e.g. ., oxalic acid, maleic acid, succinic acid and citric acid.
[00126] [00126] Representative acid addition salts include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexane , hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isothionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmitoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, tartarate, propionate, tartarate phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate.
[00127] [00127] Basic addition salts can be prepared in situ during the final isolation and purification of IL-21 mutein or by reacting a fraction containing carboxylic acid with a suitable base such as hydroxide, carbonate or bicarbonate of a cation of pharmaceutically acceptable metal or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and non-toxic quaternary ammonia and amine cations including ammonium, tetramethylammonium , tetraethylammonium, methylammonium, dimethylammonium, trimethylammonium, triethylammonium, diethylammonium and ethylammonium, among others. Other representative organic amines useful for the formation of base addition salts include, for example, ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.
[00128] [00128] Additionally, groups containing basic nitrogen can be quaternized with such active agents as lower alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides such as benzyl and phenethyl bromides and others. Products soluble or dispersible in water or oil are thus obtained. Purification
[00129] [00129] The IL-21 muteins of the present disclosure can be purified. The term "purified" as used here means it has been increased in purity, where "purity" is a relative term and is not necessarily to be interpreted as absolute purity. In exemplary aspects, the purity of the compound (e.g., in the composition) is at least or about 50%, at least or about 60%, at least or about 70%, at least or about 80%, at least or about 90%, at least or about 95% or at least or about 98% or is about 100%.
[00130] [00130] In some respects, IL-21 mutein is a peptidomimetic, or at least a portion of the mutein is peptidomimetic. Peptidomimetics as well as methods of making them are known in the art. See, for example, Advances in Amino Acid Mimetics and Peptidomimetics, Volumes 1 and 2, ed., Abell, A., JAI Press Inc., Greenwich, CT,
[00131] [00131] In exemplary embodiments, IL-21 muteins bind to the IL-21 receptor (IL-21R) with reduced affinity, in relation to the wild-type IL-21 affinity for IL-21R. In exemplary embodiments, IL-21 muteins bind to human IL-21R with reduced affinity, compared to the affinity of wild-type human IL-21 for IL-
[00132] [00132] In exemplary embodiments, IL-21 muteins bind to the human IL-21R gamma chain with a reduced affinity, relative to the wild-type human IL-21 affinity for the human IL-21R gamma chain. In specific embodiments, IL-21 muteins that bind to the human IL-21R gamma chain with a reduced affinity, relative to the affinity of wild-type human IL-21 for the human IL-21R gamma chain, contain one, two or more substitutions located at an amino acid position selected from the group consisting of: 11, 14, 15, 109, 110, 112, 113, 116, 117, 119, 120 and 123, according to the numbering of amino acid positions of SEQ ID NO: 1. Specific amino acid substitutions that can be made at such positions are discussed here (see, eg, Tables A, B and C).
[00133] [00133] In exemplary embodiments, IL-21 muteins bind to the human IL-21R gamma chain with a reduced affinity, relative to the wild-type human IL-21 affinity for the human IL-21R alpha chain. In exemplary embodiments, IL-21 muteins bind to monkey-cinomologist IL-21R with a reduced affinity with respect to the affinity of wild-type cinomologist IL-21 for cinomologist IL-21R. In exemplary embodiments, IL-21 muteins bind to the monkey-cinomologist IL-21R alpha chain with a reduced affinity with respect to the wild-type cinomologist IL-21 affinity for the cinomologist IL-21R alpha chain . In exemplary embodiments, IL-21 muteins bind to the monkey-cinomologist IL-21R gamma chain with a reduced affinity, in relation to the wild-type cinomologist IL-21 affinity for the cinomologist IL-21R gamma chain . In exemplary embodiments, the IL-21 muteins bind to the monkey-cinomologist IL-21R gamma chain with a reduced affinity with respect to the wild-type cinomologist IL-21 affinity for the cinomologist IL-21R alpha chain. .
[00134] [00134] The IL-21 muteins provided here bind to IL-21R in a non-covalent and reversible manner. In exemplary embodiments, the strength of mutein binding to IL-21R can be described in terms of its affinity, a measure of the strength of interaction between the mutein binding site and IL-21R. In exemplary aspects, the IL-21 muteins provided here have a high affinity for IL-21R and will thus bind to a greater amount of IL-21R in a shorter period of time than low-affinity IL-21 muteins. In exemplary aspects, the IL-21 muteins provided here have low affinity for IL-21R and will thus bind to a smaller amount of IL-21R over a longer period of time than the high-affinity IL-21 muteins. In exemplary aspects, IL-21 mutein has an equilibrium association constant, KA, which is at least 105 M-1, at least 106 M-1, at least 107 M-1, at least 108 M-1, at least 109 M-1 or at least 1010 M-1. As understood by the expert expert, KA can be influenced by factors including pH, temperature and buffer composition.
[00135] [00135] In exemplary embodiments, the binding strength of the IL-21 mutein to IL-21R can be described in terms of its sensitivity. KD is the equilibrium dissociation constant, a koff / kon ratio, between the IL-21 and IL-21R mutein. KD and KA are inversely related. The KD value is related to the concentration of mutein (the amount of mutein needed for a particular experiment) and therefore the lower the KD value (less concentration required), the higher the affinity of mutein. In exemplary aspects, the binding strength of the IL-21 mutein to IL-21R can be described in terms of KD. In exemplary aspects, the KD of the IL-21 muteins provided here is about 10-1 M, about 10-2 M, about 10-3 M, about 10-4 M, about 10-5 M, about 10-6 M or less. In exemplary aspects, the KD of the IL-21 muteins provided here is micromolar, nanomolar, picomolar or femtomolar. In exemplary aspects, the KD of the IL-21 muteins provided here is within a range of about 10-4 to 10-6 M or 10-7 to 10-9 M or 10-10 to 10-12 M or 10 -13 to 10-15 M. In exemplary aspects, the IL-21 mutein binds to human IL-21R with a KD that is greater than or is about 0.04 nM. In exemplary aspects, the IL-21 mutein binds to human IL-21R with a KD of about 0.01 nM to about 20 nM, 0.02 nM to 20 nM, 0.05 nM to 20 nM, 0 , 05 nM to 15 nM, 0.1 nM to 15 nM, 0.1 nM to 10 nM, 1 nM to 10 nM or 5 nM to 10 nM. In exemplary aspects, the IL-21 mutein binds to monkey-cinomologist IL-21R with a KD that is greater than or is about 0.055 nM. In exemplary aspects, IL-21 mutein binds to monkey-cinomologist IL-21R with a KD of about 0.01 nM to about 20 nM, 0.02 nM to 20 nM, 0.05 nM to 20 nM, 0.05 nM to 15 nM, 0.1 nM to 15 nM, 0.1 nM to 10 nM, 1 nM to 10 nM or 5 nM to 10 nM.
[00136] [00136] In exemplary embodiments, IL-21 mutein exhibits a reduction in binding affinity for the α-chain of IL-21R. In exemplary aspects, the IL-21 mutein is a mutein (eg, single or double) that exhibits a reduction of about 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975 times, 1000 times or more in binding affinity for the α-chain of IL-21R. In exemplary aspects, IL-21 mutein is a double mutein exhibiting a reduction in binding affinity for the α-chain of IL-21R.
[00137] [00137] In exemplary aspects, the reduction in binding affinity above the IL-21 mutein (e.g., single or double mutein) results in reduced affinity for the IL-21R α chain compared to the affinity of about 0.025 nM of wild-type human IL-21 via the IL-21R α chain. Accordingly, a 2-fold reduction in affinity as discussed above would result in an IL-21 mutein with an affinity of about 0.05 nM for the IL-21R α chain. Thus, in exemplary embodiments, IL-21 mutein (eg, single or double) has an affinity of about 0.05, 0.125, 0.25, 0.375, 0.5, 0.625, 0.75, 0.875, 1.0, 1.125, 1.25, 1.375, 1.5, 1.625, 1.75, 1.875, 2.0, 2.125, 2.25, 2.375, 2.5, 2.625, 2.75, 2.875, 3.0, 3.125, 3.25, 3.375, 3.5, 3.625, 3.75, 4.375, 5, 5.625, 6.25, 6.875, 7.5, 8.125, 8.75, 9.375, 10.0, 10.625, 11.25, 11.875, 12.5, 13.125, 13.75, 14.375, 15.0, 15.625, 16.25, 16.875, 17.5, 18.125, 18.75, 19.375, 20.0, 20.625, 21.25, 21.875, 22.5, 23.125, 23.75, 24.375, 25 nM or more by the IL-21R α chain. In exemplary aspects, IL-21 mutein is a double mutein exhibiting reduced binding affinity for the IL-21R α chain.
[00138] [00138] In exemplary embodiments, IL-21 mutein exhibits a reduction in activity as measured by an in vitro STAT3 phosphorylation assay. In exemplary aspects, the IL-21 mutein is a mutein (eg, single or double) that exhibits a reduction of about 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550,
[00139] [00139] The present disclosure also provides conjugates comprising one or more of the IL-21 muteins of the present disclosure linked to a heterologous moiety. As used here, the term "heterologous fraction" is synonymous with the term "conjugated fraction" and refers to any molecule (chemical or biochemical, naturally occurring or uncoded) that is different from the IL-21 muteins described here. Exemplary conjugated fractions that can be linked to any of the IL-21 muteins described herein include, but are not limited to, a heterologous peptide or polypeptide (including, for example, an immunoglobulin or its portion (e.g., variable region , CDR or Fc region)), a targeting agent, a diagnostic tag such as a radioisotope, fluorophore or enzyme tag, a polymer including water-soluble polymers or other therapeutic or diagnostic agents. In some embodiments, a conjugate is provided comprising an IL-21 mutein of the present disclosure and an immunoglobulin. The conjugate in some embodiments comprises one or more of the IL-21 muteins described here and one or more of: a peptide (which is distinct from the IL-21 muteins described here), a polypeptide, a nucleic acid molecule, an antibody or its fragment, a polymer, a quantum dot, a small molecule, a toxin, a diagnostic agent, a carbohydrate, an amino acid.
[00140] [00140] In exemplary embodiments, the conjugate of the present disclosure comprises an IL-21 mutein as described herein and a heterologous moiety that is a polypeptide (e.g., a polypeptide distinct from any of the IL-21 muteins described here ), and the conjugate is a fusion polypeptide or fusion protein or a chimeric protein or chimeric polypeptide. Additional descriptions of such conjugates are provided here under "Fusion proteins".
[00141] [00141] In some embodiments, the heterologous fraction is attached via non-covalent or covalent binding to the IL-21 mutein of the present disclosure. In exemplary aspects, the link between the IL-21 mutein and the heterologous fraction is achieved through covalent chemical bonds, eg, peptide bonds, disulfide bonds and the like, or through physical forces, such as electrostatics, hydrogen, ionic, van der Waals or hydrophobic or hydrophilic interactions. A variety of non-covalent coupling systems can be used, including, eg, biotin-avidin, ligand / receptor, enzyme / substrate, nucleic acid / nucleic acid binding protein, lipid / lipid binding protein, molecule partners cell adhesion; or any liaison partners or fragments that have an affinity for each other.
[00142] [00142] IL-21 mutein in exemplary embodiments is linked to a conjugated fraction by direct covalent bonding by reacting targeted amino acid residues from IL-21 mutein with an organic derivatizing agent that is capable of reacting with side chains selected or the N- or C-terminal residues of these target amino acids. Reactive groups on the IL-21 mutein or conjugated fraction include, e.g., an aldehyde, amino, ester, thiol, α-haloacetyl, maleimido or hydrazine group. Derivatizing agents include, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation via cysteine residues), N-hydroxysuccinimide (via lysine residues), glutaraldehyde, succinic anhydride or other agents known in the art. Alternatively, the conjugated fractions can be linked to the IL-21 mutein via intermediate transporters, such as polysaccharide or polypeptide transporters. Examples of polysaccharide transporters include aminodextran. Examples of suitable polypeptide carriers include polylysine, polyglutamic acid, polyaspartic acid, their copolymers and mixed polymers of these amino acids and others, e.g., serines, to impart desirable solubility properties to the resulting loaded carrier.
[00143] [00143] Cysteinyl residues are most commonly reacted with α-haloacetates (and corresponding amines), such as chloroacetic acid, chloroacetamide to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues are also derivatized by reaction with bromotrifluoroacetone, alpha-bromo-β- (5-imidozoyl) propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2- disulfide
[00144] [00144] Histidyl residues are derivatized by reaction with diethylpyrocarbonate at pH 5.5-7.0 because this agent is relatively specific for histidyl side chain. Para-bromophenacil bromide is also useful; the reaction is preferably carried out in 0.1 M sodium cacodylate at pH 6.0.
[00145] [00145] Lysinyl and amino-terminal residues are reacted with anhydrides of succinic acid or other carboxylic acid. Derivatization with these agents has the effect of reversing the load of lysinyl residues. Other reagents suitable for derivatization of residues containing alpha-amino include imidoesters such as methyl picolinimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4-pentanedione and transaminase catalyzed reaction with glyoxylate.
[00146] [00146] Arginyl residues are modified by reaction with one or more conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione and ninhydrin. Derivatization of arginine residues requires that the reaction be carried out in alkaline conditions due to the high pKa of the guanidine functional group. Furthermore, these reagents can react with the lysine groups as well as the epsilon-amino group of arginine.
[00147] [00147] The specific modification of tyrosyl residues can be made, with particular interest in the introduction of spectral labels in tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.
[00148] [00148] The carboxyl side groups (aspartame or glutamyl) are selectively modified by reaction with carbodiimides (RN = C = N-R '), where R and R' are different alkyl groups, such as 1-cyclohexyl- 3- (2-morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3- (4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, asparta and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
[00149] [00149] Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the alpha-amino groups of side chains of lysine, arginine and histidine (TE Creighton, Proteins: Structure and Molecular Properties, WH Freeman & Co., San Francisco, pp. 79-86 (1983)), deamidation of asparagine or glutamine, acetylation of the N-terminal amine and / or amidation or esterification of the C-terminal carboxylic acid group.
[00150] [00150] Another type of covalent modification involves chemical or enzymatic coupling of glycosides to the IL-21 mutein. The sugar (s) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl group such as those of serine, threonine or hydroxyproline,
[00151] [00151] In exemplary aspects, the heterologous fraction is attached to the IL-21 mutein of the present disclosure via a linker. In some respects, the linker comprises a chain of atoms of 1 to about 60 or 1 to 30 atoms or more, 2 to 5 atoms, 2 to 10 atoms, 5 to 10 atoms or 10 to 20 atoms in length. In some embodiments, carbon atoms are all carbon atoms. In some embodiments, the chain atoms in the ligand skeleton are selected from the group consisting of C, O, N and S. The chain atoms and ligands can be selected according to their expected solubility (hydrophilicity) in order to provide a more soluble conjugate. In some embodiments, the ligand provides a functional group that is subject to cleavage by an enzyme or other catalytic or hydrolytic conditions found in the target tissue or organ or cell. In some embodiments, the length of the ligand is long enough to reduce the potential for steric hindrance. If the linker is a covalent bond or a peptidyl bond and the conjugate is a polypeptide, the entire conjugate can be a fusion protein. Such peptidyl linkers can be of any length. Exemplary peptidyl linkers are about 1 to 50 amino acids in length, 5 to 50, 3 to 5, 5 to 10, 5 to 15 or 10 to 30 amino acids in length and are flexible or rigid. In exemplary aspects, the linker is a peptide comprising about 2 to about 20 amino acids. In exemplary aspects, the linker is a peptide comprising about 2 to about 15 amino acids, about 2 to about 10 amino acids, or about 2 to about 5 amino acids. Suitable peptide linkers are known in the art. See, eg, Chen et al., Adv Drug Delivery Reviews 65 (10): 1357-1369 (2013); Arai et al., Protein Eng Des Sel 14 (8): 529-532 (2001); and Wriggers et al., Curr Trends in Peptide Science 80 (6): 736-746 (2005). In exemplary aspects, the linker is a peptide comprising the amino acid sequence GGGGS (SEQ ID NO: 262). Fusion proteins
[00152] [00152] In exemplary embodiments, the IL-21 mutein is linked to a polypeptide that is distinct from any of the IL-21 muteins described here, and the conjugate is a fusion polypeptide or fusion protein or a chimeric protein or chimeric polypeptide. Accordingly, the present disclosure provides fusion polypeptides or fusion proteins comprising an IL-21 mutein of the present disclosure and a heterologous polypeptide or peptide. In exemplary aspects, the fusion protein of the present disclosure comprises an IL-21 mutein of the present disclosure linked to an antigen-binding protein. In exemplary aspects, the antigen-binding protein is an antibody or immunoglobulin, or an antigen-binding antibody fragment thereof, or an antibody protein product
[00153] [00153] Collectively, antibodies form a family of plasma proteins known as immunoglobulins and comprise of immunoglobulin domains. (Janeway et al., Immunobiology: The Immune System in Health and Disease, 4th ed., Elsevier Science Ltd./Garland Publishing, 1999). As used herein, the term "antibody" refers to a protein having a conventional immunoglobulin format, comprising heavy and light chains and comprising variable and constant regions. For example, an antibody can be an IgG which is a “Y-shaped” structure of two identical pairs of polypeptide chains, each pair having a “light” chain (typically having a molecular weight of about 25 kDa) and a "Heavy" (typically having a molecular weight of about 50-70 kDa). An antibody has a variable region and a constant region. In IgG formats, the variable region generally has about 100-110 or more amino acids, comprises three complementarity determining regions (CDRs), is mainly responsible for antigen recognition and varies substantially among other antibodies that bind to different antigens. The constant region allows the antibody to recruit immune system cells and molecules. The variable region is made up of the N-terminal regions of each light chain and heavy chain, while the constant region is made up of the C-terminal portions of each of the heavy and light chains. (Janeway et al., “Structure of the Antibody Molecule and the Immunoglobulin Genes”, Immunobiology: The Immune System in Health and Disease, 4th ed. Elsevier Science Ltd./Garland Publishing, (1999)).
[00154] [00154] The general structure and properties of antibody CDRs have been described in the art. Briefly, in an antibody template, the CDRs are embedded within a framework in the variable region of heavy and light chain where they constitute the regions largely responsible for the binding and recognition of the antigen. A variable region typically comprises at least three heavy or light chain CDRs (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Public Health Service NIH, Bethesda, Md .; see also Chothia and Lesk, 1987, J. Mol Biol. 196: 901-917; Chothia et al., 1989, Nature 342: 877-883), within a framework region (referred to as framework regions 1-4, FR1, FR2, FR3 and FR4, by Kabat et al., 1991; see also Chothia and Lesk, 1987, supra).
[00155] [00155] Antibodies can comprise any constant region known in the art. Human light chains are typically classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha or epsilon and define the antibody isotype as IgM, IgD, IgG, IgA and IgE, respectively. IgG has several subclasses, including, but not limited to, IgG1, IgG2, IgG3 and IgG4. IgM has subclasses, including, but not limited to, IgM1 and IgM2. The modalities of the present disclosure include all such classes or isotypes of antibodies. The light chain constant region can be, for example, a kappa or lambda light chain constant region, e.g., a human kappa or lambda light chain constant region. The heavy chain constant region can be, for example, an alpha, delta, epsilon, gamma or mu heavy chain constant region, e.g., an alpha, delta, epsilon, gamma or mu heavy chain constant region. human. Accordingly, in exemplary embodiments, the antibody is an antibody of the IgA, IgD, IgE, IgG or IgM isotype, including any of IgG1, IgG2, IgG3 or IgG4.
[00156] [00156] The antibody can be a monoclonal antibody or a polyclonal antibody. In some embodiments, the antibody comprises a sequence that is substantially similar to a naturally occurring antibody produced by a mammal, e.g., mouse, rabbit, goat, horse, chicken, hamster, human and the like. In this regard, the antibody can be considered as a mammalian antibody, e.g., a mouse antibody, rabbit antibody, goat antibody, horse antibody, chicken antibody, hamster antibody, human antibody and the like. In certain aspects, the antibody is a human antibody. In certain aspects, the antibody is a chimeric antibody or a humanized antibody. The term "chimeric antibody" refers to an antibody containing domains of two or more different antibodies. A chimeric antibody may, for example, contain the constant domains of one species and the variable domains of a second or, more generally, it may contain portions of the amino acid sequence of at least two species. A chimeric antibody can also contain domains of two or more different antibodies within the same species. The term "humanized" when used in connection with antibodies refers to antibodies having at least CDR regions from a non-human source that are engineered to have an immunological structure and function more similar to true human antibodies than the original antibodies of the source. For example, humanization may involve grafting a CDR from a non-human antibody, such as a mouse antibody, to a human antibody. Humanization may also involve selecting amino acid substitutions to make a non-human sequence more similar to a human sequence.
[00157] [00157] An antibody can be cleaved into fragments by enzymes, such as, for example, papain and pepsin. Papain cleaves an antibody to produce two Fab fragments and a single Fc fragment. Pepsin cleaves an antibody to produce an F (ab ') 2 fragment and a pFc' fragment. In exemplary aspects of the present disclosure, the fusion protein of the present disclosure comprises an antigen-binding antibody fragment. As used here, the term "antigen binding antibody fragment" refers to a portion of an antibody molecule that is capable of binding to the antibody antigen and is also known as an "antigen binding fragment" or "portion of antigen binding ”. In exemplary cases, the antigen-binding antibody fragment is an Fab fragment or an F (ab ') 2 fragment.
[00158] [00158] Antibody architecture has been explored to create an increasing range of alternative formats that span a molecular weight range of at least 12-150 kDa and have a range of valencies (n) from monomeric (n = 1), to dimeric (n = 2), trimeric (n = 3), tetrameric (n = 4) and potentially higher; such alternative formats are referred to here as "antibody protein products". Antibody protein products include those based on the entire antibody structure and those that mimic antibody fragments that retain binding capacity to the entire antigen, e.g., scFvs, Fabs and VHH / VH (discussed below). The smallest antigen binding antibody fragment that retains its full antigen binding site is the Fv fragment, which consists entirely of variable regions (V). A flexible, soluble amino acid peptide linker is used to connect the V regions to a scFv fragment (single chain fragment variable) for stabilizing the molecule, or constant domains (C) are added to the V regions to generate a Fab fragment [fragment, antigen binding]. Both scFv and Fab fragments can be easily produced in host cells, e.g., prokaryotic host cells.
[00159] [00159] Other antibody protein products include a single chain antibody (SCA); a diabody; a triacorp; a tetrabody; bispecific or triespecific antibodies and the like. Bispecific antibodies can be divided into five main classes: BsIgG, IgG pendant, BsAb fragments, bispecific fusion proteins and BsAb conjugates. See, e.g., Spiess et al., Molecular Immunology 67 (2) Part A: 97-106 (2015).
[00160] [00160] In exemplary aspects, the fusion protein of the present disclosure comprises any of these antibody protein products. In exemplary aspects, the fusion protein of the present disclosure comprises any one of a scFv, Fab VHH / VH, Fv fragment, ds-scFv, scFab, dimeric antibody, multimeric antibody (e.g., a diabody, triacorp, tetribody) , miniAb, camelid heavy chain antibody VHH / VH peptibody, sdAb, diabody; a triacorp; a tetrabody; a bispecific or triespecific antibody, BsIgG, pendant IgG, BsAb fragment, bispecific fusion protein and BsAb conjugate.
[00161] [00161] In exemplary cases, the fusion protein of the present disclosure comprises an antibody protein product in monomeric or polymeric, oligomeric or multimeric form. In certain embodiments in which the antibody comprises two or more fragments of distinct antigen-binding regions, the antibody is considered to be bispecific, triespecific or multispecific, or bivalent, trivalent or multivalent, depending on the number of distinct epitopes that are recognized and linked by the antibody .
[00162] [00162] In exemplary embodiments, the antibody, antigen-binding antibody fragment or antibody protein product binds to a tumor antigen. In exemplary aspects, the tumor antigen is an antigen derived from a viral protein, an antigen derived from point mutations, or an antigen encoded by a cancer germline gene. In exemplary aspects, the tumor antigen is p53, KRAS, NRAS, MAGEA, MAGEB, MAGEC, BAGE, GAGE, LAGE / NY-ESO1, SSX, tyrosinase, gp100 / pmel17, Melan- A / MART-1, gp75 / TRP1, TRP2, CEA, RAGE-1, HER2 / NEU, WT1. In exemplary aspects, the antibody, antigen binding antibody fragment or antibody protein product of the fusion protein of the present disclosure binds to an immunotherapy agent or is an immunotherapy agent, as described herein. In exemplary aspects, the antibody, antigen-binding antibody fragment or antibody protein product of the fusion protein of the present disclosure binds to a cytokine, lymphokine, growth factor or hematopoietic factor, as described herein.
[00163] [00163] In exemplary embodiments, the fusion protein of the present disclosure comprises a cytokine (e.g., an IL-21 mutein described here) and an antibody, its antigen binding antibody fragment or antibody protein product , which binds to a protein from the immune control point pathway, a tumor antigen, a cytokine, lymphokine, growth factor or other hematopoietic factor, including but not limited to any of those described here. In exemplary embodiments, the fusion protein of the present disclosure comprises a cytokine (e.g., an IL-21 mutein described here) and an antibody, its antigen-binding antibody fragment or antibody protein product, which binds to a protein from the immune control point pathway selected from the group consisting of: CTLA-4, PD-1, PD-L1, PD-L2, B7-H3, B7-H4, CEACAM-1, TIGIT, LAG3, CD112 , CD112R, CD96, TIM3, BTLA or co-stimulating receptor: ICOS, OX40, 41BB, CD27, GITR.
[00164] [00164] In other embodiments, the fusion protein of the present disclosure comprises a cytokine and an antibody (or its antigen-binding antibody fragment) that binds to a protein via the immune control points pathway. Suitable cytokines include, for example, cytokines that enhance TH-1 type responses; and cytokines that activate STAT 1, 3, 4 or 5. In some embodiments, the cytokine is an interleukin. In other embodiments, the cytokine is an interleukin that enhances the activity of T cells such as, for example, IL-2, IL-7, IL-10, IL-12, IL-15 or IL-21. Such cytokines can be modified (eg, through mutations) to attenuate their affinity for their respective receptor. Such muteins can exhibit improved safety profiles by reducing off-target and unwanted interactions. Thus, cytokines can be modified to generate IL-2, IL-7, IL-10, IL-12, IL-15 or IL-21 muteins. In a particular embodiment, the cytokine is an IL-21 mutein described here. Suitable antibodies (or their antigen-binding antibody fragments) that bind to a protein from the immune control point pathway include, for example,
[00165] [00165] In other embodiments, the fusion protein of the present disclosure is a multispecific fusion protein comprising a cytokine, an antibody (or its antigen binding antibody fragment) and at least an additional targeting fraction. For example, the fusion protein of the present disclosure can be a triespecific fusion protein comprising a cytokine, an antibody (or its antigen binding antibody fragment) and an additional targeting fraction.
[00166] [00166] In exemplary embodiments, the fusion protein of the present disclosure comprises an IL-21 mutein described herein and a PD-1 binding antagonist. The term "PD-1 binding antagonist" refers to a molecule that decreases, blocks, inhibits, revokes or interferes with signal transduction resulting from the interaction of PD-1 with one or more of its binding partners, such as PD-L1, PD-L2. In some embodiments, the PD-1 binding antagonist is a molecule that inhibits PD-1 binding to one or more of its binding partners. In a specific aspect, the PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1 and / or PD-L2. For example, PD-1 binding antagonists include anti-PD-1 antibodies, their antigen binding antibody fragments, immunoadhesins, fusion proteins, oligopeptides and other molecules that decrease, block, inhibit, revoke or interfere with signal transduction resulting from the interaction of PD-1 with PD-L1 and / or PD-L2 In one embodiment, a PD-1 binding antagonist reduces the negative co-stimulating signal mediated by or through cell surface proteins expressed in mediated signaling by T-lymphocytes through PD-1 in order to make a dysfunctional T cell less dysfunctional (eg, by intensifying effector responses to antigen recognition). In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody. Examples of anti-PD-1 antibodies include nivolumab (BMS-936558), pembrolizumab (MK-3475), BMS 936558, BMS-936559, TSR-042 (Tesaro), ePDR001 (Novartis) and pidilizumab (CT-011). Additional specific examples of PD-1 binding antagonists are provided below.
[00167] [00167] In exemplary embodiments, the PD-1 binding antagonist comprises, consists essentially of, or consists of an antigen binding protein that binds PD-1. In exemplary aspects, the antigen-binding protein is an antibody, its antigen-binding antibody fragment, or an antibody protein product that binds to PD-1.
[00168] [00168] In exemplary aspects, the fusion protein of the present disclosure comprises an IL-21 mutein, as described here, and an anti-PD-1 antibody (as described here), an antigen-binding antibody fragment thereof or an anti-PD-1 antibody protein product. In exemplary cases, the anti-PD-1 antibody is a monoclonal IgG. In exemplary cases, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product is a monovalent or divalent. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product binds to human PD-1, which has the amino acid sequence of SEQ ID NO: 263. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product binds to a cinomologist PD-1, which has the SEQ amino acid sequence ID NO: 264. In exemplary cases, the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product binds to both human PD-1 and PD-1 from cinomologist. In exemplary cases, the fusion protein of the present disclosure comprises an IL-21 mutein (as described here) and an anti-PD-1 antibody (as described here).
[00169] [00169] In exemplary embodiments, the binding strength of the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product to PD-1 can be described in terms of KD. In exemplary aspects, the KD of the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product provided here is about 10-1 M, about 10-2 M, about 10-3 M, about 10-4 M, about 10-5 M, about 10-6 M, about 10-7 M, about 10-8 M, about 10-9 M or less . In exemplary aspects, the KD of the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product provided herein is micromolar, nanomolar, picomolar or femtomolar. In exemplary aspects, the KD of the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product provided herein is within a range of about 10-4 to 10-6 M or 10-7 to 10-9 M or 10-10 to 10-12 M or 10-13 to 10-15 M. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product has high affinity for human PD-1, cinomologist PD-1, or both. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product has a KD for human PD-1 of less than 100 pM, optionally about 1 pM to about 50 pM. In exemplary aspects, the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product has a KD for human PD-1 within about 1 pM to about 20 pM or less than about 10 pM. In exemplary aspects, the anti-PD-1 antibody, an antigen-binding antibody fragment thereof or anti-PD-1 antibody protein product has a kinomologist PD-1 KD of less than 100 pM, optionally about 1 pM to about 75 pM. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product has a kinomologist PD-1 KD within about 1 pM to about 20 pM or less than 10 pM.
[00170] [00170] In exemplary cases, the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product is a PD-1 binding antagonist that decreases, blocks, inhibits, revokes or interferes with signal transduction resulting from the interaction of PD-1 with one or more of its binding partners, such as PD-L1, PD-L2. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product blocks PD-1 from binding to its PD-L1 or PD-L2 ligand. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product inhibits at least 50% of the binding interactions between PD-1 and PD-L1 or PD -L2. In exemplary aspects, the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product exhibits at least about 50%, at least about 60% or at least about 70% inhibition of the binding interaction between PD-1 and PD-L1 or PD-L2.
[00171] [00171] In exemplary examples, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product inhibits PD-1 mediated IL-2 production by T cells in a mixed lymphocyte reaction (MLR). In exemplary aspects, the IC50 of the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product in the MLR is within about 0.1 nM to about 5 nM. In exemplary aspects, the IC50 of the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product in the MLR is less than 2 nM or less than 1 nM. In exemplary aspects, the IC50 of the anti-HIV antibody
[00172] [00172] In exemplary cases, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises (a) an amino acid sequence from the complementarity determining region (CDR) 1 of the heavy chain (HC) selected from the group consisting of: SEQ ID NOs: 312, 322, 332, 342, 352, 362, 372 and 382, (see Table D) or a variant sequence that differs only by one or two amino acids or has at least or about 70% sequence identity; (b) an HC CDR2 amino acid sequence selected from the group consisting of: SEQ ID NOs: 313, 323, 333, 343, 353, 363, 373 and 383, (see Table D) or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (c) an HC CDR3 amino acid sequence selected from the group consisting of: SEQ ID NOs: 314, 324, 334, 344, 354, 364, 374 and 384, (see Table D) or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (d) an amino acid sequence of light chain CDR1 (LC) selected from the group consisting of: 315, 325, 335, 345, 355, 365, 375 and 385, (see Table D) or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (e) an LC CDR2 amino acid sequence selected from the group consisting of: 316, 326, 336, 346, 356, 366, 376 and 386,
[00173] [00173] In exemplary aspects, the anti-PD-1 antibody (or its antigen-binding antibody fragment) comprises an LC CDR1 amino acid sequence, an LC CDR2 amino acid sequence and a CDR3 amino acid sequence LC numbers shown in Table D and at least 1 or 2 of the HC CDR amino acid sequences shown in Table D. In exemplary aspects, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises a sequence of HC CDR1 amino acids, an HC CDR2 amino acid sequence and an HC CDR3 amino acid sequence shown in Table D and at least 1 or 2 of the LC CDR amino acid sequences shown in Table D. In some embodiments , the anti-PD-1 antibody protein product comprises such CDRs.
[00174] [00174] In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises 3, 4, 5, or all 6 of the amino acid sequences designated by SEQ ID NOs: in a single column of Table D. In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises each of the LC CDR amino acid sequences designated by SEQ ID NOs: from a single column in Table D and at least 1 or 2 of the HC CDR amino acid sequences designated by SEQ ID NOs: in the same single column or in another single column in Table D. In exemplary embodiments, the anti-PD-1 antibody (or its antibody fragment from antigen binding) comprises each of the HC CDR amino acid sequences designated by SEQ ID NOs: from a single column of Table D and at least 1 or 2 of the LC CDR amino acid sequences designated by SEQ ID NOs: in the same single column or another single column single from Table D. In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises six CDR amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 312- 317 ; (b) SEQ ID NOs: 322-327; (c) SEQ ID NOs: 332-337; (d) SEQ ID NOs: 342-347; (e) SEQ ID NOs: 352-357; (f) SEQ ID NOs: 362-367; (g) SEQ ID NOs: 372-377; and (h) SEQ ID NOs: 382-387. In specific embodiments, the anti-PD-1 antibody (or its antigen-binding antibody fragment) comprises all 6 of the CDR amino acid sequences in Table D for any of the 20A2, 20C1, 22D4, 20C1.006 antibodies, 20C1.009, 20A2.003, 22D4.006 or 22D4.017. In some embodiments, the anti-PD-1 antibody protein product comprises such CDRs.
[00175] [00175] In exemplary cases, the amino acid sequences in Table D are separated by at least one or more (eg, at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) intervening amino acid (s). In exemplary cases, there are about 10 to about 20 amino acids between the LC CDR1 and LC CDR2 sequences and about 25 to about 40 amino acids between the LC CDR2 and LC CDR3 sequences. In exemplary cases there are about 14 to about 16 amino acids between the LC CDR1 and LC CDR2 sequences and about 30 to about 35 amino acids between the LC CDR2 and LC CDR3 sequences. In exemplary cases, there are about 10 to about 20 amino acids between the HC CDR1 and HC CDR2 sequences and about 25 to about 40 amino acids between the HC CDR2 and HC CDR3 sequences. In exemplary cases, there are about 14 to about 16 amino acids between the HC CDR1 and HC CDR2 sequences and about 30 to about 35 amino acids between the HC CDR2 and HC CDR3 sequences.
[00176] [00176] In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises (a) an amino acid sequence of the heavy chain variable region selected from the group consisting of: 318, 328, 338 , 348, 358, 368, 378 and 388, (see Table E) or a variant sequence that differs only by one or two amino acids or has at least or about 70% sequence identity; or (b) a light chain variable region amino acid sequence selected from the group consisting of: 319, 329, 339, 349, 359, 369, 379 and 389, (see Table E) or a variant sequence that differs only in one or two amino acids or that has at least or about 70% sequence identity; or (c) either (a) or (b). In some embodiments, the anti-PD-1 antibody protein product comprises such variable regions.
[00177] [00177] In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 318 and 319; (b) SEQ ID NOs: 328 and 329; (c) SEQ ID NOs: 338 and 339; (d) SEQ ID NOs: 348 and 349; (e) SEQ ID NOs: 358 and 359; (f) SEQ ID NOs: 368 and 369; (g) SEQ ID NOs: 378 and 379; and (h) SEQ ID NOs: 388 and 389.
[00178] [00178] In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises (a) a heavy chain amino acid sequence selected from the group consisting of: 320, 330, 340, 350, 360, 370, 380 and 390, (see Table E) or a sequence variant that differs only by one or two amino acids or has at least or about 70% sequence identity; or (b) a light chain amino acid sequence selected from the group consisting of: 321, 331, 341, 351, 361, 371, 381 and 391, (see Table E) or a variant sequence that differs only in one or two amino acids or that has at least or about 70% sequence identity; or (c) either (a) or (b). In some embodiments, the anti-PD-1 antibody protein product comprises such variable regions.
[00179] [00179] In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 320 and 321; (b) SEQ ID NOs: 330 and 331; (c) SEQ ID NOs: 340 and 341; (d) SEQ ID NOs: 350 and 351; (e) SEQ ID NOs: 360 and 361; (f) SEQ ID NOs: 370 and 371; (g) SEQ ID NOs: 380 and 381; and (h) SEQ ID NOs: 390 and 391. In some embodiments, the anti-PD-1 antibody protein product comprises such regions.
[00180] [00180] In exemplary aspects, the heavy chain amino acid sequences of the anti-PD-1 antibody (or its antigen binding antibody fragment) comprise a set of charge pair mutations, as described here. In particular aspects, the heavy chain amino acid sequences of the anti-PD-1 antibody (or its antigen binding antibody fragment) comprise mutations of charge pairs selected from the mutations of charge pairs V1, V103 and V131.
[00181] [00181] In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises an amino acid sequence that is similar to an amino acid sequence referenced above, however, the antigen-binding protein substantially retains its biological function, eg, its ability to bind to PD-1, eg, human PD-1, cinomologist PD-1, or to decrease, block, inhibit, revoke or interfere with signal transduction resulting from the interaction of PD-1 with one or more of its binding partners, such as PD-L1 or PD-L2.
[00182] [00182] In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises an amino acid sequence that differs only by 1, 2, 3, 4 , 5, 6 or more amino acids in relation to the amino acid sequence (s) referenced above. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises a sequence variant of the referenced sequence, which variant sequence differs only by one or two amino acids , in relation to the referenced sequence. In exemplary aspects, the antigen-binding protein comprises one or more amino acid substitutions that occur outside the CDRs, e.g., one or more amino acid substitutions occur within the heavy chain framework region (s) or light. In exemplary aspects, the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product comprises one or more amino acid substitutions, however the antigen binding protein retains the sequences of amino acids from the six CDRs. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises an amino acid sequence having only 1, 2, 3, 4, 5, 6 or more conservative amino acid substitutions, in relation to the above-mentioned amino acid sequence (s).
[00183] [00183] In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises an amino acid sequence that is more than or about 30%, more than or about 50% or more than or about 70% sequence identity to the above-referenced amino acid sequence (s). In exemplary aspects, the antigen-binding protein comprises an amino acid sequence that is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85 %, at least 90% or has more than 90% sequence identity with the amino acid sequence referenced above. In exemplary aspects, the antigen-binding protein comprises an amino acid sequence that has at least 70%, at least 80%, at least 85%, at least 90% or has more than 90% sequence identity over the entire length of the amino acid sequence referenced above. In exemplary aspects, the antigen-binding protein comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity along the entire length of the aforementioned amino acid sequence.
[00184] [00184] In exemplary aspects, the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product comprises a sequence variant of the referenced sequence, which variant sequence has at least or about 70% sequence identity, relative to the sequence referenced above. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises a sequence variant of the referenced sequence, which variant sequence has at least or about 80 % sequence identity, in relation to the sequence referenced above. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises a sequence variant of the referenced sequence, which variant sequence has at least or about 90 % sequence identity, in relation to the sequence referenced above. In exemplary aspects, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises a sequence variant of the referenced sequence, which variant sequence is at least or about 95 % sequence identity, in relation to the sequence referenced above.
[00185] [00185] In exemplary embodiments, the anti-PD-1 antibody (or its antigen-binding antibody fragment) comprises one, two, three, four or five sequences of SEQ ID NOs. in a single column of Table D and at least one variant sequence having at least about 70% (e.g., at least about 80%, at least about 90%, at least about 95%) identity of sequence with any of SEQ ID NOs: 312-387. In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises one, two, three, four or five sequences from a set of sequences selected from: (a) SEQ ID NOs: 312- 317; (b) SEQ ID NOs: 322-327; (c) SEQ ID NOs: 332-337; (d) SEQ ID NOs: 342-347; (e) SEQ ID NOs: 352-357; (f) SEQ ID NOs: 362-367; (g) SEQ ID NOs: 372-377; and (h) SEQ ID NOs:
[00186] [00186] In exemplary embodiments, the anti-PD-1 antibody product (or its antigen binding antibody fragment) comprises a pair of variant sequences having at least or about 70% (e.g., at least about 80%, at least about 90%, at least about 95%) sequence identity with any of SEQ ID NOs: 318, 319, 328, 329, 338, 339, 348, 349, 358, 359, 368, 369, 378, 379, 388 and
[00187] [00187] In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises a pair of variant sequences having at least or about 70% (e.g., at least about 80 %, at least about 90%, at least about 95%) sequence identity with any of SEQ ID NOs: 320, 321, 330, 331, 340, 341, 350, 351, 360, 361, 370, 371, 380, 381, 390 and 391. In exemplary cases, the anti-PD-1 antibody (or its antigen-binding antibody fragment) comprises a pair of variant sequences that are at least or about 70% (e.g. at least about 80%, at least about 90%, at least about 95%) of sequence identity with (a) SEQ ID NOs: 320 and 321; (b) SEQ ID NOs: 330 and 331; (c) SEQ ID NOs: 340 and 341; (d) SEQ ID NOs: 350 and 351; (e) SEQ ID NOs: 360 and 361; (f) SEQ ID NOs: 370 and 371; (g) SEQ ID NOs: 380 and 381; and (h) SEQ ID NOs: 390 and 391. In exemplary embodiments, the anti-PD-1 antibody product (or its antigen binding antibody fragment) comprises a pair of sequences: a sequence from Table E and another sequence which is a variant sequence having at least or about 70% (e.g., at least about 80%, at least about 90%, at least about 95%) of sequence identity with any of SEQ ID NOs: 320, 321, 330, 331, 340, 341, 350, 351, 360, 361, 370, 371, 380, 381, 390 and
[00188] [00188] In additional exemplary aspects, the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product comprises one or more amino acid modifications, relative to the naturally occurring counterpart, in order to improve half-life / stability or to make the antibody more suitable for expression / manufacture (eg, as a fusion protein with IL-21 mutein). In exemplary cases, the anti-PD-1 antibody is designed to prevent or reduce the interaction between the anti-PD-1 antibody and Fc receptors. In exemplary cases, the anti-PD-1 antibody is an antibody without Stable Effector Function (SEFL) comprising a constant region that does not have the ability to interact with Fcγ receptors. SEFL antibodies are well known in the art. See, e.g., Liu et al., J Biol Chem 292: 1876-1883 (2016); and Jacobsen et al., J. Biol. Chem. 292: 1865-1875 (2017). In exemplary aspects, the SEFL antibody comprises one or more of the following mutations, numbered according to the EU system: L242C, A287C, R292C, N297G, V302C, L306C and / or K334C. In exemplary aspects, the SEFL antibody comprises N297G. In exemplary aspects, the SEFL antibody comprises A287C, N297G and L306C. In other exemplary aspects, the SEFL antibody comprises R292C, N297G and V302C (i.e., SEFL2-2).
[00189] [00189] The anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product may comprise other half-life extension (HLE) modifications. In exemplary cases, the HLE modification occurs in the heavy chain constant region and comprises one or more of the following mutations, numbered according to the EU system: M252Y, S254T and T256E. In exemplary cases, the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product comprises one or two of M252Y, S254T and T256E. In exemplary cases, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises all three of M252Y, S254T and T256E. In exemplary aspects, the heavy chain constant region comprises an amino acid sequence of SEQ ID NO: 545 or SEQ ID NO: 547 or SEQ ID NO: 549 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or has more than about 90% (e.g., about 91% , about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 545 or SEQ ID NO: 547 or SEQ ID NO: 549. In exemplary cases, the HLE modification occurs in the heavy chain constant region and comprises one or more of the following mutations, numbered according to the EU system: L309D, Q311H and N434S .
[00190] [00190] In exemplary aspects, the anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product comprises SEFL2-2 modifications and HLE modifications.
[00191] [00191] Two types of glycosylation reactions occur in eukaryotic cells: (1) N-linked glycosylation, in which glycans are attached to the asparagine of the Asn-X-Thr / Ser recognition sequence, where “X” is any amino acid except proline and (2) O-linked glycosylation, in which glycans are attached to serine or threonine. N-linked glycosylation begins at the Endoplasmic Reticulum (ER), where a complex set of reactions results in the attachment of a nuclear glycan structure consisting essentially of two GlcNAc residues and three Man residues. The glycan complex formed in the ER is modified by the action of enzymes in the Golgi apparatus. If the saccharide is relatively inaccessible to enzymes, it typically remains in the original HM form. If enzymes are able to access the saccharide, then many of Man's residues are separated by cleavage and the saccharide is further modified, resulting in the complex type N-glycans structure. For example, mannosidase-1 located in cis-Golgi can cleave or hydrolyze an HM glycan, while FUT-8 fucosyltransferase, located in the medial Golgi, fucosyl to glycan (Hanrue Imai-Nishiya (2007), BMC Biotechnology, 7: 84 ). In exemplary aspects, the anti-PD-1 antibody is N-glycosylated, e.g., comprises one or more fractions of sugar (e.g., glycans, saccharides) covalently attached to a specific heavy chain amino acid. In alternative aspects, the anti-PD-1 antibody is not glycosylated or does not comprise any sugar fractions (eg, glycans,
[00192] [00192] In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising an amino acid sequence of SEQ ID NO: 284 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or have more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 284 In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising an amino acid sequence of SEQ ID NO: 284 or an amino acid sequence that is at least about 50%, at least about 60% , at least about 70%, at least about 80%, at least about 85%, at least about 90%, or has more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 284 and further comprises a linker. In exemplary cases, the linker comprises the amino acid sequence of SEQ ID NO: 262. Thus, in some exemplary aspects, the anti-PD-1 antibody comprises an amino acid sequence of the heavy chain constant region of SEQ ID NO: 287 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90% or more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98 % or about 99%) sequence identity with SEQ ID NO: 287. In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising an amino acid sequence of SEQ ID NO: 284 or a sequence of amino acids that has at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least ce about 90% or more than about 90% (eg, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) sequence identity with SEQ ID NO: 284, with the C-terminal Lys cut or removed.
[00193] [00193] In exemplary aspects, the IL-21 mutein is attached to the anti-PD-1 antibody Fc. In exemplary aspects, the IL-21 mutein is attached to one of the two heavy chains of the antibody. In exemplary aspects, the IL-21 mutein is attached to the C-terminus of one of the two heavy chains of the antibody.
[00194] [00194] In exemplary aspects, the fusion protein comprises only an IL-21 mutein (i.e., the fusion protein comprises an IL-21 mutein monomer). In exemplary aspects, the IL-21 mutein is attached to the C-terminus of one of the two heavy chains of the antibody. In exemplary aspects, when the fusion protein comprises only one IL-21 mutein, the antibody Fc comprises modifications designed to direct the heterodimerization of the two heavy chains (a heavy chain fused to IL-21 mutein and a heavy chain having no IL-21 mutein). Such modifications include Fc mutations such as knobs-into-holes, DuoBodies, Azimetric, load pair, HA-TF, SEEDbody and modifications with differential protein A affinity. See, eg, Spiess et al., Molecular Immunology , 67 (2, Part A), 2015, pp. 95-106. Knobs-into-holes mutations include T366W in the first heavy chain and T366S, L368A and / or Y407V in the second heavy chain. See, e.g., Ridgway et al., Protein Eng., 9 (1996), pp. 617-621; and Atwell et al., J. Mol. Biol., 270 (1997), pp. 26-35. DuoBody mutations include F405L in the first heavy chain and K409R in the second heavy chain. See, e.g., Labrijn et al., Proc. Natl. Acad. Sci. U.S.A., 110 (2013), pp. 5145-5150. Azimetric mutations include T350V, L351Y, F405A and / or Y407V in the first heavy chain and T350V, T366L, K392L and / or T394W in the second heavy chain. See, eg, Von Kreudenstein et al., MAbs, 5 (2013), pp. 646-654. HA-TF mutations include S364H and / or F405A in the first heavy chain and Y349T and / or T394F in the second heavy chain. See, eg, Moore et al., MAbs, 3 (2011), pp. 546-557. SEEDbody mutations include IgG / A chimera mutations in the first heavy chain and IgG / A chimera mutations in the second heavy chain. See, eg, Davis et al., Protein Eng. Des. Sel., 23 (2010), pp. 195-202. Mutations with differential protein A affinity include H435R in one heavy chain and no mutations in the other heavy chain. See, e.g., U.S. Patent No. 8,586,713.
[00195] [00195] In a particular example, mutations are mutations of charge pairs. The following are examples of such charge pair mutations, numbered according to the EU system. Charge pair mutations include K409D in the first heavy chain and D399K in the second heavy chain; K392D on the first heavy chain and E356K on the second heavy chain; or K409D and K392D on the first heavy chain and D399K and E356K on the second heavy chain (the latter denoted as “V1” here). See, e.g., Gunasekaran et al., J Biol Chem 285: 19637-19646 (2010). In another particular example, charge pair mutations include K439D, K392D and K409D in the first heavy chain; and E356K and D399K on the second heavy chain (denoted “V103” here). In yet another particular example, charge pair mutations include K360E, K370E, K392E and K409D in the first heavy chain; and E357K and D399K on the second heavy chain (denoted “V131” here). Charge pair mutations can also include K370D in the first heavy chain and E357K in the second heavy chain; or all three K409D, K392D and K370D on the first heavy chain and all three D399K, E357K and E356K on the second heavy chain (the latter denoted as “V4” here). Additional charge pair mutations also include D221E, P228E and / or L368E in the first heavy chain and D221R, P228R and / or K409R in the second heavy chain. See, e.g., Strop et al., J. Mol. Biol., 420 (2012), pp. 204-219.
[00196] [00196] In embodiments where the fusion protein comprises only one IL-21 mutein (ie, the fusion protein comprises an IL-21 mutein monomer) and the heavy chain contains the V1 charge pair mutations, mutein IL-21 can be attached to the heavy chain containing the K409D and K392D mutations (eg, IL-21 mutein is attached to a heavy chain comprising SEQ ID NO: 294, 296 or 298) or to the heavy chain containing the D399K and E356K mutations (eg, IL-21 mutein is attached to a heavy chain comprising SEQ ID NO: 295, 297 or 299. In a specific embodiment, IL-21 mutein is attached to the heavy chain containing the D399K and E356K mutations.
[00197] [00197] In embodiments where the fusion protein comprises only one IL-21 mutein (ie, the fusion protein comprises an IL-21 mutein monomer) and the heavy chain contains the V4 charge pair mutations, mutein of IL-21 may be attached to the heavy chain containing the K409D, K392D and K370D mutations (eg, IL-21 mutein is attached to a heavy chain comprising SEQ ID NO: 288, 290 or 292) or to the chain heavy containing the D399K, E357K and E356K mutations (e.g., IL-21 mutein is attached to a heavy chain comprising SEQ ID NO: 289, 291 or 293). In a specific embodiment, the IL-21 mutein is attached to the heavy chain containing the D399K, E357K and E356K mutations.
[00198] [00198] In embodiments where the fusion protein comprises only one IL-21 mutein (ie, the fusion protein comprises an IL-21 mutein monomer) and the heavy chain contains the V103 charge pair mutations, mutein IL-21 may be attached to the heavy chain containing the K439D, K392D and K409D mutations (eg, IL-21 mutein is attached to a heavy chain comprising SEQ ID NO: 472, 474 or 476) or to the chain heavy containing E356K and D399K mutations (e.g., IL-21 mutein is attached to a heavy chain comprising SEQ ID NO: 473, 475 or 477). In a specific embodiment, the IL-21 mutein is attached to the heavy chain containing the E356K and D399K mutations.
[00199] [00199] In embodiments where the fusion protein comprises only one IL-21 mutein (ie, the fusion protein comprises an IL-21 mutein monomer) and the heavy chain contains the V131 charge pair mutations, mutein IL-21 can be attached to the heavy chain containing the K360E, K370E, K392E and K409D mutations (eg, IL-21 mutein is attached to a heavy chain comprising SEQ ID NO: 478, 480 or 482) or to the heavy chain containing the E357K and D399K mutations (e.g., the IL-21 mutein is attached to a heavy chain comprising SEQ ID NO: 479, 481 or 483). In a specific embodiment, the IL-21 mutein is attached to the heavy chain containing the E357K and D399K mutations.
[00200] [00200] Thus, in exemplary aspects, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises a set of charge pair mutations, as described here. In particular aspects, the anti-
[00201] [00201] In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising an amino acid sequence of SEQ ID NO: 284 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or have more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 284 , with one or more mutations of load pairs, eg mutations of load pairs V1, V4, V103 or V131. In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising an amino acid sequence of SEQ ID NO: 284 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or has more than about 90% (e.g., about 91%, about 92 %, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 284, with mutations of load pairs V1, in which a first heavy chain constant region comprises mutations K409 and K392D and a second heavy chain constant region comprises mutations D399K and E356K. Such a first heavy chain constant region can comprise the sequence of SEQ ID NO: 294 and such a second heavy chain constant region can comprise the sequence of SEQ ID NO: 295. Such first and second heavy chain constant regions can have the C-terminal Lys cut or removed such that the first and second heavy chain constant regions can comprise SEQ ID NO: 296 and 297, respectively. Such first and second heavy chain constant regions can have the C-terminal Lys cut or removed and a linker such that the first and second heavy chain constant regions can comprise SEQ ID NO: 298 and 299, respectively. In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising V1 charge pair mutations and SEFL2-
[00202] [00202] In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising an amino acid sequence of SEQ ID NO: 284 or an amino acid sequence that is at least about
[00203] [00203] In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising an amino acid sequence of SEQ ID NO: 284 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or have more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 284 , with V103 load pair mutations, where a first heavy chain constant region comprises the sequence of SEQ ID NO: 484 and a second heavy chain constant region comprises the sequence of SEQ ID NO: 485. Such first and second regions heavy chain constants can have the C-terminal Lys cut or removed such that the first and second heavy chain constant regions can comprise SEQ ID NO: 486 and 487, respectively. Such first and second heavy chain constant regions can have the C-terminal Lys cut or removed and a linker such that the first and second heavy chain constant regions can comprise SEQ ID NO: 488 and 489, respectively. In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising V103 charge pair mutations and SEFL2-
[00204] [00204] In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising an amino acid sequence of SEQ ID NO: 284 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or have more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 284 , with V131 load pair mutations, where a first heavy chain constant region comprises the sequence of SEQ ID NO: 478 and a second heavy chain constant region comprises the sequence of SEQ ID NO: 479. Such first and second regions heavy chain constants can have the C-terminal Lys cut or removed such that the first and second heavy chain constant regions can comprise SEQ ID NO: 480 and 481, respectively. Such first and second heavy chain constant regions can have the C-terminal Lys cut or removed and a linker such that the first and second heavy chain constant regions can comprise SEQ ID NO: 482 and 483, respectively. In exemplary aspects, the anti-PD-1 antibody comprises a heavy chain constant region comprising V131 charge pair mutations and SEFL2-
[00205] [00205] In alternative aspects, the fusion protein comprises more than one IL-21 mutein (i.e., the fusion protein comprises an IL-21 mutein dimer or IL-21 mutein multimer). In alternative exemplary aspects, the fusion protein comprises 2, 3 or 4 (or more) IL-21 muteins. In exemplary aspects, when the fusion protein comprises more than one IL-21 mutein, each IL-21 mutein comprises the same structure, e.g.
[00206] [00206] With respect to fusion proteins comprising one or more IL-21 muteins, each IL-21 mutein can be attached to one of the antibody heavy chains with or without a linker. In exemplary aspects, the IL-21 mutein is attached to the C-terminus of one of the antibody's heavy chains via a linker and the linker is a peptide. In exemplary cases, the peptide comprises the amino acid sequence of GGGGS (SEQ ID NO: 262). In alternative aspects, the IL-21 mutein is directly attached to the C-terminus of one of the antibody's heavy chains without a linker.
[00207] [00207] In exemplary aspects, the fusion protein comprises only an IL-21 mutein that is directly attached to the C-terminus of one of the heavy chains of the anti-PD-1 antibody. In exemplary aspects, IL-21 mutein comprises an amino acid substitution listed in Table 4 or a sequence of a SEQ ID NO: listed in Table 4. In exemplary aspects, IL-21 mutein comprises an amino acid substitution listed in Table 5 or a sequence of a SEQ ID NO: listed in Table 5. In exemplary aspects, the IL-21 mutein comprises the amino acid substitutions listed in Table 7 or a sequence of a SEQ ID NO: listed in Table 7. In exemplary aspects, the IL-21 mutein comprises the amino acid substitutions listed in any of Tables 6 and 8-14 or a sequence of a SEQ ID NO: listed in these Tables. In exemplary aspects, the IL-21 mutein comprises an amino acid sequence of any one of SEQ ID NOs: 159, 161, 238, 241, 242 or 244. In exemplary aspects, the IL-21 mutein is directly attached to the antibody anti-PD-1 and does not comprise a peptide linker.
[00208] [00208] In exemplary aspects, the fusion protein comprises two IL-21 muteins, each of which is directly attached to the C-terminus of an anti-PD-1 antibody heavy chain and each of which has the same sequence of amino acids. In exemplary aspects, IL-21 mutein comprises an amino acid substitution listed in Table 4 or a sequence of a SEQ ID NO: listed in Table 4. In exemplary aspects, IL-21 mutein comprises an amino acid substitution listed in Table 5 or a sequence of a SEQ ID NO: listed in Table 5. In exemplary aspects, the IL-21 mutein comprises the amino acid substitutions listed in Table 7 or a sequence of a SEQ ID NO: listed in Table 7. In exemplary aspects, the IL-21 mutein comprises the amino acid substitutions listed in any of Tables 6 and 8-14 or a sequence of a SEQ ID NO: listed in these Tables. In exemplary aspects, the IL-21 mutein comprises an amino acid sequence of any one of SEQ ID NOs: 159, 161, 237, 238, 241 and 244. In exemplary aspects, the IL-21 mutein is directly attached to the antibody anti-PD-1 and does not comprise a peptide linker.
[00209] [00209] In exemplary aspects, the fusion protein comprises an amino acid sequence from an antibody constant region described herein fused to an amino acid sequence from any IL-21 mutein described here. In exemplary aspects, the fusion protein comprises an amino acid sequence of an antibody constant region described here, which is not glycosylated, fused to an amino acid sequence of any IL-21 mutein described here. In exemplary cases, the fusion protein comprises a constant region comprising an amino acid sequence of any one of SEQ ID NOs: 265-267, 282, 284-311, 472-495 and 544-555 or an amino acid sequence that has at least at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90% or more than about 90% ( eg, about
[00210] [00210] In exemplary embodiments, the fusion protein comprises a construct as described in Figure 4A, 4B or 4C. In exemplary embodiments, the fusion protein comprises (i) an anti-PD-1 antibody (or its antigen binding antibody fragment) described herein; and (ii) an IL-21 mutein described here. In additional exemplary embodiments, the fusion protein comprises (i) an anti-PD-1 antibody (or its antigen binding antibody fragment) described herein; (ii) a charge pair mutation described here; and (iii) an IL-21 mutein described here (see, e.g., Figure 4C). In other exemplary embodiments, the fusion protein comprises (i) an anti-PD-1 antibody (or its antigen-binding antibody fragment) described herein, wherein the heavy chain sequences of said anti-PD-1 antibody ( or its antigen binding antibody fragment)) do not comprise a C-terminal lysine; (ii) a charge pair mutation described here; and (iii) an IL-21 mutein described here.
[00211] [00211] In exemplary cases, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises (a) an amino acid sequence of the heavy chain (HC) complementarity determining region (CDR) 1 shown in Table D or a selected sequence from the group consisting of: SEQ ID NOs: 312, 322, 332, 342, 352, 362, 372 and 382 or a variant sequence that differs only by one or two amino acids or has at least or about 70% sequence identity; (b) an HC CDR2 amino acid sequence shown in Table D or a sequence selected from the group consisting of: SEQ ID NOs: 313, 323, 333, 343, 353, 363, 373 and 383 or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (c) an HC CDR3 amino acid sequence shown in Table D or a sequence selected from the group consisting of: SEQ ID NOs:
[00212] [00212] In exemplary embodiments, the anti-PD-1 antibody (or its antigen binding antibody fragment) comprises (a) an amino acid sequence of the heavy chain variable region shown in Table E or a sequence selected from the group consisting of in: 318, 328, 338, 348, 358, 368, 378 and 388 or a variant sequence that differs only in one or two amino acids or has at least or about 70% sequence identity; or (b) a light chain variable region amino acid sequence shown in Table E or a sequence selected from the group consisting of: 319, 329, 339, 349, 359, 369, 379 and 389 or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; or (c) either (a) or (b). In exemplary embodiments, the anti-PD-1 antibody (or its antigen-binding antibody fragment) comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 318 and 319; (b) SEQ ID NOs: 328 and 329; (c) SEQ ID NOs: 338 and 339; (d)
[00213] [00213] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4A, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357) , the three heavy chain CDRs of antibody 20C1.009 (SEQ ID NOs: 352-354) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations (eg, SEQ ID NO: 265 or 266) , wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76A (ie, each comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 358 and a light chain variable region of SEQ ID NO: 359. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 360 or the light chain of SEQ ID NO: 361. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 361 and 562 or SEQ ID NOs: 361 and 563. In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 361) and two antibody heavy chains (each of which is fused to a IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 562). In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 361) and two antibody heavy chains (each of which is fused to an IL mutein) -21, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 563).
[00214] [00214] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4A, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357) , the three heavy chain CDRs of antibody 20C1.009 (SEQ ID NOs: 352-354) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations (eg, SEQ ID NO: 265 or 266) , wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76E (ie, each comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 358 and a light chain variable region of SEQ ID NO: 359. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 360 or the light chain of SEQ ID NO: 361. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 361 and 564 or SEQ ID NOs: 361 and 565. In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 361) and two antibody heavy chains (each of which is fused to a IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 564). In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 361) and two antibody heavy chains (each of which is fused to an IL mutein) -21, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 565).
[00215] [00215] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4B, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357) , the three heavy chain CDRs of antibody 20C1.009 (SEQ ID NOs: 352-354) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations and a linker (eg, SEQ ID NO:
[00216] [00216] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4B, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357) , the three heavy chain CDRs of antibody 20C1.009 (SEQ ID NOs: 352-354) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations and a linker (eg, SEQ ID NO: 267 ), wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76E (ie, each comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 358 and a light chain variable region of SEQ ID NO: 359. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 360 or the light chain of SEQ ID NO: 361. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 361 and 567. In exemplary aspects, the The fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 361) and two antibody heavy chains (each of which is fused to an IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 567).
[00217] [00217] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357), the three 20C1.009 antibody heavy chain CDRs (SEQ ID NOs: 352-354) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V1 charge pair mutations (eg SEQ ID NOs: 306 and 307 or SEQ ID NOs: 308 and 309), where the IL-21 mutein monomer is attached to the heavy chain containing the V1 E356K and D399K charge pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising any of SEQ ID NOs: 309), and where the IL-21 mutein comprises the amino acid substitutions R9E and R76A (ie , comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 358 and a light chain variable region of SEQ ID NO: 359. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 360 or the light chain of SEQ ID NO: 361. In exemplary cases, the fusion protein comprises a monomer comprising the amino acid sequences of SEQ ID NOs: 361 and 568. In exemplary aspects, the The fusion protein comprises a monomer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 361) and two different antibody heavy chains (one of which is fused to an IL-21 mutein and comprises the amino acid sequence of SEQ ID NO: 568 and one of which is not fused to an IL-21 mutein and comprises the amino acid sequence of SEQ ID NO: 574).
[00218] [00218] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357), the three 20C1.009 antibody heavy chain CDRs (SEQ ID NOs: 352-354) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V103 load pair mutations (eg SEQ ID NOs: 484 and 485 or SEQ ID NOs: 486 and 487), where the IL-21 mutein monomer is attached to the heavy chain containing the V103 E356K and D399K load pair mutations (eg, ie, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 487), and where IL-21 mutein comprises the amino acid substitutions R9E and R76A (ie, comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 358 and a light chain variable region of SEQ ID NO: 359. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 360 or the light chain of SEQ ID NO: 361. In exemplary cases, the fusion protein comprises a monomer comprising the amino acid sequences of SEQ ID NOs: 361 and 569. In exemplary aspects, the The fusion protein comprises a monomer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 361) and two different antibody heavy chains (one of which is fused to an IL-21 mutein and comprises the amino acid sequence of SEQ ID NO: 569 and one of which is not fused to an IL-21 mutein and comprises the amino acid sequence of SEQ ID NO: 575).
[00219] [00219] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357), the three 20C1.009 antibody heavy chain CDRs (SEQ ID NOs: 352-354) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V131 load pair mutations (eg SEQ ID NOs: 490 and 491 or SEQ ID NOs: 492 and 493), where the IL-21 mutein monomer is attached to the heavy chain containing the V131 E357K and D399K charge pair mutations (eg, the IL-mutein monomer
[00220] [00220] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357), the three 20C1.009 antibody heavy chain CDRs (SEQ ID NOs: 352-354) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V1 charge pair mutations (eg SEQ ID NOs: 306 and 307 or SEQ ID NOs: 308 and 309), where the IL-21 mutein monomer is attached to the heavy chain containing the V1 E356K and D399K charge pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 309), and where IL-21 mutein comprises amino acid substitutions R9E and R76E (ie, comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 358 and a light chain variable region of SEQ ID NO: 359. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 360 or the light chain of SEQ ID NO:
[00221] [00221] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357), the three 20C1.009 antibody heavy chain CDRs (SEQ ID NOs: 352-354) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V103 load pair mutations (eg SEQ ID NOs: 484 and 485 or SEQ ID NOs: 486 and 487), where the IL-21 mutein monomer is attached to the heavy chain containing the V103 E356K and D399K load pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 487), and where the IL-21 mutein comprises the amino acid substitutions R9E and R76E (ie, comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 358 and a light chain variable region of SEQ ID NO: 359. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 360 or the light chain of SEQ ID NO:
[00222] [00222] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20C1.009 antibody (SEQ ID NOs: 355-357), the three 20C1.009 antibody heavy chain CDRs (SEQ ID NOs: 352-354) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V131 load pair mutations (eg SEQ ID NOs: 490 and 491 or SEQ
[00223] [00223] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4A, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387) , the three 22D4.017 antibody heavy chain CDRs (SEQ ID NOs: 382-384) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations (eg, SEQ ID NO: 265 or 266) ,
[00224] [00224] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4A, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387) , the three 22D4.017 antibody heavy chain CDRs (SEQ ID NOs: 382-384) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations (eg, SEQ ID NO: 265 or 266) , wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76E (ie, each comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 388 and a light chain variable region of SEQ ID NO: 389. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 390 or the light chain of SEQ ID NO: 391. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 389 and 497 or SEQ ID NOs: 389 and 498. In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 391) and two antibody heavy chains (each of which is fused to a IL-21 mutein, and the fused IL-21 heavy-mutein chain comprises the amino acid sequence of SEQ ID NO: 497). In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 391) and two antibody heavy chains (each of which is fused to an IL mutein -21, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 498).
[00225] [00225] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4B, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387) , the three 22D4.017 antibody heavy chain CDRs (SEQ ID NOs: 382-384) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations and a linker (eg, SEQ ID NO: 267 ), wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76A (ie, each comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 388 and a light chain variable region of SEQ ID NO: 389. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 390 or the light chain of SEQ ID NO: 391. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 389 and 499. In exemplary aspects, the The fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 391) and two antibody heavy chains (each of which is fused to an IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 499).
[00226] [00226] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4B, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387) , the three 22D4.017 antibody heavy chain CDRs (SEQ ID NOs: 382-384) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations and a linker (eg, SEQ ID NO: 267 ), wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76E (ie, each comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 388 and a light chain variable region of SEQ ID NO: 389. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 390 or the light chain of SEQ ID NO: 391. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 389 and 500. In exemplary aspects, the The fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 391) and two antibody heavy chains (each of which is fused to an IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 500).
[00227] [00227] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387), the three heavy chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 382-384) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V1 charge pair mutations (e.g., SEQ ID NOs: 306 and 307 or SEQ ID
[00228] [00228] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387), the three heavy chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 382-384) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V103 load pair mutations (eg SEQ ID NOs: 484 and 485 or SEQ ID NOs: 486 and 487), where the IL-21 mutein monomer is attached to the heavy chain containing the V103 E356K and D399K load pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 487), and where IL-21 mutein comprises amino acid substitutions R9E and R76A (ie, comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 388 and a light chain variable region of SEQ ID NO: 389. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 390 or the light chain of SEQ ID NO:
[00229] [00229] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387), the three heavy chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 382-384) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V131 load pair mutations (eg SEQ ID NOs: 490 and 491 or SEQ ID NOs: 492 and 493), where the IL-21 mutein monomer is attached to the heavy chain containing the V131 E357K and D399K charge pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 493), and where IL-21 mutein comprises amino acid substitutions R9E and R76A (ie, comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 388 and a light chain variable region of SEQ ID NO: 389. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 390 or the light chain of SEQ ID NO:
[00230] [00230] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387), the three heavy chain CDRs of antibody 22D4.017 (SEQ ID NOs:
[00231] [00231] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387), the three heavy chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 382-384) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V103 load pair mutations (eg SEQ ID NOs: 484 and 485 or SEQ ID NOs: 486 and 487), where the IL-21 mutein monomer is attached to the heavy chain containing the V103 E356K and D399K load pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 487), and where the IL-21 mutein comprises the amino acid substitutions R9E and R76E (ie, comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 388 and a light chain variable region of SEQ ID NO: 389. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 390 or the light chain of SEQ ID NO:
[00232] [00232] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 385-387), the three heavy chain CDRs of the 22D4.017 antibody (SEQ ID NOs: 382-384) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V131 load pair mutations (eg SEQ ID NOs: 490 and 491 or SEQ ID NOs: 492 and 493), where the IL-21 mutein monomer is attached to the heavy chain containing the V131 E357K and D399K charge pair mutations (e.g., the IL-21 mutein monomer is attached to a heavy chain comprising any of SEQ ID NOs: 493), and the IL-21 mutein comprises amino acid substitutions R9E and R76E (ie , comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 388 and a light chain variable region of SEQ ID NO: 389. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 390 or the light chain of SEQ ID NO: 391. In exemplary cases, the fusion protein comprises a monomer comprising the amino acid sequences of SEQ ID NOs: 389 and 506. In exemplary aspects, the The fusion protein comprises a monomer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 391) and two different antibody heavy chains (one of which is fused to an IL-21 mutein and comprises the amino acid sequence of SEQ ID NO: 506 and one of which is not fused to an IL-21 mutein and comprises the amino acid sequence of SEQ ID NO: 558).
[00233] [00233] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4A, wherein the anti-PD-1 antibody comprises the three light chain CDRs of antibody 20A2.003 (SEQ ID NOs: 365-367) , the three heavy chain CDRs of antibody 20A2.003 (SEQ ID NOs: 362-364) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations (eg, SEQ ID NO: 265 or 266) , wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76A (ie, each comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 368 and a light chain variable region of SEQ ID NO: 369. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 370 or the light chain of SEQ ID NO: 371. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 369 and 507 or SEQ ID NOs: 369 and 508. In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 371) and two antibody heavy chains (each of which is fused to a IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 507). In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 371) and two antibody heavy chains (each of which is fused to an IL mutein -21, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 508).
[00234] [00234] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4A, where the anti-PD-1 antibody comprises the three light chain CDRs of antibody 20A2.003 (SEQ ID NOs: 365-367) , the three heavy chain CDRs of antibody 20A2.003 (SEQ ID NOs: 362-364) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations (eg, SEQ ID NO: 265 or 266) , wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76E (ie, each comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 368 and a light chain variable region of SEQ ID NO: 369. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 370 or the light chain of SEQ ID NO: 371. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 369 and 509 or SEQ ID NOs: 369 and 510. In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 371) and two antibody heavy chains (each of which is fused to a IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 509). In exemplary aspects, the fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 371) and two antibody heavy chains (each of which is fused to an IL mutein -21, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 510).
[00235] [00235] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4B, wherein the anti-PD-1 antibody comprises the three light chain CDRs of antibody 20A2.003 (SEQ ID NOs: 365-367) , the three 20A2.003 antibody heavy chain CDRs (SEQ ID NOs: 362-364) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations and a linker (eg, SEQ ID NO: 267 ), wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76A (ie, each comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 368 and a light chain variable region of SEQ ID NO: 369. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 370 or the light chain of SEQ ID NO: 371. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 369 and 511. In exemplary aspects, the The fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 371) and two antibody heavy chains (each of which is fused to an IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 511).
[00236] [00236] In exemplary cases, the fusion protein comprises a homodimer as shown in Figure 4B, wherein the anti-PD-1 antibody comprises the three light chain CDRs of antibody 20A2.003 (SEQ ID NOs: 365-367) , the three 20A2.003 antibody heavy chain CDRs (SEQ ID NOs: 362-364) and each heavy chain comprises a constant region sequence comprising SEFL2-2 mutations and a linker (eg, SEQ ID NO: 267 ), wherein each of the two IL-21 muteins comprises amino acid substitutions R9E and R76E (ie, each comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 368 and a light chain variable region of SEQ ID NO: 369. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 370 or the light chain of SEQ ID NO: 371. In exemplary cases, the fusion protein comprises a homodimer comprising the amino acid sequences of SEQ ID NOs: 369 and 512. In exemplary aspects, the The fusion protein comprises a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 371) and two antibody heavy chains (each of which is fused to an IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 512).
[00237] [00237] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in
[00238] [00238] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20A2.003 antibody (SEQ ID NOs: 365-367), the three heavy chain CDRs of the 20A2.003 antibody (SEQ ID NOs: 362-364) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V103 load pair mutations (eg SEQ ID NOs: 484 and 485 or SEQ ID NOs: 486 and 487), where the IL-21 mutein monomer is attached to the heavy chain containing the V103 E356K and D399K load pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 487), and where IL-21 mutein comprises amino acid substitutions R9E and R76A (ie, comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 368 and a light chain variable region of SEQ ID NO: 369. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 370 or the light chain of SEQ ID NO:
[00239] [00239] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20A2.003 antibody (SEQ ID NOs: 365-367), the three 20A2.003 antibody heavy chain CDRs (SEQ ID NOs: 362-364) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V131 load pair mutations (eg SEQ ID NOs: 490 and 491 or SEQ ID NOs: 492 and 493), where the IL-21 mutein monomer is attached to the heavy chain containing the V131 E357K and D399K charge pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 493), and where IL-21 mutein comprises amino acid substitutions R9E and R76A (ie, comprises the sequence of SEQ ID NO: 244). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 368 and a light chain variable region of SEQ ID NO: 369. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 370 or the light chain of SEQ ID NO:
[00240] [00240] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20A2.003 antibody (SEQ ID NOs: 365-367), the three 20A2.003 antibody heavy chain CDRs (SEQ ID NOs: 362-364) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V1 charge pair mutations (eg SEQ ID NOs: 306 and 307 or SEQ ID NOs: 308 and 309), where the IL-21 mutein monomer is attached to the heavy chain containing the V1 E356K and D399K charge pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 309), and where IL-21 mutein comprises amino acid substitutions R9E and R76E (ie, comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 368 and a light chain variable region of SEQ ID NO: 369. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 370 or the light chain of SEQ ID NO:
[00241] [00241] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of antibody 20A2.003 (SEQ ID NOs: 365-367), the three heavy chain CDRs of the 20A2.003 antibody (SEQ ID NOs: 362-364) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V103 load pair mutations (eg SEQ ID NOs: 484 and 485 or SEQ ID NOs: 486 and 487), where the IL-21 mutein monomer is attached to the heavy chain containing the V103 E356K and D399K load pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 487), and where the IL-21 mutein comprises the amino acid substitutions R9E and R76E (ie, comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 368 and a light chain variable region of SEQ ID NO: 369. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 370 or the light chain of SEQ ID NO:
[00242] [00242] In exemplary cases, the fusion protein comprises an IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three light chain CDRs of the 20A2.003 antibody (SEQ ID NOs: 365-367), the three 20A2.003 antibody heavy chain CDRs (SEQ ID NOs: 362-364) and a pair of heavy chains comprising constant region sequences comprising SEFL2-2 mutations and V131 load pair mutations (eg SEQ ID NOs: 490 and 491 or SEQ ID NOs: 492 and 493), where the IL-21 mutein monomer is attached to the heavy chain containing the V1 E357K and D399K charge pair mutations (eg, the IL-21 mutein monomer is attached to a heavy chain comprising SEQ ID NOs: 493), and where the IL-21 mutein comprises the amino acid substitutions R9E and R76E (ie, comprises the sequence of SEQ ID NO: 245). In exemplary cases, the anti-PD-1 antibody comprises a heavy chain variable region of SEQ ID NO: 368 and a light chain variable region of SEQ ID NO: 369. In exemplary cases, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NO: 370 or the light chain of SEQ ID NO:
[00243] [00243] In exemplary cases, the fusion protein comprises an IL-21 mutein homodimer as shown in Figure 4A or 4B, IL-21 mutein monomer as shown in Figure 4C and an anti-PD-1 antibody comprising three 20A2.003 antibody light chain CDRs (SEQ ID NOs: 365-367), the three 20A2.003 antibody heavy chain CDRs (SEQ ID NOs: 362-364), and a heavy chain constant region sequence comprising any of SEQ ID NOs 544-555. In exemplary cases, the fusion protein comprises an IL-21 mutein homodimer as shown in Figure 4A or 4B, IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three Antibody 20A2.003 light chain CDRs (SEQ ID NOs: 365-367), the three antibody 20A2.003 heavy chain CDRs (SEQ ID NOs: 362-364) and a sequence of the SEQ heavy chain constant region ID NO: 525 or 527.
[00244] [00244] In exemplary cases, the fusion protein comprises an IL-21 mutein homodimer as shown in Figure 4A or 4B, IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three 22D4.017 antibody light chain CDRs (SEQ ID NOs: 385-387), the three 22D4.017 antibody heavy chain CDRs (SEQ ID NOs:
[00245] [00245] In exemplary cases, the fusion protein comprises an IL-21 mutein homodimer as shown in Figure 4A or 4B, IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three 20C1.009 antibody light chain CDRs (SEQ ID NOs: 355-357), the three 20C1.009 antibody heavy chain CDRs (SEQ ID NOs: 352-354), and a sequence of the constant region of heavy chain comprising any of SEQ ID NOs 544-555. In exemplary cases, the fusion protein comprises an IL-21 mutein homodimer as shown in Figure 4A or 4B, IL-21 mutein monomer as shown in Figure 4C, wherein the anti-PD-1 antibody comprises the three 20C1.009 antibody light chain CDRs (SEQ ID NOs: 355-357), the three 20C1.009 antibody heavy chain CDRs (SEQ ID NOs: 352-354) and a sequence of the SEQ heavy chain constant region ID NO 521 or 523.
[00246] [00246] The present disclosure provides PD-1 antigen binding proteins. In exemplary aspects, the PD-1 antigen binding protein is an anti-PD-1 antibody, its antigen binding antibody fragment or anti-PD-1 antibody protein product described herein. In exemplary cases, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises (a) an amino acid sequence of the chain complementarity determining region (CDR) 1 heavy (HC) presented in Table D or a sequence selected from the group consisting of: SEQ ID NOs: 312, 322, 332, 342, 352, 362, 372 and 382 or a variant sequence that differs only by one or two amino acids or which has at least or about 70% sequence identity; (b) an HC CDR2 amino acid sequence shown in Table D or a sequence selected from the group consisting of: SEQ ID NOs: 313, 323, 333, 343, 353, 363, 373 and 383 or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (c) an HC CDR3 amino acid sequence shown in Table D or a sequence selected from the group consisting of: SEQ ID NOs: 314, 324, 334, 344, 354, 364, 374 and 384 or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (d) a light chain CDR1 (LC) amino acid sequence shown in Table D or a sequence selected from the group consisting of: 315, 325, 335,
[00247] [00247] In exemplary embodiments, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises six CDR amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 312-317; (b) SEQ ID NOs: 322- 327; (c) SEQ ID NOs: 332-337; (d) SEQ ID NOs: 342-347; (e) SEQ ID NOs: 352-357; (f) SEQ ID NOs: 362-367; (g) SEQ ID NOs: 372-377; and (h) SEQ ID NOs: 382-387. In exemplary cases, the amino acid sequences in Table D are separated by at least one or more (eg, at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid (s ) intervener (s). In exemplary embodiments, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises (a) an amino acid sequence of the heavy chain variable region shown in Table E or a sequence selected from the group consisting of: 318, 328, 338, 348, 358, 368, 378 and 388 or a variant sequence that differs only by one or two amino acids or has at least or about 70% sequence identity ; or (b) a light chain variable region amino acid sequence shown in Table E or a sequence selected from the group consisting of: 319, 329, 339, 349, 359, 369, 379 and 389 or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; or (c) either (a) or (b). In exemplary embodiments, the anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs : 318 and 319; (b) SEQ ID NOs: 328 and 329; (c) SEQ ID NOs: 338 and 339; (d) SEQ ID NOs: 348 and 349; (e) SEQ ID NOs: 358 and 359; (f) SEQ ID NOs: 368 and 369; (g) SEQ ID NOs: 378 and 379; and (h)
[00248] [00248] In some embodiments, the antigen-binding protein described above is an anti-PD-1 antibody or an antigen-binding antibody fragment thereof.
[00249] [00249] The present disclosure further provides conjugates comprising a PD-1 antigen binding protein described herein and a heterologous fraction. The heterologous fraction can be any molecule that is different from the PD-1 antigen binding protein described here. The heterologous fraction, in exemplary aspects, is a heterologous peptide or polypeptide, a targeting agent, a diagnostic tag, a polymer, a nucleic acid, a quantum dot, a small molecule, a toxin, a carbohydrate, an amino acid or other therapeutic or diagnostic agent. In exemplary aspects, the heterologous fraction is an IL-21 mutein as described here.
[00250] [00250] The present disclosure further provides fusion protein comprising a PD-1 antigen binding protein described herein and a heterologous polypeptide or peptide. In exemplary aspects, the heterologous polypeptide is an IL-21 mutein as described here. Antibody Preparation Methods
[00251] [00251] Suitable methods of preparing antibodies, antigen binding antibody fragments and antibody protein products are known in the art. For example, standard hybridoma methods for producing antibodies are described in, eg, Harlow and Lane (eds.), Antibodies: A
[00252] [00252] Depending on the host species, several adjuvants can be used to increase the immune response leading to increased production of antibodies by the host. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, lapa Californian hemocyanin and dinitrophenol. BCG (bacilli Calmette-Guérin) and Corynebacterium parvum are potentially useful human adjuvants.
[00253] [00253] Other methods of antibody production are summarized in Table F.
[00254] [00254] Antibody testing methods for the ability to bind to PD-1 regardless of how antibodies are produced are known in the art and include any antibody-antigen binding assay, such as, for example, radioimmunoassay (RIA) , ELISA, Western blotting, immunoprecipitation, SPR and competitive inhibition assays (see, eg, Janeway et al., Infra and US Patent Application Publication No. 2002/0197266 and the section above relating to assays competition). Other binding assays, eg, competitive binding assays or competition assays, which test an antibody's ability to compete with a second antibody for binding to an antigen, or an epitope thereof, are known in the art and can be used to test an antibody's ability to bind to PD-1. See, e.g., U.S. Patent Application Publication No. US20140178905, Chand et al., Biologicals 46: 168-171 (2017); Liu et al., Anal Biochem 525: 89-91 (2017); ed Goolia et al., J Vet Diagn Invest 29 (2): 250-253 (2017). Likewise, other methods of comparing two antibodies are known in the art and include, for example, surface plasmon resonance (SPR). SPR can be used to determine the binding constants of the antibody and second antibody and the two binding constants can be compared.
[00255] [00255] In exemplary embodiments, the conjugate of the present disclosure comprises an IL-21 mutein bound to a polymer. In some embodiments, the polymer is selected from the group consisting of: polyamides, polycarbonates, polyalkylene and their derivatives including polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, acrylic and methacrylic ester polymers, including poly (methyl methacrylate), poly (methacrylate), poly (methacrylate) ethyl), poly (butylmethacrylate), poly (isobutyl methacrylate), poly (hexylmethacrylate), poly (isodecyl methacrylate), poly (lauryl methacrylate), poly (phenyl methacrylate), poly (methyl acrylate), poly (methyl acrylate), poly (isopropyl acrylate), poly (isobutyl acrylate) and poly (octadecyl acrylate), polyvinyl polymers including polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, poly (vinyl acetate) and polyvinylpyrrolidone, , polysiloxanes, polyurethanes and their copolymers, celluloses including alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocelluloses, cellulose methyl, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxybutylmethyl cellulose, cellulose acetate, cellulose propionate, cellulose butyrate acetate, cellulose acetate phthalate, carboxyethyl cellulose, cellulose triacetate and sodium salt cellulose sulfate, polypropylene, polyethylene including poly (ethylene glycol), poly (ethylene oxide) and poly (ethylene terephthalate) and polystyrene. In specific embodiments, the polymer is a polyalkylene glycol, including, for example, polyethylene glycol (PEG).
[00256] [00256] In exemplary embodiments, the conjugate of the present disclosure comprises an IL-21 mutein bound to a carbohydrate. In some embodiments, the carbohydrate is a monosaccharide (eg, glucose, galactose, fructose), a disaccharide (eg, sucrose, lactose, maltose), an oligosaccharide (eg, raffinose, stachyose) or a polysaccharide (eg, starch, amylase, amylopectin, cellulose, chitin, callose, laminarin, xylan, mannan, fucoidan or galactomannan).
[00257] [00257] In some embodiments, the heterologous fraction is a lipid. The lipid, in some embodiments, is a fatty acid, eicosanoid, prostaglandin, leukotriene, thromboxane, N-acyl ethanolamine), glycerolipid (eg, mono-, di-, tri-substituted glycerols), glycerophospholipid (eg ., phosphatidylcholine, phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine), sphingolipid (eg, sphingosine, ceramide), sterol lipid (eg, steroid, cholesterol), prenol lipid, saccharolipid or ceretide, oil, ceretide, oil, ceretide, oil, ceretide, oil, ceretide, oil, ceretide, oil, ceretide, oil, ceretide, oil, ceretide, oil, ceretide cholesterol, sterol, fat-soluble vitamin, monoglyceride, diglyceride, triglyceride, a phospholipid.
[00258] [00258] In exemplary embodiments, the conjugate of the present disclosure comprises an IL-21 mutein bound to a therapeutic agent. The therapeutic agent can be any of those known in the art. In exemplary aspects, the therapeutic agent is an immunotherapy agent as long as the agent stimulates an immune response. In exemplary aspects, the immunotherapy agent is a cancer vaccine. In exemplary aspects, the immunotherapy agent is a monoclonal antibody. In exemplary aspects, the immunotherapy agent is an inhibitor of immune control points, e.g., a CTLA4, PD-1, PD-L1 inhibitor. In exemplary cases, the monoclonal antibody is specific for a protein in an immune control pathway. The protein of the immune control points pathway can be, for example, CTLA4, PD-1, PD-L1, B7-H3, B7H4 or TIM3. For example, the antigen-binding proteins of the present disclosure can be conjugated to atezolizumab, avelumab, ipilimumab, tremelimumab, BMS-936558, MK3475, CT-011, AM-224, MDX-1105, IMP321, MGA271.
[00259] [00259] In exemplary aspects, the therapeutic agent is a cytokine, lymphokine, growth factor or hematopoietic factor effective in inhibiting tumor metastases and / or having an antiproliferative effect in at least one cell population. Such cytokines, lymphokines, growth factors or other hematopoietic factors include, but are not limited to: M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL- 18, IFN, TNFα, TNF1, TNF2, G-CSF, Meg-CSF, GM-CSF, thrombopoietin, stem cell factor and erythropoietin. Additional growth factors for use here include angiogenin, bone morphogenic protein-1, bone morphogenic protein-2, bone morphogenic protein-3, bone morphogenic protein-4, bone morphogenic protein-5, bone morphogenic protein-6, bone morphogenic protein- 7, bone morphogenic protein-8, bone morphogenic protein-9, bone morphogenic protein-10, bone morphogenic protein-11, bone morphogenic protein-12, bone morphogenic protein-13, bone morphogenic protein-14, bone morphogenic protein-15, bone morphogenic protein-15, bone morphogenic protein-15 bone morphogenic protein receptor IA, bone morphogenic protein receptor IB, brain-derived neurotrophic factor, ciliary neurotrophic factor, ciliary neurotrophic factor receptor α, cytokine-induced neutrophil chemotactic factor 1, cytokine-induced neutrophil chemotactic factor 2 α, chemotactic neutrophil factor induced by cytokines 2 β, endothelial cell growth factor β, endothelin 1, neutrophil attractor derived from e pythelium, neurotrophic factor receptor derived from the glial cell line α 1, neurotrophic factor receptor derived from the glial cell line α 2, growth-related protein, growth-related protein α, growth-related protein β, related protein with γ growth, heparin-binding epidermal growth factor, hepatocyte growth factor, hepatocyte growth factor receptor, insulin type growth factor I, insulin type growth factor receptor, insulin type growth factor II, insulin-like growth factor binding protein, keratinocyte growth factor, leukemia inhibitory factor, leukemia inhibitory factor receptor α, nerve growth factor, nervous growth factor receptor, neurotrophin-3, neurotrophin-4, factor pre-B cell growth stimulant, stem cell factor, stem cell factor receptor, transfo growth factor α α, transforming growth factor β, transforming growth factor β1, transforming growth factor β1.2, transforming growth factor β2, transforming growth factor β3, transforming growth factor β5, latent transforming growth factor β1, protein binding I to transforming growth factor β, binding protein II to transforming growth factor β, transforming growth factor β binding protein III, type I tumor necrosis factor receptor, type II tumor necrosis factor receptor, receptor plasminogen activator type urokinase and chimeric proteins and their biologically or immunologically active fragments. In exemplary embodiments, the therapeutic agent comprises an antibody specific to any of the cytokines, lymphokines, growth factors or other hematopoietic factors mentioned above. Nucleic acids
[00260] [00260] The present disclosure further provides nucleic acids comprising a nucleotide sequence encoding an IL-21 mutein of the present disclosure, a conjugate comprising an IL-21 mutein or a fusion protein comprising an IL-21 mutein. For example, the nucleic acid may comprise a nucleotide sequence encoding an anti-PD-1 antibody heavy chain followed by a nucleotide sequence encoding a mutein of
[00261] [00261] In exemplary aspects, the nucleic acid comprises a sequence of nucleotides encoding an IL-21 mutein comprising an amino acid sequence of SEQ ID NOs: 3-21, 23-56, 58-112, 114-208, 210- 222, 224-255 and 283 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least less than 90% or more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) sequence identity with an amino acid sequence of SEQ ID NOs: 3-21, 23-56, 58-112, 114-208, 210-222, 224 -255 and
[00262] [00262] In exemplary aspects, the nucleic acid comprises a nucleotide sequence encoding a peptide linker of SEQ ID NO: 262 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or has more than about 90% (eg, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 262.
[00263] [00263] In exemplary aspects, the nucleic acid comprises a nucleotide sequence encoding a fusion protein comprising an amino acid sequence from an antibody constant region described herein fused to an amino acid sequence from any IL-21 mutein described here. In exemplary cases, the nucleic acid comprises a nucleotide sequence encoding a fusion protein comprising an amino acid sequence of any one of SEQ ID NOs: 265-267 and 282 or an amino acid sequence that is at least about 50%, at least at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or has more than about 90% (eg, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with any one of SEQ ID NOs: 265-267 and 282, fused to any of SEQ ID NOs: 3-21, 23-56, 58-112, 114-208, 210-222, 224- 255 and 283 or an amino acid sequence which is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90% or has more than about 90% (eg, about 91%, about 92%, about 93% , about 94%, about 95%, about 96%, about 97%, about 98% or about 99%) of sequence identity with SEQ ID NO: 3-21, 23-56, 58- 112, 114-208, 210-222, 224-255 and 283. In exemplary aspects, the nucleic acid comprises a sequence of nucleotides encoding a fusion protein comprising an amino acid sequence of any one of SEQ ID NOs: 268-281 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90% or more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98 % or about 99%) of sequence identity with SEQ ID NO: 268-281.
[00264] [00264] In exemplary aspects, the nucleic acid comprises a sequence of nucleotides encoding an anti-PD-1 antibody comprising an amino acid sequence of the heavy chain constant region of any one of SEQ ID NOs: 265-267, 282, 284- 311, 472-495 and 544-555 or an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85% , at least about 90%, or more than about 90% (e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96 %, about 97%, about 98% or about 99%) of sequence identity with any of SEQ ID NO: 265-267, 282, 284-311, 472-495 and 544-555.
[00265] [00265] The present disclosure further provides nucleic acids comprising a nucleotide sequence encoding a PD-1 antigen binding protein of the present disclosure. In exemplary aspects, the nucleotide sequence comprises a sequence encoding a heavy chain CDR or light chain CDR, a heavy chain variable region or light chain variable region or heavy chain sequence or light chain sequence. See Table G below. In exemplary cases, the nucleotide sequence comprises any one of SEQ ID NOs: 392-471. The present disclosure further provides pairs of nucleotide sequences comprising (a) SEQ ID NOs: 398 and 399, (b) SEQ ID NOs: 408 and 409, (c) SEQ ID NOs: 418 and 419, (d) SEQ ID NOs : 428 and 429, (e) SEQ ID NOs: 438 and 439, (f) SEQ ID NOs: 448 and 449, (g) SEQ ID NOs: 458 and 459 or (h) SEQ ID NOs: 468 and 469. A The present disclosure further provides pairs of nucleotide sequences comprising (a) SEQ ID NOs: 400 and 401, (b) SEQ ID NOs: 410 and 411, (c) SEQ ID NOs: 420 and 421, (d) SEQ ID NOs: 430 and 431, (e) SEQ ID NOs: 440 and 441, (f) SEQ ID NOs: 450 and 451, (g) SEQ ID NOs: 460 and 461 or (h) SEQ ID NOs: 470 and 471.
[00266] [00266] In exemplary aspects, the nucleic acid molecule comprises a nucleotide sequence encoding a conjugate or fusion protein of the present disclosure. By "nucleic acid" as used here includes "polynucleotide", "oligonucleotide" and "nucleic acid molecule" and it generally means a polymer of DNA or RNA, or its modified forms, which may have single strand or double strand, synthesized or obtained (eg, isolated and / or purified) from natural sources, which may contain natural, unnatural or altered nucleotides and which may contain a natural, unnatural or altered internucleotide bond, such as a phosphoramidate bond or a phosphorothioate binding, instead of the phosphodiester found between the nucleotides of an unmodified oligonucleotide. The nucleic acid can comprise any nucleotide sequence that encodes any of the antigen-binding proteins or polypeptides of the present disclosure. In some embodiments, the nucleic acid does not comprise any insertions, deletions, inversions and / or substitutions. In other embodiments, the nucleic acid comprises one or more insertions, deletions, inversions and / or substitutions.
[00267] [00267] In some respects, the nucleic acids of the present disclosure are recombinant. As used here, the term "recombinant" refers to (i) molecules that are constructed outside living cells by joining natural or synthetic nucleic acid segments to nucleic acid molecules that can replicate in a living cell or (ii) molecules that result from the replication of those described in (i) above. For purposes here, replication can be in vitro replication or in vivo replication.
[00268] [00268] Nucleic acids in some aspects are constructed based on chemical synthesis and / or enzymatic binding reactions using procedures known in the art. See, for example, Sambrook et al., Supra; and Ausubel et al., supra. For example, a nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed after hybridization (eg, phosphorothioate derivatives and substituted nucleotides with acridine). Examples of modified nucleotides that can be used to generate nucleic acids include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-
[00269] [00269] The nucleic acids of the present disclosure in some aspects are incorporated into a vector. In this regard, the present disclosure provides vectors comprising any of the nucleic acids presently disclosed. In exemplary aspects, the vector is a recombinant expression vector. For purposes here, the term "recombinant expression vector" means a genetically modified oligonucleotide or polynucleotide construct that allows the expression of a mRNA, protein, polypeptide or peptide by a host cell, when the construct comprises a sequence of nucleotides encoding the mRNA , protein, polypeptide or peptide, and the vector is contacted with the cell under conditions sufficient for mRNA, protein, polypeptide or peptide to be expressed within the cell. The vectors of the present disclosure are not naturally occurring as a whole. However, parts of the vectors can be naturally occurring. The vectors currently disclosed may comprise any type of nucleotide, including, but not limited to, DNA and RNA, which may be single or double stranded, synthesized or obtained in part from natural sources and which may contain natural, unnatural nucleotides or changed. The vectors may comprise naturally occurring or non-naturally occurring internucleotide bonds, or both types of bonds. In some respects, the altered nucleotides or internucleotide bonds not occurring naturally do not restrict the transcription or replication of the vector.
[00270] [00270] The vector of the present disclosure can be any suitable vector and can be used to transform or transfect any suitable host. Suitable vectors include those designed for propagation and expansion or for expression or both, such as plasmids and viruses. The vector can be selected from the group consisting of the pUC series (Fermentas Life Sciences), the pBluescript series (Stratagene, LaJolla, CA), the pET series (Novagen, Madison, WI), the pGEX series (Pharmacia Biotech, Uppsala, Sweden) and in the pEX series (Clontech, Palo Alto, CA). Bacteriophage vectors, such as λGTIO, λGTl 1, λZapII (Stratagene), λEMBL4 and λNMl 149, can also be used.
[00271] [00271] The vectors of the present disclosure can be prepared using standard recombinant DNA techniques described in, for example, Sambrook et al., Supra and Ausubel et al., Supra. Expression vector constructs, which are circular or linear, can be prepared to contain a functional replication system in a prokaryotic or eukaryotic host cell. The replication systems can be derived, for example, from CoIEl, plasmid 2 μ, λ, SV40, bovine papilloma virus and the like.
[00272] [00272] In some aspects, the vector comprises regulatory sequences, such as initiation and termination codons for transcription and translation, which are specific to the type of host (eg, bacteria, fungus, plant or animal) in which the vector is to be introduced, as appropriate and taking into account whether the vector is based on DNA or RNA.
[00273] [00273] The vector can include one or more marker genes, which allow selection of transformed or transfected hosts. The marker genes include resistance to biocides, e.g., resistance to antibiotics, heavy metals, etc., complementation in an auxotrophic host to provide prototrophy and the like. Suitable marker genes for the currently disclosed expression vectors include, for example, neomycin / G418 resistance genes,
[00274] [00274] The vector may comprise a native or normative promoter operably linked to the nucleotide sequence encoding the polypeptide (including its functional portions and functional variants) or the nucleotide sequence that is complementary to or that hybridizes to the nucleotide sequence encoding the IL -21, conjugate or fusion protein. The selection of promoters, eg, strong, weak, inducible, tissue-specific and developmental, is within the skill of the specialist. Similarly, the combination of a nucleotide sequence with a promoter is also within the skill of the art. The promoter can be a non-viral promoter or a viral promoter, e.g., a cytomegalovirus (CMV) promoter, an SV40 promoter, an RSV promoter, and a promoter found in the long terminal repeat of the stem cell virus of murine. Host cells
[00275] [00275] Host cells comprising a nucleic acid or vector of the present disclosure are provided herein. As used herein, the term "host cell" refers to any type of cell that may contain the currently disclosed vector and is capable of producing an expression product encoded by the nucleic acid (eg, mRNA, protein). The host cell in some respects is an adherent cell or a suspended cell, i.e., a cell that grows in suspension. The host cell in exemplary aspects is a cultured cell or a primary cell, i.e., isolated directly from an organism, e.g., a human. The host cell can be any type of cell, it can originate from any type of tissue and it can be from any stage of development.
[00276] [00276] In exemplary aspects, the cell is a eukaryotic cell, including, but not limited to, a yeast cell, filamentous fungal cell, protozoan cell, algae cell, insect cell or mammalian cell. Such host cells are described in the art. See, e.g., Frenzel, et al., Front Immunol 4: 217 (2013). In exemplary aspects, eukaryotic cells are mammalian cells. In exemplary aspects, mammalian cells are non-human mammalian cells. In some ways, the cells are Chinese Hamster Ovary (CHO) cells and their derivatives (eg, CHO-K1, CHO pro-3, CS9), mouse myeloma cells (eg, NS0, GS-NS0, Sp2 / 0), cells engineered to be deficient in dihydrofolatorreductase (DHFR) activity (eg, DUKX-X11, DG44), human embryonic kidney 293 cells (HEK293) or their derivatives (p. HEK293T, HEK293- EBNA), green African monkey kidney cells (eg COS cells, VERO cells), human cervical cancer cells (eg HeLa), U2 human bone osteosarcoma epithelial cells -OS, A549 human adenocarcinoma basal alveolar epithelial cells, HT1080 human fibrosarcoma cells, CAD human brain tumor cells, P19 embryonic carcinoma cells, NIH 3T3 mouse embryo fibroblast cells, mouse fibroblast cells
[00277] [00277] For purposes of vector amplification or replication, the host cell is in some respects a prokaryotic cell, eg, a bacterial cell.
[00278] [00278] A population of cells comprising at least one host cell described herein is also provided by the present disclosure. The population of cells in some respects is a heterogeneous population comprising the host cell comprising described vectors, in addition to at least one other cell, which does not comprise any of the vectors. Alternatively, in some respects, the cell population is a substantially homogeneous population, in which the population comprises mostly host cells (eg, consisting essentially of) comprising the vector. The population in some respects is a clonal population of cells, in which all cells in the population are clones of a single host cell comprising a vector, such that all cells in the population comprise the vector. In exemplary embodiments of the present disclosure, the cell population is a clonal population comprising host cells comprising a vector as described herein.
[00279] [00279] Compositions comprising an IL-21 mutein, a conjugate comprising IL-21 mutein, a fusion protein comprising IL-21 mutein and a polypeptide, a PD-1 antigen binding protein (e.g. ., an anti-PD-1 antibody), a conjugate comprising the PD-1 antigen binding protein (e.g., an anti-PD-1 antibody), a fusion protein comprising the PD antigen binding protein -1 (e.g., an anti-PD-1 antibody), a nucleic acid, vector or host cell, of the present disclosure, or a combination thereof, are provided herein. The compositions in some ways comprise IL-21 mutein, PD-1 antigen binding protein (e.g., an anti-PD-1 antibody), a conjugate, fusion protein, nucleic acid, vector or host cell of the present disclosure, or a combination thereof, in isolated and / or purified form. In some respects, the composition comprises a single type (eg, structure) of an IL-21 mutein, PD-1 antigen binding protein (eg, an anti-PD-1 antibody), a conjugate, fusion protein, nucleic acid, vector or host cell of the present disclosure or comprises a combination of two or more different types (e.g., different structures) of IL-21 muteins, PD-1 antigen binding proteins , conjugates, fusion proteins, nucleic acids, vectors or host cells of the present disclosure.
[00280] [00280] In exemplary aspects, the composition comprises agents that enhance the physicochemical characteristics of the IL-21 mutein, antigen-binding protein
[00281] [00281] In exemplary aspects of the present disclosure, the composition further comprises a pharmaceutically acceptable carrier, diluents or excipient. In some embodiments, IL-21 muteins, PD-1 antigen-binding proteins (e.g., anti-PD-1 antibodies), conjugates, fusion proteins, nucleic acids, vectors or host cells as currently disclosed ( hereinafter referred to as "active agents") are formulated in a pharmaceutical composition comprising the active agent, together with a pharmaceutically acceptable carrier, diluent or excipient. In this regard, the present disclosure further provides pharmaceutical compositions comprising an active agent (ie, any of the IL-21 muteins, PD-1 antigen binding proteins (e.g., anti-PD-1 antibodies), conjugated , fusion proteins, nucleic acids, vectors or host cells of the present disclosure), which pharmaceutical composition is intended for administration to a subject, e.g., a mammal.
[00282] [00282] In some embodiments, the active agent is present in the pharmaceutical composition at a level of purity suitable for administration to a patient. In some embodiments, the active agent has a purity level of at least about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% and a pharmaceutically acceptable diluent, carrier or excipient. In some embodiments, the compositions contain an active agent at a concentration of about 0.001 to about 30.0 mg / ml.
[00283] [00283] In exemplary aspects, the pharmaceutical compositions comprise a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline, water, emulsions such as an oil / water or water / oil emulsion and various types of wetting agents. The term also encompasses any of the agents approved by a US federal government regulatory agency or listed in the U.S. Pharmacopoeia for use on animals, including humans.
[00284] [00284] The pharmaceutical composition can comprise any pharmaceutically acceptable ingredients, including, for example, acidifying agents, additives, adsorbents, aerosol propellants, air displacement agents,
[00285] [00285] In exemplary aspects, the pharmaceutical composition comprises formulation materials that are non-toxic to the recipients at the dosages and concentrations employed. In specific embodiments, the pharmaceutical compositions comprise an active agent and one or more pharmaceutically acceptable salts; polyols; surfactants; osmotic balancing agents; tonicity agents; antioxidants; antibiotics; antimycotics; bulking agents; lyoprotectants; antifoaming agents; chelating agents; preservatives; dyes; painkillers; or additional pharmaceutical agents. In exemplary aspects, the pharmaceutical composition comprises one or more polyols and / or one or more surfactants, optionally, in addition to one or more excipients, including, but not limited to, pharmaceutically acceptable salts; osmotic balancing agents (tonicity agents); antioxidants; antibiotics; antimycotics; bulking agents; lyoprotectants; antifoaming agents; chelating agents; preservatives; dyes; and painkillers.
[00286] [00286] In certain embodiments, the pharmaceutical composition may contain formulation materials to modify, maintain or preserve, for example, pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, adsorption or penetration of the composition. In such embodiments, suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antibiotics; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylene diaminetetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose or dextrin); proteins (such as albumin, gelatin or immunoglobulins); coloring, flavoring and thinning agents; emulsifiers; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate, triton, tromethamine, lecithin, cholesterol, tiloxapal); stability-enhancing agents (such as sucrose or sorbitol); tonicity-enhancing agents (such as alkali metal halides, preferably sodium or potassium chloride, mannitol, sorbitol); distribution vehicles; diluents; pharmaceutical excipients and / or adjuvants.
[00287] [00287] Pharmaceutical compositions can be formulated to achieve a physiologically compatible pH. In some embodiments, the pH of the pharmaceutical composition can be for example between about 4 or about 5 and about 8.0 or about 4.5 and about 7.5 or about 5.0 to about 7, 5. In exemplary embodiments, the pH of the pharmaceutical composition is between 5.5 and 7.5. Routes of Administration
[00288] [00288] With respect to the present disclosure, the active agent, or pharmaceutical composition comprising the same, can be administered to the subject through any suitable route of administration. For example, the active agent can be administered to a subject through parenteral, nasal, oral, pulmonary, topical, vaginal or rectal administration. The following discussion of routes of administration is merely provided to illustrate exemplary modalities and should not be construed as limiting the scope in any way.
[00289] [00289] Formulations suitable for parenteral administration include sterile isotonic, aqueous and non-aqueous injection solutions, which may contain antioxidants, buffers, bacteriostats and solutes that make the formulation isotonic with the intended recipient's blood, and aqueous and non-aqueous sterile suspensions which may include suspending agents, solubilizers, thickening agents, stabilizers and preservatives. The term “parenteral” means not through the alimentary canal but in some other way such as subcutaneous,
[00290] [00290] Oils that can be used in parenteral formulations include petroleum, animal, vegetable or synthetic oils. Specific examples of oils include peanut oil, soy, sesame, cottonseed, corn, olive oil, petrolatum and mineral. Fatty acids suitable for use in parenteral formulations include oleic acid, stearic acid and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acids.
[00291] [00291] Soaps suitable for use in parenteral formulations include salts of fatty alkali metals, ammonium and triethanolamine, and suitable detergents include (a)
[00292] [00292] Parenteral formulations in some embodiments contain from about 0.5% to about 25% by weight of the active agent of the present disclosure in solution. Preservatives and buffers can be used. In order to minimize or eliminate irritation at the injection site, such compositions may contain one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 12 to about 17. The amount of surfactant in such formulations will normally vary from about 5% to about 15% by weight. Suitable surfactants include esters of polyethylene glycol sorbitan fatty acids, such as sorbitan monooleate and high molecular weight ethylene oxide adducts with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. Parenteral formulations in some respects are presented in sealed unit dose or multidose containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water for injections, immediately before use. Extemporaneous injection solutions and suspensions in some respects are prepared from sterile powders, granules and tablets of the type previously described.
[00293] [00293] Injectable formulations are in accordance with the present disclosure. The requirements for effective pharmaceutical carriers for injectable compositions are well known to those of skill in the art (see, e.g., Pharmaceutics and Pharmacy Practice, JB Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., Pages 238-250 (1982 ) and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986)). Dosages
[00294] [00294] Active agents of the disclosure are believed to be useful in methods of inhibiting a PD-1 signaling, while providing IL-21 signaling, as described here, and are thus believed to be useful in methods of treatment or prevention one or more diseases, eg cancer. For purposes of disclosure, the amount or dose of the active agent administered should be sufficient to effect, for example, a therapeutic or prophylactic response, on the subject or animal, over a reasonable period of time. For example, the dose of the active agent of the present disclosure should be sufficient to treat cancer as described here in a period of about 1 to 4 minutes, 1 to 4 hours, or 1 to 4 weeks or more, eg, 5 20 or more weeks from the time of administration. In certain embodiments, the time period could be even longer. The dose will be determined by the effectiveness of the particular active agent and the condition of the animal (eg, human), as well as the body weight of the animal (eg, human) to be treated.
[00295] [00295] Many assays for determining an administered dose are known in the art. For purposes here, an assay, which comprises comparing the extent of cancer treatment after administering a given dose of the active agent of the present disclosure to a mammal among a set of mammals, each set of which is given a different dose of the active agent , could be used to determine a starting dose to be administered to a mammal. The extent of cancer treatment after administration of a certain dose can be represented, for example, by the cytotoxicity of the active agent or the extent of tumor regression achieved with the active agent in a mouse xenograft model. Methods for measuring the cytotoxicity of fusion proteins and methods for assessing tumor regression are known in the art.
[00296] [00296] The dose of the active agent in this disclosure will also be determined by the existence, nature and extent of any adverse side effects that could accompany the administration of a particular active agent in this disclosure. Typically, the attending physician will decide the dosage of the active agent of the present disclosure with which each patient should be treated, taking into account a variety of factors, such as age, body weight, general health, diet, sex, active agent of the present disclosure to be administered, route of administration and the severity of the condition being treated. As an example and not wishing to limit the present disclosure, the dose of the active agent of the present disclosure can be about 0.0001 to about 1 g / kg of body weight of the subject being treated / day, from about 0.0001 at about 0.001 g / kg body weight / day or about 0.01 mg to about 1 g / kg body weight / day. Controlled Release Formulations
[00297] [00297] In some embodiments, the active agents described here can be modified into a form of deposit, such that the manner in which the active agent of the present disclosure is released into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Patent No. 4,450,150). The forms of depositing active agents of the present disclosure can be, for example, an implantable composition comprising the active agents and a porous or non-porous material, such as a polymer, in which the active agent is encapsulated by or diffused throughout the material. and / or degradation of the non-porous material. The deposit is then implanted at the desired location within the subject's body and the active agent is released from the implant at a predetermined rate.
[00298] [00298] The pharmaceutical composition comprising the active agent in certain aspects is modified to have any type of in vivo release profile. In some respects, the pharmaceutical composition is a formulation of immediate release, controlled release, sustained release, prolonged release, delayed release or biphasic release. Methods of formulating peptides for controlled release are known in the art. See, for example, Qian et al., J Pharm 374: 46-52 (2009) and International Patent Application Publications Nos. WO 2008/130158, WO2004 / 033036; WO2000 / 032218; and WO 1999/040942.
[00299] [00299] The present compositions may additionally comprise, for example, mycelia or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and / or distribution effect. Combinations
[00300] [00300] In some embodiments, the fusion proteins or antigen-binding proteins (eg, anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product) described herein are administered alone and, in alternative embodiments, are administered in combination with another therapeutic agent, e.g., another active agent of the invention of a different type (e.g., structure). In some respects, the other therapeutic is intended to treat or prevent cancer. In some modalities, the other therapeutic is a chemotherapeutic agent. In some modalities, the other therapeutic is an agent used in radiotherapy for the treatment of cancer. Accordingly, in some respects, the fusion proteins or antigen-binding proteins (e.g., anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product) described here they are administered in combination with one or more of platinum coordinating compounds, topoisomerase inhibitors, antibiotics, antimitotic alkaloids and difluoronucleosides. In exemplary aspects, an IL-21 fusion protein described here (eg, an anti-PD-1 antibody fused to an IL-21 mutein) is combined with an antigen binding protein (eg,
[00301] [00301] In specific embodiments, any of the antibodies 20A2, 20C1, 22D4, 20C1.006, 20C1.009, 20A2.003, 22D4.006, 22D4.017 is administered in combination with an IL-21 fusion protein described including, for example, a fusion protein comprising a homodimer or monomer selected from: a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 391) and two antibody heavy chains (each of which is fused to an IL-21 mutein, and each IL-21 heavy chain-mutein fusion comprises the amino acid sequence of SEQ ID NO: 496); a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 391) and two antibody heavy chains (each of which is fused to an IL-21 mutein, and the mutein heavy chain fused IL-21 comprises the amino acid sequence of SEQ ID NO: 497); a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID NO: 391) and two antibody heavy chains (each of which is fused to an IL-21 mutein, and each heavy-chain fusion IL-21 mutein comprises the amino acid sequence of SEQ ID NO: 498); a homodimer comprising two antibody light chains (each comprising the amino acid sequence of SEQ ID
[00302] [00302] In some embodiments, fusion proteins or antigen-binding proteins (e.g., anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product) described here are administered in combination with a engineered immune cell. The manipulated immune cells have been shown to have desired qualities in therapeutic treatments, particularly in oncology. Two main types of engineered immune cells are those that contain chimeric antigen receptors (called "CARs" or "CAR-Ts") and T cell receptors ("TCRs"). These engineered cells are engineered to give them specificity for the antigen while retaining or enhancing their ability to recognize and kill a target cell. Chimeric antigen receptors can comprise, for example, (i) a specific component of the antigen ("antigen binding molecule"), (ii) one or more co-stimulating domains (iii) one or more activating domains. Each domain can be heterogeneous, that is, comprised of sequences derived from different protein chains. Immune cells expressing chimeric antigen receptors (such as T cells) can be used in a variety of therapies, including cancer therapies. It will be appreciated that the co-stimulating polypeptides as defined here can be used to enhance the activation of cells expressing CAR against target antigens and, therefore, increase the potency of adoptive immunotherapy. T cells can be engineered to have specificity for one or more desired targets. For example, T cells can be transduced with DNA or other genetic material encoding an antigen-binding molecule, such as one or more single chain variable fragments (“scFv”) of an antibody, in conjunction with one or more molecules of signaling and / or one or more activating domains, such as CD3 zeta.
[00303] [00303] In some embodiments, the engineered immune cells (such as CARs or TCRs) have specificity for DLL3. Delta-like 3 (DLL3) is a member of the Delta / Serrate / Lag-2 ligand family for the Notch receptor and is thought to play a role in Notch signaling. DLL3 is a Notch signaling inhibitor ligand normally expressed exclusively on intracellular membranes (Geffers et al. (2007) J Cell Biol; 178: 465–76.) And as described in U.S. Patent Application No. 62/655725, which is hereby incorporated by reference in its entirety. The chimeric antigen receptors of the invention typically comprise: (i) a DLL3 specific antigen binding molecule, (ii) one or more co-stimulating domains and (iii) one or more activating domains. It will be appreciated that each domain can be heterogeneous, therefore comprised of sequences derived from different protein chains.
[00304] [00304] In some embodiments, the chimeric antigen receptor comprises an antigen binding molecule that specifically binds to DLL3, wherein the antigen binding molecule comprises at least one of: (a) a variable heavy chain CDR1 comprising an amino acid sequence differing from that of SYYWT (SEQ ID NO: 42) or GYYMH (SEQ ID NO: 730) in no more than 3, 2, 1 or 0 amino acid residues; (b) a variable heavy chain CDR2 comprising an amino acid sequence differing from that of YIYYSGTTNYNPSLKS (SEQ ID NO: 731) or WIDPNSGDTNYAQKFQG (SEQ ID NO: 732) or WINPNSGDTSYAQRFLG (SEQ ID NO: 733), no more than 2, 1 or 0 amino acid residues; (c) a variable heavy chain CDR3 comprising an amino acid sequence differing from that of IAVRGFFFDY (SEQ ID NO: 734) or DPNRRSWYYGMDV (SEQ ID NO: 735) or EDDSSWYGSFDY (SEQ ID NO: 736) in no more than 3, 2, 1 or 0 amino acid residues; (d) a variable light chain CDR1 comprising an amino acid sequence differing from that of RASQSVSSSYLA (SEQ ID NO: 737) or QASQDIRNYLN (SEQ ID NO: 738) or RASQGIRNYLG (SEQ ID NO: 739) in no more than 3, 2, 1 or 0 amino acid residues; (e) a variable light chain CDR2 comprising an amino acid sequence differing from that of GASTRAT (SEQ ID NO: 740) or DASNLET (SEQ ID NO: 741) or AASSLQS (SEQ ID NO: 742) in no more than 3, 2, 1 or 0 amino acid residues; (f) a variable light chain CDR3 comprising an amino acid sequence differing from that of QQYGTSPLT (SEQ ID NO: 743) or QHYDNLPLTF (SEQ ID NO: 744) or LQHDSDLRTF (SEQ ID NO: 745) in no more than 3, 2, 1 or 0 amino acid residues.
[00305] [00305] In some embodiments, the chimeric antigen receptor comprises an antigen binding molecule that specifically binds to DLL3, wherein the antigen binding molecule comprises the amino acid sequence of the construct of one of the clones 1H2.1, 8D2 and 6B2, shown in Table H: Table H Construct Name SEQ ID NO: 1H2.1 4-1BB AA 746 1H2.1 CD28T AA 747 8D2 4-1BB AA 748 8D2 CD28T AA 749 6B2 CD28T AA 750 6B2 4-1BB AA 751
[00306] [00306] In some embodiments, the engineered immune cells (such as CARs or TCRs) have specificity for FLT3. Fms-like tyrosine kinase 3 (FLT3) also known as fetal liver kinase 2 (FLK-2), human stem cell kinase 1 (SCK-1) or Differentiation Cluster antigen (CD135) is a hematopoietic receptor tyrosine kinase which was cloned by two independent groups in the 1990s. The FLT3 gene, located on chromosome 13q12 in humans, encodes a Class III receptor tyrosine kinase protein that shares homology with other members of the Class III family including stem cell factor receptor (c-KIT), macrophage colony stimulating factor receptor (FMS) and platelet-derived growth factor receptor (PDGFR) and is further described in WO2017173410, which is hereby incorporated by reference in its entirety. The chimeric antigen receptors of the invention typically comprise: (i) a FLT3 specific antigen binding molecule, (ii) one or more co-stimulating domains and (iii) one or more activating domains. It will be appreciated that each domain can be heterogeneous, therefore comprised of sequences derived from different protein chains.
[00307] [00307] In some embodiments, the invention relates to a chimeric antigen receptor comprising an antigen binding molecule that specifically binds to FLT3, wherein the antigen binding molecule comprises at least one of: (a) a CDR1 variable heavy chain comprising an amino acid sequence differing from that of the NARMGVS amino acid sequence (SEQ ID NO: 752) by no more than 3, 2, 1 or 0 amino acid residues; (b) a variable heavy chain CDR2 comprising an amino acid sequence differing from that of the HIFSNAEKSYRTSLKS amino acid sequence (SEQ ID
[00308] [00308] In some embodiments, the chimeric antigen receptor comprises an antigen binding molecule that specifically binds to FLT3, wherein the antigen binding molecule comprises the amino acid sequence of the construct of one of clones 10E3, 8B5, 4E9 and 11F11, shown in Table I:
[00309] [00309] The invention relates further to polynucleotides encoding the chimeric antigen receptors and vectors comprising the polynucleotides. The vector can be, for example, a retroviral vector, a DNA vector, a plasmid, an RNA vector, an adenoviral vector, an adenovirus-associated vector, a lentiviral vector or any combination thereof. The invention relates further to immune cells comprising the vectors. In some embodiments, the lentiviral vector is a pGAR vector, such as that shown in publication WO2017173410, which is hereby incorporated by reference in its entirety.
[00310] Exemplary immune cells include, but are not limited to, T cells, tumor infiltrating lymphocytes (TILs), NK cells, cells expressing TCR, dendritic cells or NK-T cells. T cells can be autologous, allogeneic or heterologous.
[00311] [00311] In specific embodiments, any of the antibodies 20A2, 20C1, 22D4, 20C1.006, 20C1.009, 20A2.003, 22D4.006 and 22D4.017 is administered in combination with a engineered immune cell comprising a receptor construct of chimeric antigen as shown above. In other embodiments, any of the IL-21 fusion proteins described herein is administered in combination with a engineered immune cell comprising a chimeric antigen receptor construct as shown above. With a view to DLL3, such combinations can be used to treat a variety of tumor types including, but not limited to, adrenal, liver, kidney, bladder, breast, gastric, ovary, cervical, uterine, esophageal, colorectal, prostate (e.g. eg prostate adenocarcinoma), pancreas, lung (both small and non-small cells), thyroid, carcinomas, sarcomas, glioblastomas, tumors of the head and neck, large cell neuroendocrine carcinoma (LCNEC), medullary thyroid cancer, glioblastoma , neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic cancer (GEP) and malignant melanoma. In a particular embodiment, the type of tumor is small cell lung cancer. Aiming at FLT3, such combinations can be used to treat a variety of tumor types including, but not limited to, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), chronic myelomonocytic leukemia, leukemia juvenile myelomonocytic, atypical chronic myeloid leukemia, acute promyelocytic leukemia (APL), acute monoblastic leukemia, acute erythroid leukemia, acute megakarioblastic leukemia, myelodysplastic syndrome (myeloproliferative dysfunction, myeloid neoplasm, mycoma or sarcoma). Additional diseases include inflammatory and / or autoimmune diseases such as rheumatoid arthritis, psoriasis, allergies, asthma, Crohn's disease, IBD, IBS, fibromyalgia, mastocytosis and celiac disease. In a particular embodiment, the tumor type is AML.
[00312] [00312] In some embodiments, fusion proteins or antigen-binding proteins (eg, anti-PD-1 antibody, its antigen-binding antibody fragment or anti-PD-1 antibody protein product) described here are administered in combination with an oncolytic virus. Oncolytic viruses have demonstrated anti-cancer activity in a variety of tumor types. Oncolytic immunotherapy is a treatment modality that uses replicating competent oncolytic viruses that selectively infect and damage cancerous tissues without causing damage to normal tissues. Ongoing studies are using a variety of engineered viruses not limited to the herpes simplex virus (HSV), vaccinia and reovirus.
[00313] [00313] In exemplary aspects, the oncolytic virus is derived from a strain of herpes simplex virus 1 (HSV-1) or herpes simplex virus 2 (HSV-2), or a derivative thereof, preferably HSV-1. Derivatives include recombinant intertypes containing DNA from strains HSV-1 and HSV-2. Such intertype recombinants are described in the art, for example in Thompson et al., (1998) Virus Genes 1 (3); 275286 and Meignier et al., (1998) J. Infect. Dis. 159; 602614.
[00314] [00314] Herpes simplex virus strains can be derived from clinical isolates. Such strains are isolated from infected individuals, such as those with recurrent thrush. Clinical isolates can be screened for a desired capacity or characteristic such as enhanced replication in tumors and / or other cells in vitro and / or in vivo compared to standard laboratory strains, as described in U.S. Patent Numbers 7,063,835 and 7,223,593, each. one of which is incorporated by reference in its entirety. In one embodiment, the herpes simplex virus is a clinical isolate from a recurrent cold sore. Additional strains of the herpes simplex virus 1 include, but are not limited to, strain JS1, strain 17+, strain F, strain KOS and strain Patton.
[00315] [00315] Examples of HSV genes that can be modified include virulence genes encoding proteins such as ICP34.5 (γ34.5). CP34.5 acts as a virulence factor during HSV infection, limits replication in cells that do not divide and makes the virus non-pathogenic. Another HSV gene that can be modified is the gene encoding ICP47. ICP47 sub-regulates the expression of the class I major histocompatibility complex (MHC) on the surface of infected host cells and the binding of Class I MHC to the carrier associated with antigen presentation (TAP). Such actions block the transport of antigenic peptides in the endoplasmic reticulum and load of MHC class I molecules. Another HSV gene that can be modified is ICP6, the large subunit of the ribonucleotide reductase, involved in the nucleotide metabolism and viral DNA synthesis in cells that do not divide but not cells that divide. Thymidine kinase, responsible for phosphorylation of acyclovir into acyclovir-monophosphate, vmw65 trans-activating protein, glycoprotein H, vhs, ICP43 and immediate early genes encoding ICP4, ICP27, ICP22 and / or ICP0 can also be modified (additionally or alternatively to genes referenced above).
[00316] [00316] Herpes virus strains and how to prepare such strains are also described in U.S. Patent Numbers 5,824,318; 6,764,675; 6,770,274; 7,063,835; 7,223,593; 7,749,745; 7,744,899; 8,273,568; 8,420,071; and 8,470,577; WIPO Publications Numbers WO199600007; WO199639841; WO199907394; WO200054795; WO2006002394; and WO201306795; Chinese Patent Numbers CN128303, CN10230334 and CN 10230335; Varghese and Rabkin, (2002) Cancer Gene Therapy 9: 967-97 and Cassady and Ness Parker, (2010) The Open Virology Journal 4: 103-10 108, which are incorporated by reference in their entirety.
[00317] [00317] In one embodiment, the oncolytic virus is the talimogene laherparepvec (IMLYGIC®), derived from a clinical strain (HSV-1 JS1 strain) deposited in the European cell culture collection (ECAAC) under accession number 01010209. In talimogene laherparepvec, the HSV-1 viral genes encoding ICP34.5 and ICP47 were functionally deleted. The functional deletion of ICP47 leads to the early expression of US11,
[00318] [00318] Other examples of oncolytic viruses include RP1 (HSV-1 / ICP34.5- / ICP47- / GM-CSF / GALV-GP R (-); RP-2 (HSV- 1 / ICP34.5- / ICP47- / GM-CSF / GALV-GP R (-) / anti-CTLA-4 ligand; and RP3 (HSV-1 / ICP34.5- / ICP47- / GM-CSF / GALV-GP R (-) / anti- CTLA-4 / co-stimulating ligands (eg, CD40L, 4-1BBL, GITRL, OX40L, ICOSL). In such oncolytic viruses, GALV (gibbon monkey leukemia virus) has been modified with a specific R peptide deletion , resulting in GALV-GP R (-). Such oncolytic viruses are discussed in WO2017118864, WO2017118865, WO2017118866, WO2017118867 and WO2018127713A1, each of which is incorporated by reference in its entirety.
[00319] [00319] Additional examples of oncolytic viruses include NSC-733972, HF-10, BV-2711, JX-594, Myb34.5, AE-618, Brainwel ™ and Heapwel ™, Cavatak® (coxsackievirus, CVA21), HF-10 , Seprehvir®, Reolysin®, enadenotucirev, ONCR-177 and those described in USP 10,105,404, WO2018006005, WO2018026872A1 and WO2017181420, each of which is incorporated by reference in its entirety.
[00320] [00320] In specific modalities, any of the antibodies 20A2, 20C1, 22D4, 20C1.006, 20C1.009, 20A2.003, 22D4.006 and 22D4.017 is administered in combination with a oncolytic virus such as talimogene laherparepvec. In other embodiments, any of the IL-21 fusion proteins described herein is administered in combination with an oncolytic virus such as talimogene laherparepvec. Such combinations can be used to treat a variety of tumor types including, but not limited to, melanoma, head and neck cancer, breast cancer (eg, triple negative breast cancer), colorectal cancer, hepatocellular carcinoma , gastroesophageal cancer (eg, adenocarcinoma or squamous cell carcinoma), non-small cell lung cancer and clear cell renal cell carcinoma. In a particular embodiment, the type of tumor is melanoma. Cases
[00321] [00321] The present disclosure additionally provides kits comprising an IL-21 mutein, PD-1 antigen binding protein (e.g., an anti-PD-1 antibody), a conjugate, fusion protein, nucleic acid, vector or host cell of the present disclosure or a combination thereof. The kit in exemplary aspects comprises at least one IL-21 mutein, PD-1 antigen binding protein (eg, an anti-PD-1 antibody), a conjugate, fusion protein, nucleic acid, vector or host cell of the present disclosure, or a combination thereof, in a container. In exemplary aspects, at least one IL-21 mutein, PD-1 antigen-binding protein (eg, an anti-PD-1 antibody), a conjugate, fusion protein, nucleic acid, vector or cell host of the present disclosure is provided in the kit as a unit dose. For purposes here, "unit dose" refers to a discrete amount dispersed in a suitable carrier. In exemplary aspects, the unit dose is the amount sufficient to provide a subject with a desired effect, eg, cancer treatment.
[00322] [00322] The IL-21 muteins of the present disclosure can be obtained by methods known in the art. Suitable methods of de novo polypeptide synthesis are described in, for example, Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford University Press, Oxford, United Kingdom, 2005; Peptide and Protein Drug Analysis, ed. Reid, R., Marcel Dekker, Inc., 2000; Epitope Mapping, ed. Westwood et al., Oxford University Press, Oxford, United Kingdom, 2000; and U.S. Patent No. 5,449,752. Additional exemplary methods of preparing the peptides of the invention are presented here.
[00323] [00323] In some embodiments, the IL-21 muteins described here are commercially synthesized by companies, such as Synpep (Dublin, CA), Peptide Technologies Corp. (Gaithersburg, MD), Multiple Peptide Systems (San Diego, CA), Peptide 2.0 Inc. (Chantilly, VA) and American Peptide Co. (Sunnyvale, CA). In this regard, IL-21 muteins can be synthetic, recombinant, isolated and / or purified.
[00324] [00324] Likewise, in some respects, IL-21 muteins are recombinantly produced using a nucleic acid encoding the amino acid sequence of the peptide using standard recombinant methods. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual. 3rd ed., Cold Spring Harbor Press, Cold Spring Harbor, NY 2001; and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, NY, 1994.
[00325] [00325] Methods of preparing an IL-21 mutein are provided here. The method, in exemplary embodiments, comprises culturing a host cell of the present disclosure to express the IL-21 mutein and collecting the expressed IL-21 mutein.
[00326] [00326] Methods of preparing fusion protein comprising an IL-21 mutein are also provided herein. The method, in exemplary embodiments, comprises culturing a host cell of the present disclosure to express the fusion protein and collecting the expressed fusion protein.
[00327] [00327] In exemplary embodiments, the method comprises culturing a host cell comprising a nucleic acid encoding the IL-21 mutein or fusion protein as described herein in order to express the IL-21 mutein or fusion protein. The host cell can be any of the host cells described here. In exemplary aspects, the host cell is selected from the group consisting of: CHO cells, NS0 cells, COS cells, VERO cells and BHK cells. In exemplary aspects, the step of culturing a host cell comprises culturing the host cell in a growth medium to support the growth and expansion of the host cell. In exemplary aspects, the growth medium increases cell density, culture viability and productivity in a timely manner. In exemplary aspects, the growth medium comprises amino acids, vitamins, inorganic salts, glucose and serum as a source of growth factors, hormones and attachment factors. In exemplary aspects, the growth medium is a fully chemically defined medium consisting of amino acids, vitamins, trace elements, inorganic salts, lipids and insulin or insulin-like growth factors. In addition to nutrients, the growth medium also helps to maintain pH and osmolality. Various growth media are commercially available and are described in the art. See, eg, Arora, “Cell Culture Media: A Review” MATER METHODS 3: 175 (2013).
[00328] [00328] In exemplary aspects, the method of preparing an IL-21 mutein or fusion protein of the present disclosure comprises culturing the host cell in a feed medium. In exemplary aspects, the method comprises culture in a feed medium in a batch-fed mode. Methods of producing recombinant proteins are known in the art. See, eg, Li et al., “Cell culture processes for monoclonal antibody production” MAbs 2 (5): 466-477 (2010).
[00329] [00329] The method of preparing an IL-21 mutein or fusion protein may comprise one or more steps for purifying the mutein or protein from a cell culture or its supernatant and preferably recovering the purified protein. In exemplary aspects, the method comprises one or more chromatography steps, e.g., affinity chromatography (e.g., protein A affinity chromatography), ion exchange chromatography, hydrophobic interaction chromatography. In exemplary aspects, the method comprises purifying the protein using a Protein A affinity chromatography resin.
[00330] [00330] In exemplary embodiments, the method further comprises steps for formulating the purified protein, etc., thereby obtaining a formulation comprising the purified protein. Such steps are described in Formulation and Process Development Strategies for Manufacturing, eds. Jameel and Hershenson, John Wiley & Sons, Inc. (Hoboken, NJ), 2010. Methods of Use
[00331] [00331] Treatment methods are additionally provided by the present disclosure. The method, in exemplary embodiments, is a method of treating a subject with his need, comprising administering to the subject with his need for a pharmaceutical composition of the present disclosure in an amount effective to treat the subject.
[00332] [00332] The pharmaceutical compositions of the present disclosure are useful for inhibiting PD-1 signaling and / or activating IL-21 signaling. Without being limited to a particular theory, [1] the PD-1 inhibitory activity of the compositions provided here allows such entities to be useful in methods of enhancing T cell activity and enhancing an immune response and, in particular, an immune response. immune against a tumor or cancer; and / or [2] the activating activity of IL-21 of the compositions provided here allows such entities to enhance T cell survival and effector function, restrict terminal differentiation and loss of replicative potential, promote T cell longevity by shifting the effector cells activated towards a more naive T cell phenotype (eg, by intensifying CCR7 expression) and intensifying cytotoxicity against the target cell (eg, cancerous) (eg, by increasing production of IFNγ and granzyme B).
[00333] [00333] Accordingly, methods for enhancing T cell activity in a subject, enhancing T cell survival and effector function, restricting terminal differentiation and loss of replicative potential, promoting T cell longevity and enhancing cytotoxicity are provided here target cells (eg, cancerous). In exemplary embodiments, the methods comprise administering to the subject the pharmaceutical composition of the present disclosure in an effective amount. In exemplary aspects, T cell activity or immune response is directed against a cancer cell or cancerous tissue or a tumor cell or tumor. In exemplary aspects, the immune response is a humoral immune response. In exemplary aspects, the immune response is an innate immune response. In exemplary aspects, the immune response that is enhanced is a T cell-mediated immune response.
[00334] [00334] As used here, the term “intensify” and words arising from it may not be an intensification or increase of 100% or complete. Instead, there are varying degrees of intensification which a person skilled in the art recognizes as having a potential benefit or therapeutic effect. In this regard, the pharmaceutical compositions of the present disclosure can enhance, e.g., T cell activity or enhance an immune response, to any amount or level. In exemplary modalities, the intensification provided by the methods of the present disclosure is at least or about a 10% intensification (eg, at least or about a 20% intensification, at least or about a 30% intensification) at least or about a 40% step up, at least or about a 50% step up, at least or about a 60% step up, at least or about a 70% step up, at least or about an intensification of 80%, at least or about an intensification of 90%, at least or about an intensification of 95%, at least or about an intensification of 98%).
[00335] [00335] Methods of measuring T cell activity and immune responses are known in the art. T cell activity can be measured by, for example, a cytotoxicity assay, such as those described in Fu et al., PLoS ONE 5 (7): e11867 (2010). Other assays for T cell activity are described in Bercovici et al., Clin Diagn Lab Immunol. 7 (6): 859-864 (2000). Methods of measuring immune responses are described, eg, Macatangay et al., Clin Vaccine Immunol 17 (9): 1452-1459 (2010) and Clay et al., Clin Cancer Res. 7 (5): 1127- 35 (2001).
[00336] [00336] Methods of treating a subject with cancer and methods of treating a subject with a solid tumor are additionally provided here. In exemplary embodiments, the method comprises administering to the subject the pharmaceutical composition of the present disclosure in an amount effective for treating cancer or solid tumor in the subject.
[00337] [00337] As used here, the term "treat", as well as the words related to it, do not necessarily imply 100% or complete treatment. Instead, there are varying degrees of treatment that a person skilled in the art recognizes as having a potential benefit or therapeutic effect. In this regard, the cancer treatment methods of the present disclosure can provide any amount or any level of treatment. In addition, the treatment provided by the method of the present disclosure may include treatment of one or more conditions or symptoms or signs of the cancer being treated. Likewise, the treatment provided by the methods of the present disclosure may include slowing the progression of cancer. For example, methods can treat cancer by enhancing T cell activity or an immune response against cancer, reducing tumor or cancer growth, reducing tumor cell metastasis, increasing cell death from tumor or cancer cells and similar. In exemplary aspects, the method treats by delaying the onset or occurrence of cancer by 1 day, 2 days, 4 days, 6 days, 8 days, 10 days, 15 days, 30 days, two months, 4 months, 6 months , 1 year, 2 years, 4 years or more. In exemplary aspects, the methods try to increase the subject's survival. Subjects
[00338] [00338] In some embodiments of the present disclosure, the subject is a mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits, mammals of the order Carnivora, including Felines (cats) and Canines (dogs), mammals of the order Artiodactyla, including Bovines (cows) and Pigs (pigs) or of the order Perssodactyla, including Equidae (horses). In some respects, mammals are of the order Primates, Ceboides or Simoides (monkeys) or Anthropoids (humans and apes). In some ways, the mammal is a human.
[00339] [00339] In exemplary embodiments, the present disclosure provides an IL-21 mutein comprising the amino acid sequence of SEQ ID NO: 2, QGQDX HMXXM XXXXX XVDXL KNXVN DLVPE FLPAP EDVET NCEWS AFSCF
[00340] [00340] In exemplary aspects, IL-21 mutein comprises an amino acid sequence that differs from the human IL-21 amino acid sequence (SEQ ID NO: 1) by no more than 7 amino acids. In exemplary aspects, the IL-21 mutein comprises an amino acid sequence that differs from the human IL-21 amino acid sequence (SEQ ID NO: 1) by 3, 4, 5 or 6 amino acids. In exemplary cases, the IL-21 mutein comprises an amino acid sequence that differs from the human IL-21 amino acid sequence (SEQ ID NO: 1) by 1 or 2 amino acids. In exemplary aspects, the difference (s) between the amino acid sequence of the IL-21 mutein and the amino acid sequence of SEQ ID NO: 1 is / are within amino acids 10-15, inclusive, or amino acids 105- 123 inclusive of SEQ ID NO: 2, optionally, in which the difference (s) occurs in amino acids 11, 14, 15, 109, 110, 112, 113, 116, 119, 120 and / or 123 of SEQ ID NO: 2. In exemplary aspects, the difference (s) between the amino acid sequence of IL-21 mutein and the amino acid sequence of SEQ ID NO: 1 is / are within amino acids 5 -25 inclusive, or amino acids 65-80 inclusive of SEQ ID NO: 2, optionally, in which the difference (s) occurs in amino acids 5, 8, 9, 12, 13, 16, 19, 23, 65, 66, 69, 70, 72, 73, 75, 76, 77, 78, 79 and / or 80 of SEQ ID NO: 2.
[00341] [00341] In some respects, IL-21 mutein comprises an amino acid sequence with an amino acid substitution, in relation to the human IL-21 amino acid sequence (SEQ ID NO: 1). In some cases, amino acid substitution occurs at position 5, 8, 9, 11, 12, 13, 14, 15, 16, 19, 23, 65, 66, 68, 69, 70, 71, 72, 73, 75 , 76, 77, 78, 79, 80, 109, 110, 112, 113, 116, 117, 119, 120 or 123 of SEQ ID NO: 1. In exemplary aspects, amino acid substitution occurs at position 5, 8, 9, 11, 12, 13, 14, 15, 16, 19, 23, 65, 66, 68, 69, 70, 72, 73, 75, 76, 77, 78, 79, 80, 109, 110, 112, 113, 116, 117, 119, 120 or 123 of SEQ ID NO: 1. In exemplary cases, IL-21 mutein comprises an amino acid substitution: a. in position 5, 8, 9, 12, 14, 15, 65, 66, 69, 70, 72, 73, 75, 76, 77, 80, 116 or 119 of SEQ ID NO: 1, where the substitute amino acid is an aliphatic amino acid b. in position 5, 8, 9, 11, 12, 13, 14, 15, 16, 19, 23, 65, 66, 69, 70, 72, 73, 75, 76, 77, 78, 79, 110, 112, 116, 117, 119, 120 or 123 of SEQ ID NO: 1, wherein the substitute amino acid is an acidic amino acid; ç. in position 5, 9, 73, 76, 109, 113 or 116 of SEQ ID NO: 1, where the substitute amino acid is a basic amino acid;
[00342] [00342] In exemplary aspects, the substitute amino acid is a naturally occurring amino acid. In some cases, the IL-21 mutein comprises a substitution of amino acids for an amino acid in the position according to TABLE A. Table A is shown below.
[00343] [00343] In exemplary embodiments, the present disclosure provides an IL-21 mutein comprising an amino acid sequence of any one of SEQ ID NOs: 3-21, 23-56, 58-112, 114-208, 210-222, 224-255 and 283.
[00344] [00344] In exemplary aspects, the IL-21 mutein comprises an amino acid sequence with two amino acid substitutions, in relation to the human IL-21 amino acid sequence (SEQ ID NO: 1). In exemplary aspects, the substitution of amino acids occurs in two of the positions 5, 8, 9, 11, 12, 13, 14, 15, 16, 19, 23, 65, 66, 68, 69, 70, 71, 72, 73 , 75, 76, 77, 78, 79, 80, 109, 110, 112, 113, 116, 117, 119, 120 or 123 of SEQ ID NO: 1. In exemplary cases, amino acid substitutions occur in two of the positions 5, 9, 15, 70, 71, 72, 73 and 76 of SEQ ID NO: 1. Optionally, amino acid substitutions occur in two of positions 5, 9, 73 and 76 of SEQ ID NO: 1. In some respects , one of the substitutions occurs at position 76 of SEQ ID NO: 1. In exemplary cases, the amino acid substituted at position 76 of SEQ ID NO: 1 is an aliphatic amino acid or an acidic amino acid. In exemplary aspects, the IL-21 mutein comprises an amino acid substitution at position 5, 9 or 73 of SEQ ID NO: 1, and the substitute amino acid is an aliphatic or acidic amino acid. In some respects, the IL-21 mutein comprises an amino acid substitution at position 5 of SEQ ID NO: 1, and the substitute amino acid is an amino acid with a side chain amide. In some cases, the aliphatic amino acid is alanine, the acidic amino acid is glutamic acid, or the amino acid with a side chain amide is glutamine. The present disclosure, in exemplary embodiments, provides an IL-21 mutein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 208, 210 to 222, 224 to 248 and 255.
[00345] [00345] With respect to any of the above, IL-21 mutein can bind to the IL-21 receptor with reduced affinity, relative to the wild-type IL-21 affinity for the IL-21 receptor 21. In some respects, the IL-21 receptor has an amino acid sequence of SEQ ID NO: 256 or 261. In some cases, the IL-21 mutein binds to the gamma chain of an IL-21 receptor having a sequence of amino acids of SEQ ID NO: 257. In exemplary cases, the IL-21 mutein of the present disclosure binds to the human IL-21 receptor with a Kd that is greater than or is about 0.04 nM.
[00346] [00346] Conjugates are additionally provided. In exemplary aspects, the conjugate comprises an IL-21 mutein from any of the preceding paragraphs and a heterologous fraction. In exemplary cases, IL-21 is directly attached to the heterologous fraction. In alternative cases, IL-21 is attached to the heterologous moiety via a linker. In some aspects, the linker comprises a peptide, e.g., comprising an amino acid sequence of Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 262). In exemplary aspects, the heterologous fraction is a polypeptide, optionally, wherein the polypeptide is an antigen-binding protein. In some cases, the heterologous polypeptide is an antibody or an antigen-binding antibody fragment thereof.
[00347] [00347] In exemplary embodiments, the present disclosure provides a fusion polypeptide or fusion protein comprising an IL-21 mutein described herein and a heterologous polypeptide or peptide. In some aspects, the fusion polypeptide or fusion protein comprises an immunoglobulin or an antigen-binding antibody fragment thereof. In exemplary embodiments, the present disclosure provides a nucleic acid comprising a sequence of nucleotides encoding an IL-21 mutein described herein. In exemplary embodiments, the present disclosure provides a vector comprising the nucleic acid described herein. In exemplary embodiments, the present disclosure provides a host cell comprising the nucleic acid or the vector described herein. In exemplary embodiments, the present disclosure provides a kit comprising an IL-21 mutein, a nucleic acid, vector, host cell, conjugate, fusion protein, or a combination thereof, as described herein, and a container.
[00348] [00348] Pharmaceutical compositions further comprising an IL-21 mutein, a nucleic acid, vector, host cell, conjugate, fusion protein, or a combination thereof, of the present disclosure, and a pharmaceutically acceptable carrier, excipient or diluent are further provided.
[00349] [00349] Also provided are methods of preparing an IL-21 mutein comprising culturing the host cell of the present disclosure in order to express the IL-21 mutein and collecting the expressed IL-21 mutein. A method of treating a subject in need is additionally provided. The method comprises administering to the subject with his need for a pharmaceutical composition of the present disclosure in an amount effective to treat the subject. In exemplary aspects, the subject has a solid tumor and the pharmaceutical composition is administered to the subject in an amount effective to treat the solid tumor in the subject. Optionally, the solid tumor is selected from the group consisting of: cancers of the head and neck, ovary, cervical, bladder and esophageal, pancreatic, gastrointestinal cancers, gastric cancers, breast, endometrial and colorectal, hepatocellular carcinoma, glioblastoma, bladder cancer, lung , eg, non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma.
[00350] [00350] In exemplary embodiments, the present disclosure provides a PD-1 antigen binding protein comprising (a) an amino acid sequence of the heavy chain complementarity determining region (CDR) 1 (HC) shown in Table D or a sequence selected from the group consisting of: SEQ ID NOs: 312, 322, 332, 342, 352, 362, 372 and 382 or a variant sequence that differs only in one or two amino acids or has at least or about 70% identity of sequences; (b) an HC CDR2 amino acid sequence shown in Table D or a sequence selected from the group consisting of: SEQ ID NOs: 313, 323, 333, 343, 353, 363, 373 and 383 or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (c) an HC CDR3 amino acid sequence shown in Table D or a sequence selected from the group consisting of: SEQ ID NOs:
[00351] [00351] In exemplary embodiments, the present disclosure provides a conjugate comprising a PD-1 antigen binding protein as described in the preceding paragraphs and a heterologous fraction. In exemplary embodiments, the present disclosure provides a fusion polypeptide or fusion protein comprising a PD-1 antigen binding protein as described in the preceding paragraphs and a heterologous polypeptide or peptide. In exemplary embodiments, the present disclosure provides a nucleic acid comprising a nucleotide sequence encoding the PD-1 antigen binding protein, the fusion conjugate or polypeptide or fusion protein, as described in the preceding paragraphs. In exemplary cases, the nucleic acid comprises the sequence of any one of SEQ ID NOs: 392-471. The present disclosure in exemplary embodiments provides a vector comprising the nucleic acid, as described above, as well as a host cell comprising the nucleic acid or the vector, as described above.
[00352] [00352] In another aspect, the present invention is directed to the following modalities:
[00353] [00353] Due to the nature of the at least two constituents of the combination, namely their pharmaceutical activity, the combination can also be referred to as a therapeutic combination. In some embodiments, the combination may be in the form of a pharmaceutical composition. The definitions relating to a pharmaceutical composition provided above apply mutatis mutandis also to this aspect of the invention as specifically recited in the following. In another embodiment, the combination may be in the form of a kit comprising at least two constituents of the combination. In specific modalities, the kit allows simultaneous and / or sequential administration of the constituents of the combination. The definitions relating to a case provided here (in the section entitled "Cases") above apply mutatis mutandis also to this aspect of the invention as specifically recited in what follows.
[00354] [00354] The anti-PD-1 antibody (or its antigen binding antibody fragment) may comprise (a) an amino acid sequence from the complementarity determining region (CDR) 1 of the heavy chain (HC) selected from the group consisting of : SEQ ID NOs: 312, 322, 332, 342, 352, 362, 372 and 382, (see Table D) or a variant sequence that differs only in one or two amino acids or has at least or about 70% of sequence identity; (b) an HC CDR2 amino acid sequence selected from the group consisting of: SEQ ID NOs: 313, 323, 333, 343, 353, 363, 373 and 383, (see Table D) or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (c) an HC CDR3 amino acid sequence selected from the group consisting of: SEQ ID NOs: 314, 324, 334, 344, 354, 364, 374 and 384, (see Table D) or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (d) an amino acid sequence of light chain CDR1 (LC) selected from the group consisting of: 315, 325, 335, 345, 355, 365, 375 and 385, (see Table D) or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (e) an LC CDR2 amino acid sequence selected from the group consisting of: 316, 326, 336, 346, 356, 366, 376 and 386, (see Table D) or a variant sequence that differs only in one or two amino acids or that has at least or about 70% sequence identity; (f) an LC CDR3 amino acid sequence selected from the group consisting of: 317, 327, 337, 347, 357, 367, 377 and 387, (see Table D) or a variant sequence that differs only in one or two amino acids or that has at least or about 70% sequence identity; or (g) a combination of any two, three, four, five or six of (a) - (f).
[00355] [00355] In some embodiments, the anti-PD-1 antibody is the anti-PD-1 antibody as described above in relation to other aspects of the invention, namely any of the anti-PD-1 antibodies described above that are defined by the presence of one or more of the amino acid sequence identifiers listed in Tables D and E. Accordingly, in additional embodiments, the anti-PD-1 antibody protein product comprises such CDRs as shown in Table D and / or comprises combinations of variable light chain (LC) region and heavy chain region (HC) sequences or combinations of light chain (LC) and heavy chain sequences
[00356] [00356] The single chain antibody construct can be a bispecific single chain antibody construct. In a particular embodiment, the antibody construct for combining with the anti-PD-1 antibody (e.g., 20C1.009) is in the form of a bispecific single chain antibody construct.
[00357] [00357] The bispecific single chain antibody construct referred to here can be further characterized by the fact that a peptide linker is located between the first and second domain. Consequently it is a single chain polypeptide or a single chain antibody construct comprising a) a first domain in the form of an scFv, b) a peptide linker, preferably a glycine / serine linker, c) a second domain in the form of a scFv; and, optionally, d) a third domain providing an extended serum half-life, preferably an Fc-based domain.
[00358] [00358] Consequently, a single chain antibody construct denotes a single chain of polypeptides comprising (at least) two domains in the form of an scFv (also referred to as binding domains). According to the above, each binding domain comprises a variable region of an antibody heavy chain ("VH or H region") and a variable region of an antibody light chain ("VL or L region"), where the single chain antibody construct specifically binds to CD3 and a tumor associated antigen (TAA) through the binding domains. The two binding domains can be linked together by a linker, preferably a peptide linker. A non-limiting example of a peptide linker is Gly-Gly-Gly-Gly-Ser (G-G-G-G-S) and its repetitions. The VH region and the VL region within each of the first and second binding domains can be linked together via a peptide linker, for example of the type disclosed and claimed in EP 623679 B1, but in any case long enough to allow the VH region and the VL region of the first binding domain and the VH region and the VL region of the second binding domain to pair with each other such that, together, they are able to specifically bind to the respective targets of the first and second domains connection, namely CD3 and a TAA. For example, single-chain anti-CD19 x anti-CD3 antibody constructs are described in great detail in WO 99/54440 and WO 2004/106381 and WO2008 / 119565. For the avoidance of doubt, the single chain antibody construct includes at least two binding domains, but may include additional binding domains and / or alternative functional domains. Thus, single- or multi-specific antibody chain constructs are encompassed, and single chain antibody constructs are not limited. Since single chain antibody constructs comprise a tumor-associated antigen-binding domain (also referred to here as “TAA”) and another CD3-binding domain, they do not occur naturally and are markedly different in their function from products occurring naturally. A single chain antibody construct is therefore an artificial "hybrid" molecule comprising at least two distinct binding domains with different specificities.
[00359] [00359] As previously described, a single chain antibody construct domain binds to CD3. More preferably it binds to CD3 on the surface of a T cell. The domain is also expected to bind to human CD3,
[00360] [00360] In one embodiment of the present invention, a single chain antibody construct domain binds to human CD3 epsilon (or human CD3 epsilon on the surface of a T cell) and the CD3 epsilon of Callithrix jacchus or Saimiri sciureus . It is also envisaged that said domain will bind to an extracellular epitope of CD3 epsilon, preferably to an extracellular epitope of human CD3 epsilon. The second binding domain is also expected to bind to an extracellular epitope of the human CD3 and Macaca epsilon chain. A preferred CD3 epsilon epitope is comprised within amino acid residues 1-27 of the human CD3 epsilon extracellular domain (see SEQ ID NO: 578). Even more specifically, the epitope comprises at least the amino acid sequence Gln-Asp-Gly-Asn-Glu. Binders having such characteristics are described in detail in WO 2008/119567.
[00361] [00361] Bispecific antibodies or antibody constructs directed against CD3 (human) or specifically against CD3 epsilon are known, and their CDRs, VH and VL sequences can serve as a basis for the CD3 binding domain of the antibody construct of single chain. For example, Kung et al. reported in 1979 the development of
[00362] [00362] It is anticipated for the single chain antibody construct that the CD3-binding domain comprises a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from: (a) CDR-L1 as represented in SEQ ID NO: 590, CDR-L2 as represented in SEQ ID NO: 591 and CDR-L3 as illustrated in SEQ ID NO: 592; (b) CDR-L1 as represented in SEQ ID NO: 647, CDR-L2 as represented in SEQ ID NO: 648 and CDR-L3 as illustrated in SEQ ID NO: 649; and
[00363] [00363] It is also envisaged for the single chain antibody construct that the CD3-binding domain comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 selected from: (a) CDR-H1 as represented in SEQ ID NO: 582, CDR-H2 as represented in SEQ ID NO: 583 and CDR-H3 as illustrated in SEQ ID NO: 584; (b) CDR-H1 as represented in SEQ ID NO: 593, CDR-H2 as represented in SEQ ID NO: 594 and CDR-H3 as illustrated in SEQ ID NO: 595; (c) CDR-H1 as represented in SEQ ID NO: 605, CDR-H2 as represented in SEQ ID NO: 606 and CDR-H3 as illustrated in SEQ ID NO: 607; (d) CDR-H1 as represented in SEQ ID NO: 616, CDR-H2 as represented in SEQ ID NO: 617 and CDR-H3 as illustrated in SEQ ID NO: 618; (e) CDR-H1 as represented in SEQ ID NO: 627, CDR-H2 as represented in SEQ ID NO: 628 and CDR-H3 as illustrated in SEQ ID NO: 629; (f) CDR-H1 as represented in SEQ ID NO: 639, CDR-H2 as represented in SEQ ID NO: 640 and CDR-H3 as illustrated in SEQ ID NO: 641; (g) CDR-H1 as represented in SEQ ID NO: 650, CDR-H2 as represented in SEQ ID NO: 651 and CDR-H3 as illustrated in SEQ ID NO: 652;
[00364] [00364] It is furthermore foreseen for the single chain antibody construct that the CD3-binding domain comprises a VL region comprising CDR-L1, CDR-L2 and CDR-L3 and a VH region comprising CDR-H1, CDR -H2 and CDR-H3 selected from: (a) CDR-L1 as represented in SEQ ID NO: 579, CDR-L2 as represented in SEQ ID NO: 580, CDR-L3 as represented in SEQ ID NO: 581, CDR- H1 as represented in SEQ ID NO: 582, CDR-H2 as represented in SEQ ID NO: 583 and CDR-H3 as illustrated in SEQ ID NO: 584; (b) CDR-L1 as represented in SEQ ID NO: 590, CDR-L2 as represented in SEQ ID NO: 591, CDR-L3 as represented in SEQ ID NO: 592, CDR-H1 as represented in SEQ ID NO: 593 , CDR-H2 as represented in SEQ ID NO: 594 and CDR-H3 as illustrated in SEQ ID NO: 595; (c) CDR-L1 as represented in SEQ ID NO: 602, CDR-L2 as represented in SEQ ID NO: 603, CDR-L3 as represented in SEQ ID NO: 604, CDR-H1 as represented in SEQ ID NO: 605 , CDR-H2 as represented in SEQ ID NO: 606 and CDR-H3 as illustrated in SEQ ID NO: 607; (d) CDR-L1 as represented in SEQ ID NO: 613, CDR-L2 as represented in SEQ ID NO: 614, CDR-L3 as represented in SEQ ID NO: 615, CDR-H1 as represented in SEQ ID NO: 616 , CDR-H2 as represented in SEQ ID NO: 617 and CDR-H3 as illustrated in SEQ ID NO: 618; (e) CDR-L1 as represented in SEQ ID NO: 624, CDR-L2 as represented in SEQ ID NO: 625, CDR-L3 as represented in SEQ ID NO: 626, CDR-H1 as represented in SEQ ID NO: 627 , CDR-H2 as represented in SEQ ID NO: 628 and CDR-H3 as illustrated in SEQ ID NO: 629; (f) CDR-L1 as represented in SEQ ID NO: 636, CDR-L2 as represented in SEQ ID NO: 637, CDR-L3 as represented in SEQ ID NO: 638, CDR-H1 as represented in SEQ ID NO: 639 , CDR-H2 as represented in SEQ ID NO: 640 and CDR-H3 as illustrated in SEQ ID NO: 641; (g) CDR-L1 as represented in SEQ ID NO: 647, CDR-L2 as represented in SEQ ID NO: 648, CDR-L3 as represented in SEQ ID NO: 649, CDR-H1 as represented in SEQ ID NO: 650 , CDR-H2 as represented in SEQ ID NO: 651 and CDR-H3 as illustrated in SEQ ID NO: 652; (h) CDR-L1 as represented in SEQ ID NO: 658, CDR-L2 as represented in SEQ ID NO: 659, CDR-L3 as represented in SEQ ID NO: 660, CDR-H1 as represented in SEQ ID NO: 661 , CDR-H2 as represented in SEQ ID NO: 662 and CDR-H3 as illustrated in SEQ ID NO: 663;
[00365] [00365] It is envisaged for the single chain antibody construct that the CD3-binding domain comprises a VL region selected from the group consisting of a VL region as illustrated in any of SEQ ID NO: 598, SEQ ID NO: 599 , SEQ ID NO: 633, SEQ ID NO: 655, SEQ ID NO: 677 and SEQ ID NO:
[00366] [00366] The CD3-binding domain is also expected to comprise a VH region selected from the group consisting of a VH region as illustrated in any of SEQ ID NO: 585, SEQ ID NO: 586, SEQ ID NO: 596, SEQ ID NO: 597, SEQ ID NO: 608, SEQ ID NO: 609, SEQ ID NO: 619, SEQ ID NO: 620, SEQ ID NO: 630, SEQ ID NO: 631, SEQ ID NO: 642, SEQ ID NO: 643, SEQ ID NO: 653, SEQ ID NO: 654, SEQ ID NO: 664, SEQ ID NO: 665, SEQ ID NO: 675, SEQ ID NO: 676, SEQ ID NO: 681, SEQ ID NO: 690 and SEQ ID NO:
[00367] [00367] In specific embodiments, the single chain antibody construct is characterized by a CD3-binding domain comprising a VL region and a VH region selected from the group consisting of: (a) a VL region as represented in SEQ ID NO : 587 or 599 and a VH region as illustrated in SEQ ID NO. 585 or 586; (b) a VL region as represented in SEQ ID NO: 598 or 599 and a VH region as illustrated in SEQ ID NO. 596 or 597; (c) a VL region as represented in SEQ ID NO: 610 or 599 and a VH region as illustrated in SEQ ID NO. 608 or 609; (d) a VL region as represented in SEQ ID NO: 621 or 599 and a VH region as illustrated in SEQ ID NO. 619 or 620; (e) a VL region as represented in SEQ ID NO: 632 or 633 and a VH region as illustrated in SEQ ID NO. 630 or 631; (f) a VL region as represented in SEQ ID NO: 644 or 599 and a VH region as illustrated in SEQ ID NO. 642 or 643; (g) a VL region as represented in SEQ ID NO: 655 or 633 and a VH region as illustrated in SEQ ID NO. 653 or 654; (h) a VL region as represented in SEQ ID NO: 666 or 599 and a VH region as illustrated in SEQ ID NO. 664 or 665; (i) a VL region as represented in SEQ ID NO: 677 or 678 and a VH region as illustrated in SEQ ID NO. 675 or 676; (j) a VL region as represented in SEQ ID NO: 692 or 678 and a VH region as illustrated in SEQ ID NO. 690 or 691; and (k) a VL region as illustrated in SEQ ID NO. 682 and a VH region as represented in SEQ ID NO: 681.
[00368] [00368] A preferred embodiment of the single chain antibody construct described above is characterized in that the CD3-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
[00369] [00369] The single chain antibody construct can comprise a domain providing an extended serum half-life. Examples of means or domains for extending the serum half-life of single chain antibody constructs include peptides, proteins or protein domains, which are fused or otherwise attached to the antibody constructs. The group of peptides, proteins or protein domains includes peptides binding to other proteins with a preferred pharmacokinetic profile in the human body such as serum albumin (see WO 2009/127691). An alternative concept of such half-life extending peptides includes peptides binding to the neonatal Fc receptor (FcRn, see WO 2007/098420), which can also be used in the antibody constructs of the present invention. The concept of attachment of larger protein domains or complete proteins includes the fusion of human serum albumin, variants or mutants of human serum albumin (see WO 2011/051489, WO 2012/059486, WO 2012/150319, WO 2013/135896 , WO 2014/072481, WO 2013/075066) or their domains, as well as the fusion of an immunoglobulin constant region (Fc domain) and its variants. Such variants of Fc domains are called Fc-based domains and can, for example, be optimized / modified to allow the desired pairing of dimers or multimers, to abolish Fc receptor binding (eg, to avoid ADCC or CDC) or for other reasons. An additional concept known in the art for extending the half-life of substances or molecules in the human body is the pegylation of these molecules (such as the antibody constructs described here).
[00370] [00370] In one embodiment, single chain antibody constructs can be linked (e.g., via peptide bonds) with a fusion partner (such as a protein, polypeptide or peptide), e.g. for the purpose of extending the half-life in the construct serum. These fusion partners can be selected from human serum albumin (“HSA” or “HALB”) as well as sequence variants, peptides binding to HSA, peptides binding to FcRn (“FcRn BP”) or constructs comprising a region of Fc (antibody derived). In general, the fusion partners can be linked to the N-terminus or the C-terminus of the antibody constructs according to the invention, either directly (e.g., via peptide bonding) or via a peptide linker such as ( GGGGS) n (where "n" is an integer of 2 or more, eg, 2 or 3 or 4).
[00371] [00371] According to one embodiment, the single chain antibody construct comprises (in addition to the first and second domain) a third domain, namely an Fc-based domain as described in WO 2017/134140 (incorporated herein by reference) which extends the serum half-life, which comprises two polypeptide monomers, each comprising a hinge domain, CH2 and CH3, wherein said two polypeptide monomers are fused together via a peptide linker. Said third domain comprises an N-terminal to C-terminal order: hinge-CH2-CH3-ligand-hinge-CH2-CH3.
[00372] [00372] In line with the present invention, a "hinge" is an IgG hinge region. This region can be identified by analogy using Kabat numbering, see, for example, Kabat positions 223-243. In line with the above, the minimum requirement for a “hinge” is the amino acid residues corresponding to the IgG1 sequence stretch from D231 to P243 according to the Kabat numbering. The terms “CH2” and “CH3” refer to the immunoglobulin 2 and 3 heavy chain constant regions. These regions can also be identified by analogy using Kabat numbering, see, for example, Kabat positions 244- 360 for CH2 and Kabat positions 361-478 for CH3. It is understood that there is some variation between the immunoglobulins in terms of their IgG1 Fc region, IgG2 Fc region, IgG3 Fc region, IgG4 Fc region, IgM Fc region, IgA Fc region, region of IgD Fc and IgE Fc region (see, e.g., Padlan, Molecular Immunology, 31 (3), 169-217 (1993)). The term Fc region refers to the last two IgA and IgG heavy chain constant regions and the last three IgE and IgM heavy chain constant regions. The Fc region may also include the N-terminal flexible hinge with respect to these domains. For IgA and IgM, the Fc region can include the J chain. For IgG, the Fc region comprises the immunoglobulin domains CH2 and CH3 and the hinge between the first two domains and CH2. Although the boundaries1 of the Fc region of an immunoglobulin may vary, an example of a human IgG heavy chain Fc portion comprising a functional hinge, the CH2 and CH3 domains can be defined, e.g., to comprise D231 residues ( hinge domain) to P476 (from the C terminal of the CH3 domain) or D231 to L476, respectively, for IgG4, where the numbering is according to Kabat.
[00373] [00373] The single chain antibody construct referred to here can therefore comprise in an order from N- to C-terminal: (a) the first domain; (b) a peptide linker; (c) the second domain; (d) a peptide linker; (e) the first polypeptide monomer of the third domain (comprising a hinge, a CH2 and CH3 domain); (f) a peptide linker; and (g) the second polypeptide monomer of the third domain (comprising a hinge, a CH2 and CH3 domain).
[00374] [00374] The combination of anti-PD-1 antibody (e.g., 20C1.009) with single chain antibody constructs is particularly advantageous since it could be shown that single chain antibody constructs showed efficiency of death superior cell count when used in combination with the previously defined anti-PD-1 antibodies (such as 20C1.009). An improvement in the efficiency of cell death could be observed for different target cells, such as where the target cells were of solid malignancy or heme and also when the cells were of tumor types that are not normally recognized as being sensitive to anti-cancer treatment. PD-1 (such as, eg, prostate tumor cells; Figures 40A and 40B), as well as when T cells are not limited (E: T ratio of 1: 1), suggesting the combination of anti- PD-1 and a bispecific single chain antibody construct will be effective even in indications characterized by an abundance of T cells. In addition, improvement could be shown in single chain antibody constructs regardless of whether the constructs contained an extensor domain or not. half-life, such as an Fc-based portion. In addition, it could be shown that single chain antibody constructs consistently induce PD-1 expression in target cells.
[00375] [00375] In some embodiments, the single chain antibody constructs to be combined with the anti-PD-1 antibody (such as 20C1.009) are single chain antibody constructs that have (at least) a binding domain to TAA directed against the TAAs selected from the group consisting of CD19, CD33, PSMA, BCMA, FLT3, EGFRvIII, DLL3, MUC17, CLND18.2 and EpCAM. In such embodiments, the single-chain antibody constructs for combining with the anti-PD-1 antibody (eg, 20C1.009) are single-chain anti-CD19 x anti-CD3 antibody constructs, antibody constructs of anti-CD33 x anti-CD3 single chain, anti-PSMA x anti-CD3 single chain antibody constructs, anti-BCMA x anti-CD3 single chain antibody constructs, anti-FLT3 x anti-CD3 single chain antibody constructs CD3, anti-EGFRvIII x anti-CD3 single chain antibody constructs, anti-DLL3 x anti-CD3 single chain antibody constructs, anti-MUC17 x anti-CD3 single chain antibody constructs, single chain antibody constructs anti- CLND18.2 x anti-CD3 and anti-EpCAM x anti-CD3 single chain antibody constructs.
[00376] [00376] In other embodiments, the invention relates to a method of treating a subject with his need, comprising administering to the subject the combination of modalities 1 to 3. In some modalities, the subject has a cancer and the combination of any of modalities 1 to 3 is administered to the subject in an amount effective to treat the subject's cancer. As such, said combination is for therapeutic use and is for use in the treatment of cancer. The definitions for treatment, administration and cancer (including any of the recited types of cancer) provided above apply mutatis mutandis to this aspect of the invention as specifically recited in the following.
[00377] [00377] The anti-CD19 x anti-CD3 single-chain antibody constructs combined with an anti-PD-1 antibody (eg, 20C1.009) are used according to the invention for the treatment of acute lymphoblastic leukemia (ALL), diffuse relapsed or refractory large diffuse B-cell lymphoma (DLBCL), mantle cell lymphoma and / or follicular lymphoma. The justification for the treatment of said cancers with anti-CD19 x anti-CD3 single chain antibody constructs as well as preferred anti-CD19 x anti-CD3 single chain antibody constructs is provided in WO 99/54440 and WO 17/134140 .
[00378] [00378] The single-chain anti-CD33 x anti-CD3 antibody constructs combined with an anti-PD-1 antibody (eg, 20C1.009) are used according to the invention for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The rationale for treating said cancer with preferred anti-CD33 x anti-CD3 single chain antibody constructs as well as preferred anti-CD33 x anti-CD3 single chain antibody constructs is described in WO 2008/119567 and WO 2017/134140 .
[00379] [00379] Anti-PSMA x anti-CD3 single-chain antibody constructs combined with an anti-PD-1 antibody (eg, 20C1.009) are used according to the invention for the treatment of prostate cancer The rationale for treating said cancer with preferred anti-PSMA x anti-CD3 single chain antibody constructs as well as preferred anti-PSMA x anti-CD3 single chain antibody constructs is described in WO 2010/037836 and WO 2017/134158 .
[00380] [00380] Anti-BCMA x anti-CD3 single-chain antibody constructs combined with an anti-PD-1 antibody (e.g., 20C1.009) are used according to the invention for the treatment of multiple myeloma. The justification for treating said cancer with preferred anti-BCMA x anti-CD3 single chain antibody constructs as well as preferred anti-BCMA x anti-CD3 single chain antibody constructs is described in WO 2013/072406 and WO 2017/134134 .
[00381] [00381] Anti-FLT3 x anti-CD3 single-chain antibody constructs combined with an anti-PD-1 antibody (eg, 20C1.009) are used according to the invention for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The justification for the treatment of said cancer with preferred anti-FLT3 x anti-CD3 single chain antibody constructs as well as preferred anti-FLT3 x anti-CD3 single chain antibody constructs is described in WO 2017/021362.
[00382] [00382] The single-chain anti-EGFRvIII x anti-CD3 constructs combined with an anti-PD-1 antibody (e.g., 20C1.009) are used according to the invention for the treatment of glioblastoma. The rationale for treating said cancer with anti-EGFRvIII x anti-CD3 single chain antibody constructs as well as preferred anti-EGFRvIII x anti-CD3 single chain antibody constructs is described in WO 2017/021370.
[00383] [00383] Anti-DLL3 x anti-CD3 single chain antibody constructs combined with an anti-PD-1 antibody (eg, 20C1.009) are used according to the invention for the treatment of lung cancer small cell and neuroendocrine tumors expressing DLL3. The justification for treating said cancer with preferred anti-DLL3 x anti-CD3 single chain antibody constructs as well as preferred anti-DLL3 x anti-CD3 single chain antibody constructs is described in WO 2017/021349.
[00384] [00384] Anti-MUC17 x anti-CD3 single chain antibody constructs combined with an anti-PD-1 antibody (e.g., 20C1.009) are used according to the invention for the treatment of gastrointestinal cancers. The rationale for treating said cancers with anti-MUC17 x anti-CD3 single chain antibody constructs as well as preferred anti-MUC17 x anti-CD3 single chain antibody constructs is described in PCT / US18 / 68118.
[00385] [00385] Anti-EpCAM x anti-CD3 single-chain antibody constructs combined with an anti-PD-1 antibody (eg, 20C1.009) are used according to the invention for the treatment of lung cancer (adenocarcinoma and small cell), gastrointestinal cancer, adenocarcinoma of the gastro-oesophageal junction, colorectal cancer, breast cancer, hormone-refractory prostate cancer, ovarian cancer, malignant nasopharyngeal neoplasm, colon cancer, pancreatic cancer or esophageal carcinoma. The rationale for treating said cancers with anti-EpCAM x anti-CD3 single chain antibody constructs as well as preferred anti-EpCAM x anti-CD3 single chain antibody constructs is described in WO 2005/040220.
[00386] [00386] Furthermore, single chain antibody constructs as referred to herein can be bivalent and polyvalent / multivalent constructs as well as bispecific and polyspecific / multispecific constructs, which specifically bind to two, three or more antigenic structures, across domains separate connection points. Such constructs may have more binding strengths than specificities, eg, in a case where there are two binding domains for the first target and one binding domain for the second target (CD3), or vice versa, if that where the construct is trivalent and bispecific. In general, the term “bispecific” as used in relation to the bispecific single chain antibody construct referred to here includes the meaning that said construct binds to (at least) two different antigens, one of which is CD3 and the other is a TAA.
[00387] [00387] The bispecific single chain antibody constructs of the present invention are preferably "in vitro generated bispecific single chain antibody constructs" and / or "recombinant bispecific single chain antibody constructs". In the context of the present invention, the term "generated in vitro" refers to a bispecific single chain antibody construct according to the above definition where all or part of the binding domain or a variable region (eg, at least one CDR) is generated in a selection of non-immune cells, eg an in vitro phage display, on a protein chip or any other method in which candidate amino acid sequences can be tested for their ability to bind to an antigen. This term, therefore, preferably excludes sequences generated only by genomic redeployment in an immune cell in an animal. The first and / or second binding domain of the bispecific single chain antibody construct is predicted to be produced by or obtainable by phage display or library screening methods rather than by grafting CDR sequences from a pre-existing antibody (monoclonal) in a mold. A "recombinant bispecific single chain antibody construct" is a bispecific single chain antibody construct generated or produced using (inter alia) recombinant DNA technology or genetic manipulation.
[00388] [00388] Bispecific single chain antibody constructs are expected to be monoclonal. As used here,
[00389] [00389] In the context of this aspect of the present invention, the term "epitope" refers to the part or region of the antigen that is recognized / immunospecifically recognized by the binding domain. An "epitope" is antigenic, so the term epitope is sometimes also referred to as "antigenic structure" or "antigenic determinant". The part of the binding domain that binds to the epitope is called a paratope. Specific binding is believed to be achieved for specific reasons in the amino acid sequence of the binding domain and the antigen. Thus, the connection is achieved as a result of its primary, secondary and / or tertiary structure as well as the result of potential secondary modifications of the referred structures. The specific interaction of the parotope with its antigenic determinant can result in a simple binding of that site to the antigen. In some cases, the specific interaction may alternatively or additionally result in the initiation of a signal, eg, due to the induction of a change in antigen conformation, an antigen oligomerization, etc.
[00390] [00390] Methods for producing bispecific single chain antibody constructs are well known to the skilled person. For example, it is known that for “single chain Fv” (scFv) the two domains of the Fv fragment, VL and VH, are encoded by separate genes, but can be joined, using recombinant methods, by an artificial ligand - as described above - which allows them to be constructed as a single protein chain in which the VL and VH regions pair to form a monovalent molecule; see, e.g., Huston et al. (1988) Proc. Natl. Acad. Sci USA 85: 5879-5883. These antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are evaluated for function in the same way as are full-length antibodies or IgGs. A single chain variable fragment (scFv) is therefore a fusion protein of the immunoglobulin heavy chain (VH) and light chain (VL) variable region, usually connected with a short peptide linker. The binder is usually rich in glycine for flexibility, as well as serine or threonine for solubility (as previously described). This protein retains the specificity of the original immunoglobulin, despite the removal of the constant regions and the introduction of the binding agent.
[00391] [00391] The techniques described for producing single chain antibody constructs (see, inter alia, U.S. Patent No. 4,946,778, Kontermann and Dübel (2010), loc. Cit. And Little (2009), loc. Cit.) they can be adapted to produce single chain antibody constructs specifically by recognizing an elected target (s).
[00392] [00392] Variable fragments of bivalent chain (also called divalent) or single chain (bi-scFvs or di-scFvs) having the format (scFv) 2 can be genetically modified by linking two scFv molecules (for example, with ligands according to described earlier in this document). Linking can be done by producing a single polypeptide chain with two VH regions and two VL regions, giving rise to tandem scFvs (see, eg, Kufer P. et al., (2004) Trends in Biotechnology 22 (5 ): 238-244).
[00393] [00393] It is also provided that the bispecific single chain antibody construct of the invention has, in addition to its function to bind to target molecules, namely the tumor-associated antigen (TAA) and CD3, an additional function. In this format, the antibody construct can be a trifunctional or multifunctional antibody construct by targeting target cells through binding to TAA, mediating cytotoxic T cell activity through binding to CD3 and providing an additional function such as means or domains to enhance or extend serum half-life, a fully functional or modified Fc constant domain mediating ADCC through the recruitment of effector cells, a marker (fluorescent, etc.), a therapeutic agent such as a toxin or radionuclide, a additional domain for connection to an additional TAA, etc.
[00394] [00394] The following examples are given merely to illustrate the present disclosure and not in any way to limit its scope.
[00395] [00395] This example demonstrates that combination therapy comprising a recombinant PD-1 and IL-21 blocking antibody is superior to a corresponding monotherapy.
[00396] [00396] In a preclinical study, the effects of a combination treatment of a monoclonal PD-1 blocking antibody and recombinant murine IL-21 (rmIL-21) were compared with the effects of monotherapy treatment of the blocking antibody PD-1 or rmIL-21.
[00397] [00397] On Day 1, CT26 / 3E5 colon carcinoma cells were implanted in BALB / c mice to initiate tumor growth. On Day 12, tumors were measured and mice were randomized into 4 groups (10 mice per group): Group 1 received an intraperitoneal (IP) injection of 300 µg isotype control antibody (mIgG1), Group 2 received an IP injection of 300 µg of an antibody against PD-1 blocker, Group 3 received 50 µg of rmIL-21 and Group 4 received both an antibody against PD-1 blocker (300 µg) and rmIL-21 (50 µg) . Groups 1, 2 and 4 received antibody once every 3 days, and Groups 3 and 4 received rmIL-21 3x weekly for 3 weeks. Dosing ended on Day 33.
[00398] [00398] The tumor volume was monitored throughout the study. As shown in Figures 1A-1D, the tumor size increased to a greater extent for Group 1 and to a lesser extent for Group 4.
[00399] [00399] Survival, as measured by the Kaplan-Meier log-rank Mantel-Cox analysis, was the main end point of this study. As shown in Figure 2 and Table 1, the percentage of survival and median survival were the highest for Group 4. Notably, two subjects were tumor-free in Group 4 (Table 1). TABLE 1 Survival Group Subjects Exempt Median (Days) of Tumor 1 25 0 2 29 0 3 27 0 4 37.5 2
[00400] [00400] These results demonstrate that a combination of a monoclonal PD-1 blocking antibody and recombinant mIL-21 provides superior survival advantage versus any of the components alone as monotherapy.
[00401] [00401] This example demonstrates the design and construction of multiple platforms aimed at providing a combination of PD-1 inhibition and IL-21 signaling.
[00402] [00402] The results obtained in Example 1 demonstrate that the advantages of a combinatorial approach to IL-21 signaling and PD-1 inhibition for the treatment of subjects with tumors. Careful consideration was required of how IL-21 should be administered, however, due to IL-21's ability to both potentiate CD8 T cell responses and suppress antigen presentation and T cell initiation. Additionally, IL- 21R is widely expressed in human tissues (eg, antigen presenting cells (APCs), NK, B and T cells), thus requiring careful consideration to avoid off-target effects (eg, IL activity - 21 outside a tumor environment) and elimination of IL-21 as it binds to its receptor in different tissues.
[00403] [00403] A two-pronged approach was devised to deal with the above considerations. Firstly, IL-21 muteins with attenuated activity were generated - through reduced binding of IL-21 muteins to IL-21R -. It was conceived that such IL-21 muteins would have reduced activity when spread throughout the body, but that such activity would be "rescued" if IL-21 muteins could be concentrated in target T cells (eg, cancerous). That is, IL-21 muteins, once present and concentrated in target cells, would exhibit IL-21 therapeutic activity in the aggregate. Second, IL-21 muteins were fused to a targeting arm, such as a monoclonal antibody, in order to target IL-21 muteins to relevant cells (eg, cancer cells). In order to deliver the IL-21 muteins to a target cancer cell, they were fused to an anti-PD-1 mAb. The use of an anti-PD-1 mAb had the added benefit of preventing signaling via PD-1 / PD-L1 (thus acting as a checkpoint inhibitor).
[00404] [00404] Without being limited by any particular theory, it was hypothesized that a fusion protein comprising an anti-PD-1 antibody fused to an IL-21 mutein would provide a more durable response against cells targeted for destruction. For example, [1] CD8 + T cells expressing PD-1 would be linked by the fusion protein's anti-PD-1 mAb and [2] the simultaneous binding of the IL-21 mutein of the fusion protein to the expressed IL-21 receptor. by CD8 + T cells would lead to increased proliferation of T cells as well as increased production and secretion of IFNγ by T cells, which would improve overall cytotoxicity against target cells. It was further hypothesized that the intracellular signaling pathways activated by IL-21 would prevent terminal differentiation and loss of associated effector function and apoptosis. See Figure 3.
[00405] [00405] Added design considerations included the mAb valency (eg, monovalent or bivalent mAb), requirement for Fc effector function, cytokine fusion site (mAb C or N terminus), inclusion of a ligand and remediation of planned secondary modification or cutting sites.
[00406] [00406] Various fusion protein formats were considered and four fusion constructs were cloned and expressed for proof of concept experiments. Wild-type IL-21 (WT) was fused to the C-terminus of a mAb IgG against bivalent PD-1 as (1) an IL-21 homodimer without any linker; (2) an IL-21 homodimer with a GGGGS linker (SEQ ID NO: 262); (3) an IL-21 monomer without any ligand, but with charge pair mutations in the IgG Fc to drive heterodimerization; and (4) an IL-21 monomer with both a GGGGS linker (SEQ ID NO: 262) and charge pair mutations. All four fusion protein constructs included the following modifications in the mAb Fc region, numbered according to the EU system: N297G, R292C, V302C (SEFL2-2 mutations). The charge pair mutations used were the V1 mutations (i.e., K409D & K392D in one heavy chain and D399K & E356K in the other heavy chain). All four fusion protein constructs were designed to have a C-terminal lysine removed to prevent cutting.
[00407] [00407] The fusion constructs were screened for IL-21 activity in cell assays using two variants (PD-1 + vas and PD-1-vas) from an IL-21R positive Hut78 cell line ( IL-21R +). In each cell line, phosphorylation of STAT3 was measured as a surrogate measure of IL-21 activity. Both Hut78 cell variants were exposed to (i) recombinant human IL-21 (rhIL-21) alone, (ii) anti-PD-1 mAb alone, (iii) anti-PD-1 mAb fused to an IL homodimer -21 with a linker, (iv) anti-PD-1 mAb fused to an IL-21 homodimer without a linker, (v) anti-PD-1 mAb fused to an IL-21 monomer with a linker or (vi ) anti-PD-1 mAb fused to an IL-21 monomer without a linker. The results of the STAT3 phosphorylation assay and the EC50s of each molecule for STAT signaling are shown in Figures 5A and 5B and Table 2, respectively. TABLE 2 PD-1-vas PD-1 + vas Molecule EC50 (pM) EC50 (pM) rhIL-21 153 204 anti-PD-1 mAb - Fusion of anti-PD-1 mAb + 1,184 97 IL-21 homodimer , without anti-PD-1 mAb fusion linker + 1,822 60 IL-21 homodimer, + anti-PD-1 mAb fusion linker + 523 70 IL-21 monomer, without anti-PD-1 + mAb fusion linker 392 58 IL-21 monomer + ligand
[00408] [00408] As shown in Figure 5A and Table 2 (middle column), the fusion protein comprising an anti-PD-1 mAb with an IL-21 homodimer exhibited 10 times less potency compared to rhIL-21 in PD cells -1-vas. RhIL-21 was also more potent compared to the fusion protein comprising the IL-21 monomer. Despite having only a fraction of IL-21, the monomeric fusion protein showed greater potency compared to the homodimer having two fractions of IL-21. These results suggest that the monomer exhibits higher IL-21 activity in PD-1-vas cells and / or suggest that the homodimer fusion protein format may confer partial attenuation of IL-21 activity (eg, possibly through steric interactions between IL-21 fractions).
[00409] [00409] This study also allowed evaluation of the ligand between the IL-21 portion and the C-terminal of IgG. As shown in Table 2 (middle column) and Figures 5A and 5B (solid line = no ligand; dotted line = ligand), the presence of a ligand does not appear to affect IL-21 activity. Consequently, all future constructs were made without the linker to reduce the amount of non-native sequences in the fusion proteins.
[00410] [00410] The effect of PD-1 expression on IL-21 activity was evaluated by comparing the results of the STAT3 phosphorylation assay between PD-1-vas cells and PD-1 + vas cells. As shown in Figure 5B, the IL-21 activity of each of the IL-21 homodimer and monomer fusion proteins in PD-1 + vas cells was essentially the same.
[00411] Together, these results demonstrate that IL-21 signaling, in the absence of PD-1 expression in a target cell, can be attenuated by fusing IL-21 to an anti-PD-1 mAb. In addition, IL-21 signaling from an IL-21 fused to an anti-PD-1 mAb is rescued in cells expressing PD-1.
[00412] [00412] This example demonstrates the design, construction and characterization of multiple IL-21 muteins.
[00413] [00413] To gain an understanding of the pharmacokinetic / pharmacodynamic profile (PK / PD) of the fusion protein, a fusion protein comprising an IgG fused to an IL-21 WT homodimer was tested in vivo on a monkey-kinomologist.
[00414] [00414] The homodimer fusion protein comprising IL-21 WT fused to an anti-PD-1 mAb was intravenously administered to 6 animals at a low dose (250 µg / kg) or a high dose (1000 µg / kg). An IgG antibody domain (150 µg / kg) was operated as a control. Serum concentrations were measured over time, and Cmax, AUClast, half-life (t1 / 2), Vss and Cl were determined. The results are shown in Figure 6 and Table 3. TABLE 3 No. Dose Cmax AUCLast half-Vss CL Animal (µg / kg) (µg / mL) (hr * µg / mL) life (mL / kg) (mL / hr / (t1 / 2) kg) (hr) 979 250 78.5 331 9.99 7,400 635 980 250 72.4 463 10.6 7,136 521 981 250 101 429 19.6 8,904 366 Dose 250 84,0 ± 408 ± 69 13,4 7,813 ± 507 ± Low 15 , 1 ± 5.4 954 135 Average 982 1,000 401 3,500 43 6,943 281
[00415] [00415] Regarding IgG control (data not shown), the homodimer fusion protein comprising an anti-PD-1 mAb and IL-21 WT exhibited increased elimination and lower exposures. It was thus determined that, in order to intensify the exposure of the fusion protein and to minimize the effects of off-target IL-21 (ie, to minimize IL-21 signaling in immune cells that do not express the PD-1 receptor) , IL-21 mutagenesis would be required to attenuate signaling through IL-21R. Accordingly, a fusion protein comprising a mutated IL-21 was designed to bind less strongly to IL-21R in cells that did not express PD-1. It was hypothesized that the fusion protein would first bind to the PD-1 target (by binding to the anti-PD-1 antibody) with high affinity which would then drive the second lower affinity interaction between the mutein of IL-21 and IL-21R (alpha chain). In the absence of PD-1 receptor, it was hypothesized that the fusion proteins would not bind to cells not expressing the PD-1 receptor, regardless of IL-21R expression.
[00416] [00416] Structure-guided manipulation was used to create a panel of 141 muteins of IL-21, each having a unique amino acid substitution compared to the IL-21 WT amino acid sequence. Each mutein is designed to have reduced affinity for the IL-21R alpha subunit (101 muteins) or the IL-21R gamma subunit (40 muteins). Each mutein in the panel was expressed as a fusion protein with a PD-1 mAb (PD-1 x IL-21 mutein) and subsequently assessed for its ability to bind IL-21R using the FortéBio Octet® system (Pall FortéBio; Fremont, CA) and screened for activity using the IL-21R + T cell line (Hut78) using STAT3 phosphorylation as a substitute for IL-21 activity. To select muteins that have the least potential for off-target activity, the selection criterion was set to an attenuation greater than 20 times in IL-21 signaling vs. 3.7 nM rhIL-21 in PD-1-vas cells.
[00417] [00417] A complete list of 141 muteins is shown in Table 4. TABLE 4 SEQ ID mutein NO: Times of IL-21R α Kd chain replacement- Mutant reduction of IL- or Fc AA (nM) of 21 γ chain Affinity of IL-21 1 R5D 74 α NB 2 R5E 75 α NB 3 R5G 76 α NB 4 R5H 77 α WB 5 R5I 78 α WB 6 R5K 79 α WB
[00418] [00418] Exemplary results from the STAT3 phosphorylation assays using IL-21 muteins are shown in Figure 7 (muteins with reduced affinity for IL-21Rα) and Figure 8 (muteins with reduced affinity for IL-21Rγ). As shown in these figures, several muteins demonstrated a more than 20-fold attenuation in IL-21 activity in PD-1-vas cells but retained activity in PD-1 + vas cells. As shown in Figures 9A-9B, mutant 51 (R65P) (solid triangles) was one such mutant that demonstrated a greater than 20x reduction in IL-21 activity in PD-vas cells but exhibited a level of IL- 21 that was similar to that achieved by rhIL-21 in cells expressing PD-1. A listing of exemplary muteins for attenuation greater than 20x of the STAT3 signal in poor / negative cells for PD-1 is provided in Table 5. TABLE 5 N1 N2 Affinity for IL-21R
[00419] [00419] This example demonstrates the selection of candidate IL-21 muteins for use in the construction of fusion proteins and their in vivo testing.
[00420] [00420] The 22 top-performing IL-21 muteins have been staggered for further testing. Based on this additional test (in Hut78 pSTAT3 assays as discussed here), four candidate fusion proteins were selected such that the collection of four would exhibit an attenuation range (power deviation from rhIL-21 in the Hut78 pSTAT3).
[00421] [00421] This example demonstrates the generation of a panel of IL-21 double mutants and the expression and characterization of fusion proteins comprising IL-21 double mutant homodimers (unless otherwise specified).
[00422] [00422] Three muteins having a single amino acid substitution, including (Mutant No. 77 (R76A) and Mutant No. 79 (R76E), were selected for further manipulation based on cell activity data (e.g., attenuation higher activity in Hut78 PD-1-vas T cells) and manufacturability, structure-guided manipulation was used to generate an additional mutation within the IL-21 single mutant sequence (ie, to generate a double mutant) to further attenuate cytokine binding to the IL-21R alpha chain (IL-21Rα) .The double mutant sequence was fused to the sequence of an anti-PD-1 mAb, and the fusion proteins were expressed and tested in cell assays. A list of the double mutant fusion proteins prepared and tested is provided in Table 7. TABLE 7 No. Double Mutein SEQ ID NO Substitutions: amino acids 1 D15N, I71L 214 2 D15N, K72A 215 3 D15N, K73A 216 4 D15N, S70T 213 5 I71L, K73Q 217
[00423] [00423] As double mutant fusion proteins with high attenuation properties were desired, the selection criterion was defined at a potency (EC50) greater than 1000 nM in IL-21R positive T-cells, negative for PD- 1 (PD-1-vas), in relation to the potency of rhIL-21. In addition, as with muteins containing a single amino acid substitution, double mutant fusion proteins were characterized for binding to IL-21R (ForteBio Octet). Finally, the double mutant fusion proteins were characterized for PD-1 activity using a PD-1 Jurkat reporter gene assay. The results of these assays are shown in Table 8. TABLE 8 EC50 (nM) of pSTAT3 in T cells Hut78 PD-1 + EC50 (nM) of pSTAT3 in T cells Hut78 PD-1 + EC50 (nM) of pSTAT3 in T cells Hut78 PD-1- EC50 (nM) of pSTAT3 in Hut78 T cells PD-1- Cino IL-21R fusion protein Cino PD-1 IL-21R Hu PD-1 Hu KD (nM) KD (nM) KD ( nM) KD (nM) (n1) (n2) (n1) (n2) rhIL 0.05 0.05 0.028- 0.019-
[00424] [00424] As shown in Table 8, the double mutant fusion proteins exhibited very low IL-21 activity on T cells expressing low levels of PD-1 (e.g., below detectable levels of PD-1) but retained significant IL-21 activity in cells expressing PD-1. The double mutant fusion proteins exhibited poor binding to IL-21R (Kd> 300 nM), but retained the ability to bind to PD-1 and block PD-1 signaling. EXAMPLE 6
[00425] [00425] This example demonstrates an in vitro primary cell assay comparing a fusion protein comprising an anti-PD-1 mAb and an IL-21 double mutant homodimer or an IL-21 single mutant homodimer.
[00426] [00426] A fusion protein comprising an anti-PD-1 and IL-21 mAb with amino acid substitutions R5Q and R76E was tested in an in vitro primary cell assay (a mixed lymphocyte reaction (MLR)). MLR comprised a mixed population of IL-21R + cells, including dendritic cells (DCs) expressing IL-21R but not expressing PD-1, T cells expressing PD-1 and T cells not expressing PD-1. The MLR was exposed (i) to the fusion protein comprising the amino acid substitutions R5Q and R76E, (ii) to the fusion protein comprising only the amino acid substitution R76E, (iii) to recombinant human IL-21 (rHu IL-21) , (iv) anti-PD-1 mAb, (v) a combination of rHu IL-21 and anti-PD-1 mAb or (vi) a control IgG.
[00427] [00427] As shown in Figure 11, rhIL-21 suppressed DC function and is dominant over the PD-1 response when coded. The fusion protein comprising the IL-21 double mutein with attenuated activity exhibited reduced off-target activity. Likewise, each of the rhIL-21 and the fusion protein comprising only the R76E amino acid substitution exhibited significant off-target activity in DCs and suppressed cytokine production. In contrast, the PD-1 mAb and fusion protein comprising amino acid substitutions R5Q and R76E administered only IL-21 signals to target PD-1 + vas T cells (and not PD-1-vas dendritic cells) and retained the ability (through the PD-1 arm) to increase cytokine production. Accordingly, these results suggest that fusion proteins comprising the IL-21 double mutant have reduced immunosuppression and detrimental impacts on CD initiation and may allow the recruitment of new T cell clones and more durable anti-tumor immune responses.
[00428] [00428] This example demonstrates the activity of different fusion proteins comprising double IL-21 muteins (homodimers) and an anti-PD-1 mAb in primary cytotoxic T lymphocytes (CTLs). Phosphorylation of endogenous STAT3 in primary CTLs (CTL lines reactive with CMV from a human donor) was measured by FACs and was used as a measure of IL-21 signaling. After resting the CTLs for 48 hours (in order to reduce the expression of PD-1), the cells were exposed (for 10 min) to (i) a fusion protein comprising an IL-21 R5E / R76A double mutein (triangles open in the left graph), (ii) a fusion protein comprising an IL-21 R5Q / R76E double mutein (open triangles in the middle graph), (iii) a fusion protein comprising an IL- 21 R9E / R76E mutein 21 (open triangles in the right graph), (iv) an IgG1 control (closed diamonds in each graph), (v) rhIL-21 (open squares in each graph), (vi) an anti-PD-1 mAb (line dotted in each graph), (vii) a combination of rhIL-21 and anti-PD-1 mAb (dashed line with closed circles in each graph) or (viii) a fusion protein comprising a single IL-21 R76E mutein ( open diamonds on each chart). The results of FACs are shown in Figures 12A-12C. The IL-21 activity of each fusion protein comprising an IL-21 double mutein is plotted against the activity achieved with (iv) an IgG1 control, (v) rhIL-21, (vi) anti-PD- mAb 1, (vii) a combination of rhIL-21 and anti-PD-1 mAb and (viii) a fusion protein comprising a single IL-21 R76E mutein. This primary cell assay demonstrates that double mutant fusions weakly stimulate IL-21-induced STAT3 signaling in resting CTLs (which express low levels of PD-1). IL-21 activity is most attenuated with double mutein fusions (and is similar to that seen with anti-PD-1 mAb and IgG1 control), with single mutant fusion exhibiting moderate attenuation of IL-21 activity , and the combination of rhIL-21 and anti-PD-1 mAb having similar activity to rhIL-21
[00429] [00429] The effect of fusion proteins comprising an anti-PD-1 mAb and IL-21 double mutein homodimers on CTL-mediated cell cytotoxicity function after chronic stimulation has also been explored. CTLs were activated with CD3 / CD28 and were exposed to (i) a fusion protein comprising IL-21 R5E / R76A double mutein, (ii) a fusion protein comprising an IL-21 R5Q / R76E double mutein, ( iii) a fusion protein comprising an IL-21 R9E / R76A double mutein, (iv) an IgG4 control, (v) rhIL-21, (vi) anti-PD-1 mAb or (vii) a combination of rhIL -21 and anti-PD-1 mAb. After seven days of stimulation, the cells were co-cultured with a melanoma cancer cell line pulsed with CMV peptide and cytotoxicity was measured. The results of this test are shown in Figures 13A-13C.
[00430] [00430] As shown in Figures 13A-13C, fusion proteins are able to sustain CTL function in a superior manner compared to anti-PD-1 mAb monotherapy. IL-21 mutein fusion proteins can support CTL-mediated cell cytotoxicity function after chronic stimulation. These results support the idea that IL-21 is able to sustain CTL function under conditions of chronic activation as seen in cancer. The administration of IL-21 to specific T cells of the PD-1 + antigen is able to selectively sustain the function of a population of T cells that drive therapeutic efficacy. EXAMPLE 8
[00431] [00431] This example demonstrates the pharmacokinetics in vivo with the double mutein constructs.
[00432] [00432] Fusion proteins comprising an anti-PD-1 mAb and an IL-21 double mutein or a single IL-21 mutein were administered to monkey-cinomologists by intravenous bolus administration to characterize drug exposure. Table 9 shows the dose of each construct administered to the animals. The simple mutein variant (IL-21 R76E) was tested in vivo as a homodimer and monomer to better understand how the exposure can be further improved.
[00433] [00433] Serum-time concentration profiles for PD-1 mAb and PD-1: IL-21 fusions after intravenous bolus administration to monkeys are shown in Figure 14 with the drug exposures observed in the first week after administration listed in Table 9. TABLE 9 Construct Number: Dose AUC0-168 / Animal Dose: (mg / kg) (hr * kg * µg / mL / mg) mAb against PD-1 a, b 8.25 2,260 ± 150 PD- homodimer 10 2.82 ± 0.93 1: IL-21 (R76A) a, c PD-803 & 804 homodimer 1: IL-21 (R5E / R76A) 5 39.1 ± 14.0 d, and PD-801 homodimer & 802 5 38.0 ± 19.6 1: hIL-21 (R76E) d, and PD-1: IL-21 (R76E) 807 & 808 5 195 ± 4.8 monovalent d, and homodimer PD-805 & 806 1: IL-21 (R5Q / R76E) 5 114 ± 14 c, da Study with non-human primates b Capture of human Fc with detection of human Fc c Capture of human IL-21 with detection of human Fc d Study with non-human primates and Capture of PD-1 with detection of human IL-21
[00434] [00434] As shown in Table 9, the monomeric R76E fusion protein exhibited higher exposure after intravenous dosing compared to the homodimer R76E fusion protein. Fusion proteins comprising the double IL-21 muteins (R5Q / R76E and R5E / R76A) observed greater exposures than single mutein homodimer fusion protein constructs (R76E and R76A, respectively) (Figure 14; Table 9 ).
[00435] [00435] The pharmacodynamic parameters (PD) were also tested in vivo in monkeys-cinomologists. PD-1 expression was determined using non-competing PD-1 antibody and this PD-1 sampling occurred on Day -5, Day 7 and Day 21. Animals were given a first dose of (i) a fusion protein comprising an anti-PD-1 mAb and a homodimer of a single IL-21 R76E mutein, (ii) a fusion protein comprising an anti-PD-1 mAb and a monomer of an IL-21 R76E single mutein or ( iii) a fusion protein comprising an anti-PD-1 mAb and an IL-21 R5Q / R76E double mutein on Day 1 and a second dose on Day 8 See Figure 15A.
[00436] [00436] Figures 15B-15D show the change of cells positive for PD-1 / positive for CD4 (in relation to Day -5) as measured on Day 7 (Figure 15B), the change of cells positive for PD-1 / positive for CD8 (in relation to Day -5) as measured on Day 7 (Figure 15C) and the change of positive cells in relation to PD-1 / positive in relation to CD8 (in relation to Day -5) as measured on Day 21 (Figure 15D).
[00437] [00437] As shown in Figures 15B-15D, even a single dose of the fusion protein comprising an anti-PD-1 mAb and an IL-21 double mutant expanded the peripheral PD-1 + / CD8 + T cells. This study demonstrated that double mutant fusion proteins are capable of significantly expanding CD8 PD-1 + T cells in a way that is superior to single mutein parent variants.
[00438] [00438] PD biomarkers were also examined for differences and the data suggest that the monomeric construct has lower target range and PD responses after single dose administration, but equivalent changes in PD and target range after multiple dose administration. These data suggest that the PK properties of fusion proteins can be further enhanced with a monomeric format.
[00439] [00439] As shown in Figure 16, receptor occupancy (RO) in CD8 + cells correlated with the expansion of CD8 PD-1 + T cells into the double mutants (Animals 803, 805, 806). The single mutant homodimer constructs (Animals 801, 802) failed to expand CD8 PD-1 + T cells, probably due to their relatively weak pharmacokinetic properties. Notably, the double mutein constructs, which have more desirable pharmacokinetic properties, expanded CD8 PD-1 + T cells and PD responses correlated with the target range. The data suggest that the double mutant fusion proteins are able to expand a population of T cells known to be involved in protective antitumor immunity.
[00440] [00440] Figure 17 shows that the target range of PD-1 in CD8 + T cells after repeated dosing is similar to what is observed for an anti-PD-1 mAb (anti-PD-1 mAb data not shown). Collectively, with respect to the double mutants, Figures 16 and 17 support the idea that modulation of the target population (CD8 PD-1 + T cells) requires sufficient target range and that the improved target range is correlated with responses improved pharmacodynamics.
[00441] [00441] This example demonstrates the generation of a fusion protein panel comprising different anti-PD-1 mAbs fused to variable homodimeric IL-21 double muteins.
[00442] [00442] An anti-PD-1 mAbs panel was generated and tested as described in Example 12 and the leading mAbs were fused to certain double IL-21 muteins. Twelve fusion proteins comprising double homodimeric IL-21 muteins and anti-PD-1 mAbs were tested for IL-21 activity in HuT78 T cells both PD-1-vas and PD-1 + vas using the phosphorylation assay STAT3, binding to IL-21R and binding to PD-1 using the ForteBio Octet assay, PD-1 activity using the PD-1 Jurkat reporter assay and in vitro activity using the MLR assay (mixed lymphocyte reaction). These experiments were carried out as essentially described in the previous examples.
[00443] [00443] A list of the twelve fusion proteins comprising an anti-PD-1 mAb and an IL-21 double mutein and their activities as measured in these assays is provided in Tables 10-
[00444] [00444] Most if not all candidates performed equally if not better than two anti-PD-1 mAbs. Several demonstrated potencies for PD-1 activity and in the MLR assay that were greater than or equal to the potency of anti-PD-1 mAb.
[00445] [00445] Of the 12 candidates, two were selected for additional studies. One of the two had the double IL-21 mutein comprising the R5Q / R76E mutations and the second had the double IL-21 mutein comprising the R9E / R76A mutations. Different anti-PD-1 mAbs from the PD-1 mAb panel were used to prepare a fusion protein with one of the two IL-21 muteins. Ten anti-PD-1 mAbs were used in the R5Q / R76E fusion proteins, including anti-PD-1 mAbs 20A2.003 (line with diamonds), 20C1.006 (line with open squares), 20C1.009 (line with triangles) and 22D4.006 (line with open circles). Seven anti-PD-1 mAbs were used in the R9E / R76A fusion proteins, including the anti-PD-1 mAbs 20A2.003 (line with open triangles), 20C1.006 (line with open squares), 20C1.009 (line with open diamonds) and 22D4.006 (line with open circles). Fusion proteins were tested for IL-21 activity using the STAT3 phosphorylation assay, as essentially described here. Figures 18A-18B and 19A-19B show the activities in HUT78 PD-1-vas and PD-1 + vas T cells, in relation to rhIL-21 signals (dark pink line). As shown in these figures, the fusion proteins exhibited> 1000x attenuation in HUT78 PD-1-vas T cells but retained potency in HUT78 PD-1 + vas T cells. EXAMPLE 10
[00446] [00446] This example demonstrates the generation of a fusion protein panel comprising different anti-PD-1 mAbs fused to double monomeric and variable homodimeric IL-21 muteins.
[00447] [00447] A panel of fusion proteins comprising an anti-PD-1 mAb and a monomeric or homodimeric IL-21 mutein was generated.
[00448] [00448] Fusion proteins were tested for IL-21 activity in HuT78 T cells both PD-1-vas and PD-1 + vas using the STAT3 phosphorylation assay, binding to IL-21R and binding to PD- 1 using the ForteBio Octet assay, PD-1 activity using the PD-1 Jurkat reporter assay and in vitro activity using the MLR assay. These experiments were carried out as essentially described in the previous examples. The activities as measured in these in vitro assays are shown in Figures 20-23.
[00449] [00449] Figures 20A-20D represent the amount of pSTAT3 signaling observed with various IL-21 monomeric or homodimeric double mutein mAb fusions. The signaling of pSTAT3 stimulated with rhIL-21 is shown in line with closed circles at the top of the graphs, while the signaling of pSTAT3 stimulated with an IgG1 control is shown in dashed line with open circles (bottom of the graphs) and with a control of IgG2 is shown in line with Xs (bottom of the graphs). The signaling of pSTAT3 stimulated by anti-PD-1 mAb (present as mAb; i.e., not as a fusion) is shown in a dotted line with closed squares (bottom of the graphs). The pSTAT3 signaling stimulated with anti-PD-1 control mAbs is shown in dashed line with open squares and dotted line with open diamonds (bottom of the graphs), while the remaining lines represent the pSTAT3 signaling achieved after stimulation with anti mAb fusions. -PD-1 - double monomeric or dimeric IL-21 mutein (with several charge pair mutations) in which the double mutants are R5E / R76A; R9E / R76A; R5A / R76E or R5Q / R76E.
[00450] [00450] The fusion proteins evaluated in Figures 20A-20D were tested in a PD-1 reporter gene assay (RGA; Figures 21A and 21B) and an MLR assay (Figures 21C and 21D). The results shown in Figures 21A-21D demonstrate that IL-21 monomeric and dimeric double mutein mAb fusions of IL-21 are capable of inducing PD-1 activity.
[00451] [00451] The results of pSTAT3 assays testing the same anti-PD-1 mAb - double monomeric and dimeric IL-21 mutein fusion constructs as those in Figures 20A-20D, except with a different anti-PD-1 mAb, are shown in Figures 22A-22D. The results in Figures 22A-22D are similar to those seen in Figures 20A-20D.
[00452] [00452] Results from PD-1 reporter gene assays and MLR assays testing the same anti-PD-1 mAb-monomeric and dimeric double mutein IL-21 fusion constructs as those in Figures 21A-21D, except with a different anti-PD-1 mAb, are shown in Figures 23A-23D.
[00453] [00453] These data demonstrate that a fusion protein comprising a double IL-21 mutein may not require a homodimer configuration for partial attenuation. The following double muteins (fused as monomers or homodimers) for an anti-PD-1 mAb (Table 14) were selected for further evaluation. TABLE 14. IL-21 Format Mutein A-2-017 R5Q: R76E homodimer (22D4.017)
[00454] [00454] The cell-based data suggest that these muteins when fused to an antibody against PD-1 are able to selectively target T cells (demonstrated using T cell lines) expressing the PD-1 receptor. These bifunctional PD-1 x IL-21 molecules have unique properties acquired from each arm of the fusion molecule (anti-PD-1 mAb and IL-21 mutein). EXAMPLE 11
[00455] [00455] The following materials and methods were used in the examples.
[00456] [00456] Generation of Ab Fusions anti-PD-1 - IL-21 mutein
[00457] [00457] Recombinant IL-21 mutein anti-PD-1 Ab sequences were cloned into pTT5 for transient expression in HEK293-6E or a vector containing an antibiotic selection cassette for stable expression in CHO-K1 cells. Expression productions were carried out for 5-7 days at 36 ºC and the supernatant was collected for purification. All protein lots were purified by Protein A affinity chromatography (Mab Select SuRe) followed by cation exchange (SP Sepharose HP) and buffer exchange (UF / DF) in A5.2Su buffer. All lots had> 95% main peak by size exclusion chromatography with endotoxin <0.2 EU / mg (Endosafe LAL, Charles River).
[00458] [00458] Reporter Gene Assays for PD-1 Jurkat
[00459] [00459] Stable effector cells GloResponse Jurkat NFAT-luc2 / PD-1 (Promega, # CS187102) and the stable cell line CHO PD-L1 (Promega, # CS178103) were co-cultured at a ratio of 1.25: 1 in the presence of antibodies serially diluted in triplicate for 6 hours at 37 ° C., 5% CO2. Luminescence was measured using the Bio-Glo Luciferase Assay System (Promega, # G7940).
[00460] [00460] STAT3 Phosphorylation Assays
[00461] [00461] pSTAT3 AlphaScreen. Stable cell lines parenting HuT 78 e and HuT 78 PD-1 were then inoculated into separate plates at 40,000 cells per well in the presence of antibodies serially diluted in triplicate for 40 minutes at 37 ° C, 5% CO2. Pstat3 Tyr705 levels were measured using the AlphaLisa Surefire Ultra Pstat3 Kit (Tyr705) Assay (Perkin Elmer, # ALSU-PST3-A10K).
[00462] [00462] Phospho-STAT3 HTRF assay. The cells were depleted of serum overnight in RPMI 1860 medium supplemented with 1% L-glutamine (HyClone # from Cat SH30034.01). The cells were then resuspended in Hanks Balanced Salt Solution free of phenol red without calcium and magnesium (HBSS; ThermoFisher # by Cat 14175095) at 2.5 x 106 cells / mL and 8 μl / well were plated in a white plate. small volume with 384 wells (Perkin Elmer # from Cat 6008289). The cells were then stimulated with 4 µl / well of IL-21 mutein molecules diluted in HBSS at 37 ° C for 40 minutes.
[00463] [00463] Mixed Lymphocyte Reaction (MLR)
[00464] [00464] Leukopaks from unmatched donor pairs were obtained from AllCells Inc. Donor T cells were isolated using Pan T-cell Isolation Kit (Milteny Biotec, # 130-096-535) and monocytes from a non-donor matched were isolated using the Pan Monocyte Isolation Kit (Miltenyi Biotec, # 130-096-537). The monocytes were further matured for 10 days using the CellXVivo Human Monocyte-Derived Dendritic Cell Differentiation Kit (R&D Systems, # CDK004). Pan-T cells were co-cultured with matured monocytes at a 10: 1 ratio in the presence of serially diluted antibodies in triplicate for 72 hours at 37 ° C, 5% CO2. The levels of IL-2 in the supernatant were measured by ELISA (Mesoscale Discoveries, # K151QQD-4).
[00465] [00465] IL-21R and PD-1 binding assays
[00466] [00466] Affinity binding to human and monkey-kinomologist IL-21R: Both monovalent recombinant reagents IL-21R-FLAG-His and bivalent IL-21R-Fc were tested but produced very similar results (within ~ 2-3 times). The recombinant soluble IL-21R reagents were minimally biotinylated and captured in Streptavidin SAX tips up to a load level of 2.0 nm. The tips were then incubated in wells where the antibody samples against PD-1-IL-21 were serially diluted 3 times. For wild-type IL-21 fusions, the top sample concentration was 10 nM, while for IL-21 mutein fusions the top sample concentration was 300 nM. An association time of 20 minutes and a dissociation time of 1.5 hours were used to maximize the curvature in the connection graphs in order to obtain precise kinetic adjustments.
[00467] [00467] Affinity of binding to human and monkey-cinomologist PD-1: Affinity of binding to human PD and 1-monkey-cinomologist was tested by first capturing the antibody samples against PD-1-IL-21 through coupling of EDC-NHS amine to AR2G tips; the sample load was typically at pH 6 for 2000 seconds followed by quenching with 1 M Ethanolamine in order to immobilize at least a 2 nm level. Once the samples were immobilized, the tips were then incubated in wells containing a 3-fold serial dilution of recombinant, soluble human PD-1 (1-170) -FLAG-His or PD-1 (1-167) - Monkey-cinomologist FLAG-His. In both cases, the top PD-1 concentration was 30 nM. Association for 300 seconds and dissociation for 500 seconds were used since they produced sufficient curvature for precise kinetic adjustments.
[00468] [00468] The binding affinities to human IL-21R / monkey-cinomologist and human PD-1 / monkey-cinomologist were quantified with ForteBio Octet HTX and RED384 instruments. In all cases, standard Octet sample buffer was used for sample dilution and for all baseline steps of binding, pooling and dissociation (10 mM Tris, pH 7.5, 150 mM NaCl, 1 CaCl2 mM, 0.10 mg.mL BSA, 0.13% (v / v) Triton X-100).
[00469] [00469] All raw data from ForteBio were processed as follows using the standard instrument data analysis software (v9 and v10): (a) the average of two reference tip curves that had immobilized target but no interaction (ie, buffer only) was calculated and these were subtracted from the sample tip curves remaining in the same column; (b) the association and dissociation curves were isolated and aligned with the Y axis; (c) the association and dissociation step has been aligned; (d) Savitzky-Golay filtration was implemented to reduce signal noise and (e) the resulting set of association and dissociation curves for each target sample interaction was globally adjusted with a single 1: 1 connection model to determine the measured values of the ka association rate constant and kd dissociation rate constants; the KD equilibrium dissociation constant was calculated as a ratio of the dissociation and association rate constants (= kd / ka).
[00470] [00470] This example describes the generation of anti-PD-1 mAbs for use in fusion proteins comprising IL-muteins
[00471] [00471] Generation of Anti-PD-1 Immune Responses
[00472] [00472] Strains of Mouse
[00473] [00473] Fully human antibodies to human PD-1 were generated by immunizing transgenic XENOMOUSE® mice (U.S. Pat. 6,114,598; 6,162,963, 6,833,268; 7,049,426; 7,064,244, which are incorporated herein by references in their entirety; Green et al., 1994, Nature Genetics 7: 13-21; Mendez et al., 1997, Nature Genetics 15: 146-156; Green and Jakobovits, 1998, J. Ex. Med, 188: 483-495; Kellerman and Green, Current Opinion in Biotechnology 13, 593-597, 2002). Animals of the XENOMOUSE® XMG4-K and XMG4-KL strains were used for these immunizations.
[00474] [00474] Immunizations
[00475] [00475] A cell-based immunization pathway was used to generate anti-human PD-1 immune responses. CHO-S cells were transiently transfected with human PD-1 fused through a Gly-Ser-Ser ligand to a cinomologist T cell epitope marker E3K or PD-1 as a source of immunogen. The animals were immunized with any of these transiently transfected CHO cells mixed with Alum with CpG-ODN, 13 times over 8 weeks using TIP (tail base and intraperitoneal) injections. The initial boost was comprised of 4 million cells expressing human PD-1 while subsequent boosters contained 2 million cells expressing human or cinomologist PD-1. A total of 9 immunizations were performed with human PD-1 (1-6, 8, 10 and 13) and the remaining 4 immunizations were performed with PD-1 of a cinomologist. The animals were bled after the 10th booster to assess specific PD-1 titers.
[00476] [00476] PD-1-specific serum titers were monitored by FACS analysis of live cells on an Accuri flow cytometer. Soon, HEK293 cells were pseudotransfected or transiently transfected with human or kinomologist PD-1. Sera from immunized animals were diluted 100 times and incubated in the transfected cells for 1 hour on ice. The cells were then washed to remove unbound antibodies and a specific secondary anti-human Fc antibody labeled with Cy5 was incubated on the cells for an additional 15 minutes at 4 degrees. The cells were washed once to remove unbound secondary antibody and the fluorescent signal in the cells was quantified by FACS. The animals with the highest antigen-specific native titers in serum directed against human PD-1 and a cinomologist were used for hybridoma generation (Kohler and Milstein, 1975). Adjuvant Immunogen Strain Collection human PD-1 or PD-1 of G4K 4 cinomologist Alum + CpG mice transiently ODN G4KL 4 transfected in CHO-S mice
[00477] [00477] Preparation of Monoclonal Antibodies
[00478] [00478] Hybridoma Generation
[00479] [00479] Animals exhibiting suitable serum titers were identified and lymphocytes were obtained from the spleen and / or draining lymph nodes. Grouped lymphocytes (from each collection) were dissociated from lymphoid tissue by trituration in a suitable medium (for example, Dulbecco's Modified Eagle's Medium (DMEM); Invitrogen, Carlsbad, CA). B cells were selected and / or expanded using standard methods and fused with a suitable fusion partner using techniques that were known in the art.
[00480] [00480] Generation of Membrane Prep:
[00481] [00481] 20 million 293T cells were transfected with pTT5-mini4: huPD-1 :: GSS: E3K using 293fectin ™ Transfection Reagent (Thermo Fisher, Cat: 12347019). 24 hours after transfection, 293T cells were biotinylated by incubating them in PBS pH 8.6 PBS containing EZ-Link ™ NHS-LC-LC-Biotin (Thermo Fisher Cat: 21343) at 400 µg / ml for 30 minutes. The cells were then washed in neutral pH PBS and then resuspended in hypotonic buffer containing EDTA-free protease inhibitor and 10% triton X100. The cells were disaggregated by repeatedly pumping them through a syringe with a 26 gauge needle. The cell fragments were pelleted by centrifugation at 12000G for 20 minutes. The supernatant containing membrane particles was then collected and washed 3 times with PBS on an Amicon Ultracel 100k centrifugal hill (Millipore, # Cat UFC810024) to remove the detergent. Membrane preps were then tested on screening successes (positive control hybridoma cells with PD-1 specificity) to check for binding to IgG-correlated membrane prep. The membrane prep was then aliquoted and frozen at -20 degrees Celisus until use.
[00482] [00482] Specific Hybrid Cell Antigen Staining:
[00483] [00483] The hybridoma cells were removed from the flask and washed with sterile FACS buffer (2% FBS PBS). The cells were then mixed with PD-1 membrane prep (diluted 1:10 in FACS buffer, 1 mL reaction volume, eg 100 µL of membrane prep in 900 µL of FACS buffer) and incubated at 4 degrees Celsius for 1 hour. The cells were washed again in FACS buffer and colored with 1 ml of detection cocktail containing 5 µg / ml of goat anti-human IgG Fc fragment F (ab ') 2 conjugated with Alexa Fluor 488 (Jackson, Cat: 109 -546-098) and streptavidin conjugated to Alexa Fluor 647 (Jackson, Cat: 016-600-084), then incubated at 4 degrees Celsius for 30 minutes in the dark. The cells were washed again in FACS buffer, resuspended in medium and then placed through a 40 micron cell separator to remove the aggregated cells. Antigen-specific cells were separated using BD FACSAria 3 by acting on a population exhibiting fluorescence both Alexa Fluor 488 and Alexa Fluor 647 (IgG + and antigen-binding cells).
[00484] [00484] The separated cells were allowed to grow for a few days in hybridoma medium. A small sample of the enriched cells was taken and tested for binding to the PD-1 membrane prep using the same staining conditions as mentioned above. After confirmation of successful enrichment of PD-1 specific cells, the hybridomas were then separated into single cell terms in 384-well microtiter plates using BD FACSAria 3. After 2 weeks of culture, the supernatants from the microtiter plates were collected and screened for PD-1 binding.
[00485] [00485] Initial Selection of PD-1 Specific Binding Antibodies
[00486] [00486] Depleted hybridoma supernatants were tested for binding to human PD-1 transiently expressed in HEK293 cells by Cell Insight. Soon, HEK293 cells were transiently transfected with a mammalian expression construct encoding PD-1 using 293Fectin. The following day, 15 µL of depleted hybridoma medium was added to each well of a 384 well FMAT plate. Then, the transfected HEK293 cells (0.27 million / mL), Hoechst 33342 nuclear stain (7.5 µg / mL) and a secondary detection antibody (0.75 µg / mL - Goat anti-human IgG (H + L) Alexa 488 (Jackson ImmunoResearch)) were mixed and 30 µL of this mixture was added to each well of a 384 well FMAT plate. After ~ 3 hours, the supernatant was aspirated using an AquaMax plate reader and 30 µL of FACS buffer was added to each well using a multi-drop instrument. The plates were placed on a Big Bear Plate shaker to distribute cells evenly in the well and then read on the Cell Insight platform using the Cell Health Bio-App. This analysis led to the identification of 383 antigen-specific antibodies from this collection.
[00487] [00487] Human Jurkat PD-1 / NFAT-luciferase reporter assay
[00488] [00488] Jurkat cells stably expressing human PD-1 and NFAT-luciferase reporter (Promega) were cultured in RPMI 1640 medium (Sigma) supplemented with 10% fetal bovine serum (Sigma), 2 mM L-glutamine (Sigma), 10 mM HEPES (Hyclone, GE Healthcare Life Sciences), 500 µg / mL geneticin (Gibco Life Technologies), 100 µg / mL hygromycin B (Invitrogen) at 37 oC / 5% CO2. Jurkat cells stably expressing PD-1 from a cinomologist and NFAT-luciferase reporter (Promega) were cultured in RPMI 1640 medium (Sigma) supplemented with 10% fetal bovine serum (Sigma), 2 mM L-glutamine (Sigma), HEPES a 10 mM (Hyclone, GE Healthcare Life Sciences), hygromycin B at 200 µg / mL (Invitrogen), zeocin at 300 µg / mL (Invitrogen) at 37 oC / 5% CO2. The Chinese Hamster Ovary (CHO) 99 clonal cell line stably expressing human PD-L1 (Promega) was grown in Nutrient Mixture F12 HAM (Sigma), 10% fetal bovine serum, 10 mM HEPES, 250 µg geneticin / mL, hygromycin B at 200 µg / mL at 37 oC / 5% CO. On the day of the experiment, the 2 Jurkat NFAT-luciferase / PD-1 cells and CHO Clone 99 PD-L1 cells (detached with trypsin) were centrifuged at 200 xg for 5 minutes and resuspended in assay medium (RPMI 1640 medium, serum 2% fetal bovine, 15 mM HEPES). The test molecules were diluted and titrated using the assay buffer on 384 well black / clear bottom assay plates (Corning). The prepared cells were inoculated at 40,000 cells / well in total by first mixing the prepared cells in a 1: 1 ratio and then adding the cell mixture to the assay plates. The plates were incubated for 18 to 24 hours at 37 oC / 5% CO2. The amount of luciferase produced was measured by the Bio-Glo Luciferase Assay System reagent (Promega), after which the plates were incubated for 20 minutes at temperature, and the luminescence detected with an EnVision plate reader (PerkinElmer). For single point assay, ESN samples were first quantified, normalized and tested at 0.5 µg / mL. To determine potency, samples of purified ESN or antibodies were titrated in series 3 times in assay medium and used to treat reporter cells of human PD-1 or cinomologist. The number of antibodies showing desired activity during single concentration tracking and potency classification is shown in Table 15. TABLE 15 Classification Sequences Single potency single points 86/383 12/86 4/12
[00489] [00489] The activity of purified anti-PD-1 antibodies (n = 1 for human PD-1 assay shown) is shown in Figure 24 and the potency of purified anti-PD-1 antibodies in PD-1 reporter assays human and cynomologist is listed in Table
[00490] [00490] Molecular Rescue and Sequencing of PD-1 Antagonist Antibodies
[00491] [00491] RNA (total or mRNA) was purified from wells containing hybridoma cells producing PD-1 antagonist antibodies using a Qiagen RNeasy mini or the Invitrogen mRNA catcher plus kit. Purified RNA was used to amplify the heavy and light chain variable region (V) genes of antibodies using cDNA synthesis through reverse transcription, followed by a polymerase chain reaction (RT-PCR). The gamma heavy chain of the fully human antibody was obtained using the Qiagen One Step Reverse Transcriptase PCR kit (Qiagen). This method was used to generate the first strand cDNA from the RNA template and then to amplify the variable region of the gamma heavy chain using multiplex PCR. The specific primer of the gamma chain 5 &apos; bound to the signal sequence of the antibody heavy chain, while primer 3 &apos; bound to a region of the gamma constant domain. The fully human kappa light chain was obtained using the Qiagen One Step Reverse Transcriptase PCR kit (Qiagen). This method was used to generate the first cDNA made from the RNA template and then to amplify the variable region of the kappa light chain using multiplex PCR.
[00492] [00492] The amplified cDNA was enzymatically purified using exonuclease I and alkaline phosphatase and the purified PCR product was directly sequenced. The amino acid sequences were deduced from the corresponding nucleic acid sequences bioinformatically. Two additional cycles of amplification and sequencing by independent RT-PCR were completed for each hybridoma sample in order to confirm that any mutations observed were not a consequence of PCR. The derived amino acid sequences were then analyzed to determine the origin of the germline sequence of the antibodies and to identify deviations from the germline sequence. A comparison of each of the heavy and light chain sequences with their original germline sequences is indicated. The amino acid sequences corresponding to the complementarity determining regions (CDRs) of the sequenced antibodies were aligned and these alignments were used to group the clones by similarity.
[00493] [00493] Primary Cell Binding Assays
[00494] [00494] The binding of hybridoma supernatants to PD-1 expressed by primary human and monkey-cinomologist cells was tested by flow cytometry. For binding to primary human cells, purified human T cells (Biological Specialty Corp.) were thawed and suspended at a concentration of 2.5 x 10 6 cells / ml. T cells were stimulated with 5 µg / ml of OKT3 anti-human CD3 clones (eBioscience) and 1 µg / ml of human anti-CD28 (BD Pharmingen) for 72 hours at 37 ° C / 5% CO2 in a plate that had been pre-treated with anti-mouse IgG Fc at 5 µg / mL (Pierce). After 72 hours, the cells were removed, washed and suspended at a concentration of 0.5 x 10 6 cells / ml with 10 ng / ml IL-2 (Pepro Tech). The cells were then incubated for another 48 hours at 37 ° C / 5% CO2. For cinomologist primary cell binding assay, cinomologist PBMCs (SNBL) were thawed and suspended in a concentration between 4 x 106 and 5 x 106 cells / mL. PBMCs were stimulated with 1 µg / mL of human anti-CD3 clones SP34 (BD Pharmingen) and 1 µg / mL of human anti-CD28 (BD Pharmingen) for 72 hours at 37 ° C / 5% CO2 in a plate that had been pre-treated with anti-mouse IgG Fc at 5 µg / mL (Pierce). After 72 hours, the cells were removed, washed and suspended at a concentration of 0.5 x 10 6 cells / ml with 20 ng / ml IL-2 (Pepro Tech). The cells were then incubated for another 48 hours at 37 ° C / 5% CO2. After the final incubation, the cells were prepared for flow cytometry by incubation with normalized hybridoma supernatants, positive control antibodies and isotype control antibodies at the final concentration of 1 µg / mL. Fragment Goat Anti-IgG Human F (ab ') 2 Alexa Fluor 647 AffiniPure (H + L) (Jackson ImmunoReserach) at 5 µg / mL was used for secondary detection and 8.25 nM YoPro1 (Invitrogen) was used for a staining of living / dead cells. The cells were then introduced into a BD FACSCanto II flow cytometer to detect binding to the anti-PD-1 antibody. Results are expressed as FACS geomedia of cells expressing PD-1 and data are shown in Table
[00495] [00495] Receiver Competition Test - Ligando
[00496] [00496] The PD-1 binding hybridoma supernatants were then tested for their ability to block PD-1 binding to the ligand. Competitive binding assays were performed on samples of antigen-specific hybridoma supernatant using FACS in HEK293 cells transiently expressing human PD-1 as follows. HEK293 cells expressing human PD-1 were mixed with the antibody sample (PD-1 specific hybridoma supernatants)
[00497] [00497] Affinity Gap Analysis
[00498] [00498] The kinetic measurements of several of the antibodies were evaluated using the KinExA® method. This method involves solution-based determination of formal affinity measurements at equilibrium.
[00499] [00499] Poly (methyl methacrylate) beads or PMMA were coated with biotinylated human PD-1 by first adsorption of the PMMA beads with biotinylated BSA, Neutravidine and then with biotinylated PD-1.
[00500] [00500] KinExA experiments were performed using an automated flow immunoassay system, KinExA 3200, in which spherules coupled with PD-1 served as the solid phase. Briefly, a constant amount of anti-hPD-1 mAbs (3 nM or 1 nM or 100 pM) was incubated with titrant concentrations of h-PD-1 or ci-PD-1 starting at 100 nM in sample buffer (PBS with 0.1% BSA to reduce non-specific binding). The antigen / antibody complexes were incubated at RT for 48 hrs to 72 hrs to allow equilibrium to be achieved. The mixture was conducted through beads coupled to PD-1 to accumulate unbound antibody. The volumes and flow rates of the mixture were varied depending on the specific signal obtained in each experiment.
[00501] [00501] The secondary mAb was detected using solutions containing a secondary Ab anti-Goat IgG Hu (H + L) - Alexa647 in sample buffer. The connected signals were converted into relative values as a control ratio in the absence of hu- or ci-PD-1. Two replicates of each sample were measured for all experiments in equilibrium. The equilibrium dissociation constant (Kd) was obtained from nonlinear regression analysis of the data using a homogeneous bond model in a location contained within the KinExA n-curve analysis software. The software calculates the Kd and determines the 95% confidence interval by adjusting the data points to a theoretical Kd curve. The 95% confidence interval is given as low Kd and high Kd. TABLE 19 Affinity of purified anti-PD-1 antibodies for human PD-1 and recombinant cynomologist Affinity for PD-1 Affinity for Human Cino PD-1 KD CI% KD CI% MAb Times (pM ) 95% mAb (pM) 95% mAb difference (pM) active (pM) active Hu: Ci A-1 17 13-23 25 15 12-19 21 0.9 (20A2) A-3 16 13-21 17 60 52- 68 18 3.8 (20C1) A-2 4.5 3.6- 27 3.7 2.7- 23 0.8 (22D4) 5.5 4.8 Kd calculated taking into account PD-1 as a known concentration and leaving the software to calculate the Kd and the concentration of mAb.
[00502] [00502] Confirmation of Purified Antibody Activity in MLR Assay
[00503] [00503] Dendritic cells derived from human immature monocytes (Astarte) were thawed on mature dendritic cells by culturing on IL-4, GM-CSF and TNF-a for 72 hours using the CellXVivo Human Monocyte-Derived Dendritic Cell Differentiation Kit (R&D Systems # CDK004). The non-adherent and loosely adherent cells were removed, combined and centrifuged to pellet the cells. After the medium was removed, the cells were resuspended in X-Vivo-15 medium at 400 x 10 ^ 3 cells / ml and dendritic cells were added to each cell in a 96-well plate (20k cells in 50 µL). Human T cells (Astarte) were quickly thawed and washed in X-Vivo-15 medium. The cells were resuspended at 2 x 10 ^ 6 cells / ml and 100 µL were added to each well (200k cells / 100 µL). The antibodies were diluted and added to each well in a total volume of 50 µL. The mixture was incubated for three days at 37 degrees. At this point, the cells were spun and 175 µL were used to measure IL2 production as a measure of T cell proliferation using the IL-2 V-Plex Kit (MSD) as recommended by the manufacturer. TABLE 20 MLR IC50 ID ML50 IC50 Antibody (nM) (nM) A-1 (20A2) 0.73 0.80 A-3 (20C1) 0.97 1.65 A-2 (22D4) 0.65 0.58 EXAMPLE 13
[00504] [00504] When possible, the anti-PD-1 variable domain sequences A-1 (20A2), A-3 (20C1) and A-2 (22D4) were manipulated to remove motifs having a risk of side chain degradation . Such amino acid motifs include; (1) CDR “NG” and “NT” sequences prone to asparagine deamidation, (2) CDR “DG”, “DH”, “DS” and “DT” sequences prone to aspartic acid isomerization, (3) and oxidation prone CDR3 tryptophans. Typically, substitution identities were derived from germline sequences or sequence-related PD-1 binding mAbs. For cases in which bioinformatics or structural analyzes did not provide a clear substitution identity, types of residues chemically similar to the parent residue were selected.
[00505] [00505] Variable domain sequence motifs violating multiple residue covariance trends pairwise on the basis of multiple sequence alignment have also been removed. The remediation of covariance violators pair by substitution by types of germline or germline-related residues can lead to better manufacturability due to increased levels of mAb expression and biophysical stability. See, Kannan, G. Method of Correlated Mutational Analysis to Improve Therapeutic Antibodies. US Patent Application PCT / US2012 / 028596 filed March 9, 2012. Replacement identities for covariance violators were selected using an approach similar to that used to remedy degradation sites, as discussed above.
[00506] [00506] The handling of 20A2 led to 20A2.003. The manipulation of 20C1 led to 20C1.006 and 20C1.009. The manipulation of 22D4 led to 22D4.006 and 22D4.017. EXAMPLE 14
[00507] [00507] The in vivo activity of the fusion protein comprising the anti-PD-1 antibody 22D4.017 fused to a double mutein of IL-21 monomer comprising the mutations R9E and R76A (“[22D4.017] - [R9E: R76A] (monomer) ”) was evaluated in non-human monkeys-cinomologists without treatment. A first group of monkeys received the anti-PD-1 antibody 22D4.017 alone (not fused to an IL-21 mutein), and a second group of monkeys received the fusion protein [22D4.017] - [R9E: R76A ] (monomer). Pharmacodynamic parameters (PD) were monitored using FACS in peripheral blood and included immune cell dynamics and transcription factor phosphorylation STAT3 (pSTAT3) in lymphocytes. Cytokines and perforin in serum were also examined by Millipore Milliplex® multi-analyte profile multiplex (MPA) assay. Pre-dose analysis of peripheral blood parameters was conducted to allow normalization of data sets in relation to the baseline. Dosing started on Day 1. Blood and serum were drawn at predetermined fixed time points.
[00508] [00508] Despite the activation of Ki67 [Figures 25A and 25B] and STAT3 [Figures 25C and 25D] in T cells, no significant increase in the mass T cell population was observed in the groups to which the 22D4.017 antibody was administered. or the fusion protein [22D4.017] - [R9E: R76A] (monomer) [Figures 25A and 25B], suggesting that both of these treatments were insufficient in themselves to induce the expansion of the mass T cell population [Figures 25E and 25F]. These data support the notion that systemic blocking of PD-1 signaling may have a more global impact on the mass T cell population including activation of STAT3 and Ki67 signaling, but that these changes alone may be insufficient to manifest significant functional outcome (as also evidenced by the failure of monotherapy treatments or anti-PD-1 fusion protein to induce more generalized T-cell expansion).
[00509] [00509] To better understand how changes in proximal signaling could specifically impact T cells expressing PD-1, and how PD-1 (+) T cells reflect only a small fraction of the mass T cell population in peripheral blood, these cells were examined more directly by activation of CD4 and CD8 PD-1 (+) T cells using a non-competing PD-1 detection mAb [Figures 16 and 17]. After an initial slight reduction in absolute numbers of circulating PD-1 (+) cells, this population remained stable in the antibody group [22D4.017]. In contrast, after an initial reduction in the number of CD4 and CD8 PD-1 (+) T cells in circulation, there was a significant rebound (above the baseline) in the number of PD-1 (+) cells observed at 336 h post -dose in the group population with fusion protein treatment [22D4.017] - [R9E: R76A] (monomer) [Figure 25G]. Thus, despite the absence of significant mass population expansion, these data suggest that PD-1 (+) T cell numbers are selectively increased after administration of the fusion protein [22D4.017] - [R9E: R76A] (monomer ).
[00510] [00510] To determine a possible functional impact of PD-1 (+) T cell expansion, a relationship between CD4 / 8 PD-1 (+) T cell expansion and serum perforin was examined. In fact, the data suggest that there is a positive relationship between these two parameters: serum perforin is the highest in animals given fusion protein [22D4.017] - [R9E: R76A] (monomer), which they experienced significant increase in PD-1 (+) T cells in peripheral blood [Figure 25I].
[00511] [00511] Taken together, these data suggest that while the systemic exposure of the fusion protein [22D4.017] - [R9E: R76A] (monomer) has failed to manifest an increase in the total mass T cell population, the blocking PD-1 and simultaneous administration of the IL-21 signal in the same cell (expressing PD-1) is sufficient to induce population expansion. This is also related to an increase in serum perforin [Figure 25I]. EXAMPLE 15
[00512] [00512] The following example demonstrates the binding affinities of various anti-PD-1 antibodies.
[00513] [00513] The Octet binding affinities of anti-PD-1 :: PD-1 antibody were characterized as follows. To quantify the KD binding affinity (equilibrium dissociation constant) between the anti-human PD-1 and PD-1 antibodies and soluble recombinant monkey-cinomologist, the association and dissociation rate constants were measured using a Pall instrument ® ForteBio® Octet® RED384 in 16-point mode or a Pall® Octet® HTX instrument in 96-point mode. In all cases, fiber optic biosensor tips reactive with second generation amine (AR2G) were used to covalently capture the antibodies up to final charge levels between 2.5 and 4 nm. The bonding test method used the following immobilization steps: (1) equilibration in water, 60 seconds; (2) activation with fresh 20 mM 1-ethyl-3- [3-dimethylaminopropyl] carbodiimide (EDC) mixed with 10 mM N-hydroxysulfosuccinimide (sulfo-NHS), 600 seconds; (3) immobilization of antibodies to 20 nM diluted in acetate buffer pH 6.0 to 10 mM, 2000 seconds; (4) extinction with 1 M ethanolamine, 300 seconds; and finally (5) a baseline incubation in Octet operating buffer (TRIS pH 7.5 to 10 mM, NaCl to 150 mM, CaCl2 to 1 mM, Triton X-100 to 0.13% (v / v) and Bovine Serum Albumin (BSA) at 0.10 mg / mL, 60 seconds All experiments were operated with black sample plates with 384 wells suggested by the manufacturer (volume of 100 µL per well) at 27 ºC and 1000 RPM .
[00514] [00514] For each Ab :: PD-1 interaction, an eight-point column was also immobilized as described above with the same antibody. Three tips were used to link a three-point dilution series of soluble human PD-1 (1-170) -FLAG-His, three more tips were used to link a three-point dilution series of PD-1 (1- 167) soluble human -FLAG-His and then the remaining two tips (with Ab immobilized as the rest of the tips on the column) were exposed to Octet® buffer such that they could be reference tips. All fiber optic tips were used once and then discarded; i.e., without regeneration. Binding curves to human and cyano PD-1 were generated by creating a 1: 3-fold serial dilution series of the PD-1 receptor soluble in operation buffer
[00515] [00515] The raw data were processed with the instrument's data analysis software (v10). For each sensor column, the connection signal average of the two reference sensors was calculated and subtracted from the remaining six sample sensors. The data subtracted from the reference was then processed with the standard software options: Y axis aligned with the baseline, correction of passages with dissociation and finally processed with a Savitzky-Golay filter. The final processed data for each antibody binding to three concentrations of human PD-1 or three cino were then globally fitted to a 1: 1 binding model and plotted. All graphs show both the processed data and the fit to the 1: 1 connection model. The 1: 1 link model adjustment was used to determine the association rate constant (ka; units M-1sec-1) and the dissociation rate constant (kd; units sec-1). The equilibrium dissociation constant (KD; nanomolar units (nM) = 1 x 10-9 Mol / L) was then calculated as a kd / ka ratio.
[00516] [00516] Figure 26 shows the binding profiles for anti-PD-1 antibodies 22D4.017, 20C1.009 and 20A2.003, tested side by side with two anti-PD-1 mAbs (an anti-PD-1 mAb IgG1 and an anti-PD-1 IgG4 mAb). The connection profiles were determined using the FortéBio Octet® system. The binding is shown against human and cyano PD-1 receptors.
[00517] [00517] As shown in Figures 26A-26E, antibodies 22D4.017, 20C1.009 and 20A2.003 PD-1 exhibited KD values that were 2 to 14 times higher than commercially available antibodies when tested against the PD- 1 human. In addition, analysis of the cross-reactivity of cine PD-1 protein with antibodies 22D4.017, 20C1.009 and 20A2.003 showed a similar global affinity, whereas commercially available antibodies showed a difference of around 2 times in affinity (Figures 26F-26J). EXAMPLE 16
[00518] [00518] The following examples demonstrate the stability of several anti-PD-1 antibodies.
[00519] [00519] The thermal conformational stability of anti-PD-1 antibodies was characterized as follows. Antibodies 20C1.009 and 22D4.017 were evaluated for thermal stability by differential scanning calorimetry (DSC). DSC is a technique that measures heat capacities as a function of temperature. The signal from the sample cell is compared to a reference cell lacking the protein. As the cell temperature is increased, the enthalpy and melting temperature are increased, the peak width is measured for each split transition. This provides information on the thermal stability and higher order structure of the protein, including thermal stability of the protein domains. Figure 27 represents a DSC Thermogram of each anti-PD-1 antibody at 1 mg / ml in A52SuT and Table 21 provides the Tm for each antibody tested. TABLE 21 Antibody 20C1.009 22D4.017 Tm per DSC 75.1 ˚C 66.1 ˚C
[00520] [00520] Viscosity was additionally determined using a cone and plate (TA Instruments, New Castle, DE) by measuring flow resistance due to frictional forces between molecules. A flow scanning procedure was applied from 100 to 1000 s-1 using a 20 mm and 1,988 ° cone plate and Peltier Steel plate - 990918. Viscosity was measured in Pa▪s, where 1 m Pa▪s = 1 cP at 1000 s-1. Viscosity was measured for each antibody at 70 and 150 mg / mL with 0.01% surfactant added to the formulation buffer (A52Su). All samples were measured at room temperature. Viscosity data (Shear Rate 1000) are shown in Figure 28 and provided in Table 22. TABLE 22 Antibody cP 70 mg / mL cP 150 mg / mL 22D4.017 3.4 44.7 20C1.009 2.5 7.1
[00521] [00521] The stability properties of the antibody are important factors considered during the development of therapeutic candidates. For example, the propensity of an antibody to aggregate (formation of large complexes in solution that can lead to precipitation) can impact shelf life, mode of administration (eg, i.v. vs. subcutaneous) and activity of the molecule. Typically, the properties of an antibody's thermostability and viscosity are good indicators of an antibody's ability to maintain structural integrity at high temperatures and high concentrations. As the data above demonstrate, 20C1.009 exhibits stability properties that make it particularly suitable as a therapeutic that is amenable to both i.v. and subcutaneous (and high concentration) administration. EXAMPLE 17
[00522] [00522] This example demonstrates the activity of IL-21 caused by various fusion proteins.
[00523] [00523] Several fusion proteins comprising an IL-21 mutein were prepared and tested for IL-21 activity using the pSTAT3 AlphaLISA® assay. One comprised an anti-TIGIT monoclonal antibody (mAb), while a second comprised an anti-LAG3 mAb. Four cell lines were generated for use in these experiments: (A) a variant Hut78 T cell line that is positive for PD-1, (B) a variant Hut78 T cell line that is positive for TIGIT (C) a variant Hut78 T cell line that is positive for LAG3 and (D) the variant Hut78 T cell line that does not endogenously express PD-1, TIGIT or LAG3. All four cell lines were exposed to (i) rhIL-21 alone, (ii) anti-PD-1 mAb alone, (iii) anti-TIGIT mAb alone, (iv) anti-LAG3 mAb alone, (v) mAb anti-PD-1 fused to an IL-21 (R5Q: R76E) mutein (monomer), (vi) anti-TIGIT mAb fused to an IL-21 (R5Q: R76E) mutein (dimer) and (vii) mAb anti-LAG3 fused to an IL-21 mutein (R5Q: 76E) (dimer).
[00524] [00524] The results of the STAT3 phosphorylation assay and the EC50s of each molecule for STAT signaling are shown in Figures 29A-29D and Table 23, respectively. TABLE 23 Hut78 Hut78 / PD-1 Hut78 / TIGIT Hut78 / Lag3 Gene Molecule EC50 (pM) EC50 (pM) EC50 (pM) EC50 (pM) rhIL-21 65 59 58 68 mAb anti-PD-1 - - - - mAb anti-TIGIT - - - - anti-LAG3 mAb - - - - Fusion of anti-PD-1 + mAb - 341 - - IL-21 mutein Fusion of anti-TIGIT + mAb - - 1,390 - IL-21 mutein Fusion of anti-LAG3 + mAb - - - - - IL-21 mutein As shown in Figures 29A-29D and Table 23, the anti-TIGIT and anti-LAG3 fusion proteins exhibited significantly reduced potency (anti-TIGIT) or no measurable potency (anti-LAG3) compared to rhIL-21.
[00525] [00525] NOD.Cg-Prkdcscid Il2rgtm1Wjl / SzJ mice (Jax stock number 005557) were used at 6-8 weeks of age. As shown in Figure 30A, on day 0, the animals were reconstituted with 2.5 x 106 freshly thawed CTLs in 100 µL in PBS, 2 x 105 EU IL-2 (Peprotech, # 200-02-1mg, # lot 11172) in 0.02% BSA in 100 µL PBS by intraperitoneal injection. In addition, the mice were grafted with 1 x 106 human melanoma cells (PD-L1 +) expressing CMV peptide (SKMEL-30-Luc) engineered to express a model antigen (CMV-SKMEL-30-Luc, expressing peptide antigens ( pp65m 1E1 and UL138) derived from cytomegalovirus, CMV) in 100 μL in a 50:50 mixture of reduced Matrigel with growth factor (Corning) and serum-free RPMI subcutaneously in the right rear flank. The animals received two additional boosts of IL-2 on day 2 and day 11. On day 17, tumor volumes were determined, mice were randomized into study groups and treatments were started: Isotype 300 µg IP Q3Dx3 (BioXCell), anti-PD-1 mAb (chimera consisting of human anti-PD1 variable region and mouse IgG1 constant region), 300 µg IP Q3Dx3, anti-PD-1 x R9E mAb: R76A (chimera consisting of anti-PD- 1 human, a mouse IgG1 constant region and a C-terminal fusion of the human IL-21 variant R9E: R76A) 363 µg IP Q3DX3 fusion protein monomer. Tumor volumes were measured twice / week. All experimental studies were conducted under protocols approved by Amgen's Institutional Animal Care and Use Committee. The animals were housed in facilities accredited by the Association for Assessment and Credentialing of Laboratory Animal Care International (at Amgen) in a micro-insulating compartment ventilated in a corn cob bed. The animals had ad libitum access to sterile pelleted food and water purified by reverse osmosis and were kept on a light cycle: 12:12 pm darkness with access to opportunities for environmental enrichment.
[00526] [00526] Humanized mice (generated as described above) were grafted with human melanoma cells (PD-L1 +) (SKMEL-30-Luc) engineered to express a model antigen (CMV-SKMEL-30-Luc, expressing derived peptide antigen cytomegalovirus, CMV). The mice were treated with [1] a chimeric human-mouse anti-PD-1 mAb, with a variable domain recognizing human PD-1 and a mouse IgG1 constant Fc region; or [2] a fusion protein consisting of the same original anti-PD-1 mAb and a monomeric human IL-21 R9E: R76A (a scheme of which is shown in Figure 30C). A summary of molecule attributes is shown in Table 24. TABLE 24 Hut78 PD-1 Hut78 huIL-muIL- Kd muPD- (-) PD1 (+) PD-1 21R 21R from 1 EC50 EC50 EC50 (nM) (nM) ) hPD- (nM) interpolated interpolated interpolated 1 (nM) (nM) (nM) (nM) IgG1 isotype control - - - - - - - IgIL1 rhIL-21 0.009 0.009 - 0.052 ~ 90 - - mAb - - 2.035 - - 3.4 - against PD1 mAb> 1000 1.97 1.613> 300 - 2.6 - against PD1 x monomer R9E: R76A
[00527] [00527] On the same day as the tumor graft, the mice received adoptively transferred antigen-specific CTLs (CMV) having potent in vitro cytotoxicity against cancer cells expressing the antigen. In this model, the failure of tumor-reactive CTLs to control cancerous growth leads to the development of progressive tumors that are palpable by day 17. Therapeutic administration (in mice with established tumors of ~ 100 mm3) with an isotype control antibody or an anti-PD-1 mAb failed to resolve the disease or have any discernible impact on tumor growth (Figures 30D-30E). In contrast, therapeutic administration of a PD1 x IL-21 fusion protein (Table 24) has a significant inhibitory effect on tumor growth and improves overall survival (Figures 30B, 30E and 30F). Collectively, our data support the idea that chronic T cell activation can lead to a decreased antitumor immune response and that administration of a fusion protein consisting of an IL-21 fraction targeted to PD-1 can significantly extend the function of CTLs and support superior tumor control in a mouse model that is refractory to anti-PD-1 mAb monotherapy. EXAMPLE 19
[00528] [00528] Generation of PD-L1 overexpression cell lines.
[00529] [00529] GP2-293 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, 1% Pen / Estrep, 1% HEPES and 1% GlutaMAX. The cells were plated at 75% confluence in 10 cm plates and incubated at 37 ° C, 5% CO2 overnight. The next morning, the cells were transfected. To tube A, 45 µL of Lipofectamine 3000 and 500 µL of OptiMEM medium were added. To tube B, 15 µg of plasmid MSCV_GFP_PD-L1, 1.8 µg of plasmid VSV-g, 30 µL of reagent P3000 and 500 µL of OptiMEM medium were added. Tubes A and B were mixed and incubated at room temperature for 10 minutes, then the contents of tube B were added to tube A and incubated at room temperature for 20 minutes. The mixture was added dropwise to plates of GP2-293 cells which were incubated at 37 ° C, 5% CO2 overnight. The next morning, the medium was removed and replaced with 10 ml of fresh culture medium. That afternoon, the target cells were plated at 75% confluence in 6-well plates and incubated at 37 ° C, 5% CO2 overnight. The following morning, viral supernatants were collected from GP2-293 cells and centrifuged (5 minutes, 1200 rpm). The supernatants were collected in a new tube, and polybrene was added at 1: 1000. The medium was removed from the plates containing target cells and 2 ml of viral supernatant was added. For cells in suspension, 1E6 cells were centrifuged at 1500 rpm for 5 minutes, resuspended in 500 µL of RPMI supplemented with 10% fetal bovine serum and 1% pen / strep and plated in 6-well plates to which 2 ml was added of viral supernatant. Plates containing target cells and viral supernatants were centrifuged for 1.5 hours at 1200 x g at 32 ° C, then incubated at 37 ° C, 5% CO2. Culture medium was added after 5 hours. Four days later, the cells were analyzed for GFP and PD-L1 expression by flow cytometry with a FACSymphony. PD-L1 was detected using a PE-conjugated antibody, clone 29E.2A3. Cells <70% positive for PD-L1 expression were classified in a BD Melody classifier. EXAMPLE 20
[00530] [00530] Combination of TDCC with 20C1.009.
[00531] [00531] T cell dependent cell cytotoxicity assay (TDCC): BiTE® molecules were diluted in cell culture medium (RPMI, 10% heat inactivated fetal bovine serum, 1X GlutaMAX, 1X Pen / Estrep), diluted in series (1: 3, 22 total) and transferred to 384-well plates, black and clear, using a Bravo liquid handling robot. Human pan T cells (n = 4), pre-activated with Dynabeads CD3 / CD28 (1: 1, 48 hours), were separated from the beads using a magnet and diluted in cell culture medium. An aliquot of activated T cells from each donor was evaluated for PD-1 expression by flow cytometry. The cells were stained as described above and data were collected on a FACSymphony flow cytometer and analyzed using FlowJo v10.1. Activated T cells (2500 cells / 20 µL; 4 rows / donor) followed by target cells overexpressing PD-L1 were plated on 384-well assay plates (2500 cells / 20 µL; total plate) such that the ratio between effector cells and final target (E: T) were 1: 1. 20C1.009 (10 µg / ml final in 5 µL) was added to 2 lines from each T cell donor. The plates were covered with MicroClime caps and incubated at 37 ºC, 5% CO2 for 24 hours. To assays with target cells expressing luciferase, 30 µL of Steady-Glo, Bright-Glo or One-Glo reagent (Promega) was added. Plates with adherent target cells not expressing luciferase were washed with PBS to remove T cells using EL406 plate washer and 25 µL of Cell Titer Glo reagent was added. The plates were incubated with reagent for 10 minutes in the dark at room temperature. Luminescence was detected using a BioTek Neo plate reader. Specific cytotoxicity was calculated in relation to target cells incubated with T cells without BiTE. The Graphpad Prism software was used to graph dose curves and calculate EC50 values with variable slope curve adjustment with four parameters.
[00532] [00532] Figures 33-41 show the results of the TDCC assay described above. Figures 33A-41A show data from a representative T cell donor, while Figures 33B-41B show data from four different T cell donors.
[00533] [00533] PD-1 expression induced by single chain antibody construct in T cells.
[00534] [00534] Single chain antibody constructs were diluted in cell culture medium (RPMI, 10% heat inactivated fetal bovine serum, 1X GlutaMAX, 1X Pen / Estrep) to 50 nM and diluted in series (1: 5, 9 total). Serial dilutions were plated in duplicate on assay plates (40 µL). Flat bottom 96-well plates were used for adherent target cell lines. 96-well round bottom plates were used for suspended target cell lines. Thawed human pan T cells and resuspended in cell culture medium (80 µL of 0.625E6 cells / ml) were added to the assay plates followed by target cell lines (80 µL of 0.125E6 cells / ml). The plates were covered with MicroClime caps and incubated at 37 ºC, 5% CO2 for 48 hours. Assays grown on flat bottom plates were pipetted up and down to allow transfer of T cells to round bottom FACS plates. These and the round-bottomed assay plates were centrifuged (3 minutes, 1500 rpm, RT) and the cell culture supernatants were discarded. The cell pellets were resuspended in blocking buffer (50 µL of PBS / 2% FBS, normal 2% goat serum,
[00535] [00535] Efficacy of anti-PD-1 antibody combined with single chain antibody constructs in in vivo studies of a syngeneic tumor model.
[00536] [00536] Syngenic tumor cells engineered to express antigens recognized by single chain antibody constructs are injected subcutaneously into the lower flank of mice engineered to express both human PD-1 and human CD3. Treatment with: [1] an anti-PD-1 antibody (eg, 20C1.009); [2] a single chain antibody construct (e.g., any of the single chain antibody constructs described here); or [3] both an anti-PD-1 antibody (e.g., 20C1.009) and a single chain antibody construct are initiated when the tumors reach a volume of 50-150 mm3 and proceed for approximately 14 days. Single chain antibody constructs are administered by intravenous injection every 7 days for a total of two doses at dose levels ranging from 50 to 1000 µg / kg. The anti-PD-1 antibody is administered by intraperitoneal injection at a dose level of 300 µg every 3 days for a total of three doses. Tumor volume is assessed by measuring with forceps.
[00537] [00537] The combination of an anti-PD-1 antibody (eg, 20C1.009) with a single chain antibody construct results in greater tumor shrinkage than treatment with anti-PD-1 antibody or single chain antibody construct alone. EXAMPLE 23
[00538] [00538] Evaluation of tumor growth in mouse subcutaneous tumor (SC) model.
[00539] [00539] Efficacy of single agent and combination: mouse melanoma cells (B16F10 cells engineered to constitutively express human EpCAM (huEpCAM)) SC were injected into the right flank of mice (3 x 105 cells / mouse) expressing human CD3ε. The tumor volume (mm3) was measured using electronic tweezers twice a week (Q2W). As soon as the tumors reached an average size of 90 mm3, the animals were randomized into groups (10 mice per group) such that the average tumor volume at the beginning of treatment administration was uniform across the treatment groups. The animals were then administered intravenously (IV) with two doses of huEpCAM HLE single chain antibody construct (huEpCAM HLE BiTE®) or control single chain antibody construct (EGFRvIII HLE BiTE®; BiTE® Control) with 1 week interval. The anti-PD-1 antibody was administered intraperitoneally (IP) Q3D for 3 doses,
[00540] [00540] Tumor volume analysis: In vivo efficacy data for the single agent was analyzed by RMANOVA followed by Dunnett's correction. The in vivo efficacy data of the combination was analyzed by RMANOVA whereby each single agent vs. combination. These data demonstrate that the combination of single chain antibody constructs and an anti-PD-1 antibody results in significant inhibition of tumor growth versus any of the single agents. See Figure 31.
[00541] [00541] Survival analysis: In vivo efficacy data was analyzed by Kaplan-Meier analysis of median survival of mice treated with single agents or single agent vs. combination. These data demonstrate that the combination of single chain antibody constructs and an anti-PD-1 antibody results in improved survival versus any of the single agents. See Figure 32.
[00542] [00542] Care of Animals. Female BALB / c mice (Charles 127 River Laboratories, Wilmington, MA), 6-8 weeks old, were cared for according to the “Guide for the Care and Use of Laboratory Animals”. The animals were housed in facilities accredited by the Association for Assessment and Credentialing of Laboratory Animal Care International (at Amgen) in a micro-insulating compartment ventilated in a corn cob bed. All protocols were approved by an Institutional Animal Care and Use Committee. The animals had ad libitum access to sterile pelleted feed and water purified by reverse osmosis and were kept in a light cycle: 12:12 pm dark with access to opportunities for environmental enrichment. EXAMPLE 24
[00543] [00543] Efficacy of anti-PD-1 antibodies combined with single chain antibody constructs in in vivo tumor model studies with mixing with human addition.
[00544] [00544] Human cancer cells expressing antigens recognized by single chain antibody constructs are mixed with activated human CD3 + T cells at a ratio of 5 x 106 + 1 x 106 cells respectively. The cells are injected subcutaneously into the right flank of female athymic nude mice. Tumor volume (mm3) is measured using electronic tweezers twice a week (Q2W). As soon as the tumors reached an average of approximately 150 mm3, the animals are randomized into groups (10 mice per group) such that the average tumor volume at the beginning of treatment was uniform throughout the treatment groups. The animals are then intravenously (i.v.) administered with two doses of HLE single chain antibody construct or Control single chain antibody construct 1 week apart. The anti-PD-1 antibody (e.g., 20C1.009) is administered intraperitoneally (i.p.) Q3D for 3 doses, starting on the same day as treatment with the single chain antibody construct. Clinical signs, changes in body weight and tumor growth are measured twice a week until the study ends.
[00545] [00545] Activation of CD3 + T cells 1 x 106 human T cells are thawed and T cell stimulation beads are added to induce T cell expansion. IL-2 is added to the medium three days later at 5 µg / mL and the cells are expanded in medium containing IL-2 for two weeks. The activated T cells are collected and unwound using magnets.
[00546] [00546] Statistical Analysis.
[00547] [00547] Tumor volume analysis: The in vivo efficacy data of the single agent is analyzed by RMANOVA followed by Dunnett's correction. The in vivo efficacy data of the combination is analyzed by RMANOVA whereby each single agent vs. combination.
[00548] [00548] Survival analysis: In vivo efficacy data is analyzed by Kaplan-Meier analysis of median survival of mice treated either single agent or single agent vs. combination.
[00549] [00549] The combination of an anti-PD-1 antibody (eg, 20C1.009) with a single chain antibody construct results in greater tumor shrinkage than treatment with anti-PD-1 antibody or BiTE® antibody construct alone. EXAMPLE 25
[00550] [00550] Efficacy of CAR T cells directed against DLL3 combined with anti-PD-1 antibody in an in vivo xenograft model
[00551] [00551] Human cancer cells expressing DLL3 antigens recognized by CAR T cells directed against DLL3 (using any of SEQ ID NO: 746-751) are implanted subcutaneously in beige SCID mice (5 x 106 cells / mouse) on Day 0. O Tumor volume (mm3) is measured using tweezers twice a week (Q2W). As soon as the tumors reach an average size of 75-100 mm3, the animals are randomized into groups (9-10 mice per group) such that the average tumor volume at the start of treatment was uniform across the treatment groups. The animals are then administered intravenously (IV) with a dose of T CAR cells (1 x 107 antigen specific T CAR cells or 1 x 107 control T T cells) in a volume of 200 µL. The anti-PD-1 antibody is administered intraperitoneally (IP) Q3D at 300 µg for 3 doses, starting on the same day as treatment with CAR T cells. Clinical signs, changes in body weight and tumor growth are measured twice weekly until study completion (~ 45 days). EXAMPLE 26
[00552] [00552] Evaluation of the in vitro efficacy of T cell mediated cytotoxicity against DLL3 in combination with an anti-PD-1 antibody
[00553] [00553] CAR T cells (2500 cells / 20 µL; 4 lines / donor) directed against DLL3 (using any of SEQ ID NO: 746-751) and overexpressing PD-L1 target cells are plated on assay plates of 384 wells (2500 cells / 20 µL) such that the ratio between effector cells and final target (E: T) is 1: 1. AMG 404 (10 µg / ml final in 5 µL) is added. The plates are covered with MicroClime caps and incubated at 37 ºC, 5% CO2 for 24 hours. Then 30 µL of Steady-Glo, Bright-Glo or One-Glo reagent (Promega) is added. The plates are incubated with reagent for 10 minutes in the dark at room temperature. Luminescence is detected using a BioTek Neo plate reader. Specific cytotoxicity is calculated in relation to target cells incubated with T cells without BiTE. The Graphpad Prism software is used to graph dose-response curves and calculate EC50 values with variable slope curve adjustment with four parameters. EXAMPLE 27
[00554] [00554] Efficacy of CAR T cells directed against FLT3 combined with anti-PD-1 antibody in an in vivo xenograft model
[00555] [00555] Human cancer cells expressing antigens against DLL3 recognized by CAR T cells directed against FLT3 (using any of SEQ ID NO: 763-774) are implanted subcutaneously in SCID beige mice (5 x 106 cells / mouse) on Day 0. The tumor volume (mm3) is measured using tweezers twice a week (Q2W). As soon as the tumors reach an average size of 75-100 mm3, the animals are randomized into groups (9-10 mice per group) such that the average tumor volume at the start of treatment was uniform across the treatment groups. The animals are then administered intravenously (IV) with a dose of T CAR cells (1 x 107 antigen specific T CAR cells or 1 x 107 control T T cells) in a volume of 200 µL. The anti-PD-1 antibody is administered intraperitoneally (IP) Q3D at 300 µg for 3 doses, starting on the same day as treatment with CAR T cells. Clinical signs, changes in body weight and tumor growth are measured twice weekly until study completion (~ 45 days).
[00556] [00556] Evaluation of the in vitro efficacy of T cell mediated cytotoxicity against FLT3 in combination with an anti-PD-1 antibody
[00557] [00557] CAR T cells (2500 cells / 20 µL; 4 lines / donor) directed against FLT3 (using any of SEQ ID NO: 763-774) and overexpressing PD-L1 target cells are plated on assay plates of 384 wells (2500 cells / 20 µL) such that the ratio between effector cells and final target (E: T) is 1: 1. AMG 404 (10 µg / ml final in 5 µL) is added. The plates are covered with MicroClime caps and incubated at 37 ºC, 5% CO2 for 24 hours. Then 30 µL of Steady-Glo, Bright-Glo or One-Glo reagent (Promega) is added. The plates are incubated with reagent for 10 minutes in the dark at room temperature. Luminescence is detected using a BioTek Neo plate reader. Specific cytotoxicity is calculated in relation to target cells incubated with T cells without BiTE. The Graphpad Prism software is used to graph dose-response curves and calculate EC50 values with variable slope curve adjustment with four parameters.
[00558] [00558] All references, including publications, patent applications and patents, cited here are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated as being incorporated by reference and were presented in their entirety here.
[00559] [00559] The use of the terms "one" and "one" and "o / a" and similar referents in the context of the disclosure description (especially in the context of the following claims) is to be interpreted as covering both the singular and the plural, unless otherwise indicated here or clearly contradicted by the context. The terms "comprising", "having", "including" and "containing" are to be interpreted as open terms (i.e., meaning "including, but not limited to"), unless otherwise noted.
[00560] [00560] The recitation of ranges of values here is intended merely to serve as an abbreviated method of referring individually to each separate value residing within the range and to each end point, unless otherwise indicated here, and each value and separate end points are incorporated into the specification as if they were individually recited here.
[00561] [00561] All the methods described here can be performed in any appropriate order unless otherwise indicated here or otherwise contradicted by the context. The use of any and all examples, or exemplary language (eg, "as") provided here is intended merely to further clarify the disclosure and does not place a limitation on the scope of the disclosure unless otherwise claimed. No language in the specification should be interpreted as indicating any element not claimed as essential to the practice of disclosure.
[00562] [00562] Preferred modalities of this disclosure are described here, including the best way known by the inventors to carry out the disclosure. Variations of these preferred modalities may become apparent to those skilled in the art after reading the previous description.
The inventors expect the expert experts to employ such variations as appropriate, and the inventors intend for the disclosure to be practiced in a manner not specifically described herein.
Accordingly, this disclosure includes all modifications and equivalents of the matter recited in the appended claims here as permitted by applicable law.
In addition, any combination of the elements described above in all its possible variations is encompassed by the disclosure unless otherwise indicated here or clearly contradicted by the context.

权利要求:
Claims (16)
[1]
1. PD-1 antigen-binding protein, characterized by the fact that it comprises (a) an amino acid sequence of the heavy chain complementarity determining region (CDR) 1 shown in Table D or a sequence selected from the group consisting of in: SEQ ID NOs: 352, 312, 322, 332, 342, 362, 372 and 382 or a sequence variant that differs only in one or two amino acids or has at least or about 70% sequence identity; (b) an HC CDR2 amino acid sequence shown in Table D or a sequence selected from the group consisting of: SEQ ID NOs: 353, 313, 323, 333, 343, 363, 373 and 383 or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (c) an HC CDR3 amino acid sequence shown in Table D or a sequence selected from the group consisting of: SEQ ID NOs: 354, 314, 324, 334, 344, 364, 374 and 384 or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (d) a light chain CDR1 (LC) amino acid sequence shown in Table D or a sequence selected from the group consisting of: 355, 315, 325, 335, 345, 365, 375 and 385 or a variant sequence that differs only one or two amino acids or that has at least or about 70% sequence identity; (e) a CDR2 amino acid sequence from LC shown in Table D or a sequence selected from the group consisting of: 356, 316, 326, 336, 346, 366, 376 and 386 or a variant sequence that differs only in one or two amino acids or that have at least or about 70% sequence identity; (f) a CDR3 amino acid sequence from LC shown in Table D or a sequence selected from the group consisting of: 357, 317, 327, 337, 347.367, 377 and 387 or a variant sequence that differs only by one or two amino acids or that has at least or about 70% sequence identity; or (g) a combination of any two or more of (a) - (f).
[2]
2. PD-1 antigen-binding protein according to claim 1, characterized by the fact that it comprises six CDR amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 352-357; (b) SEQ ID NOs: 322- 327; (c) SEQ ID NOs: 332-337; (d) SEQ ID NOs: 342-347; (e) SEQ ID NOs: 312-317; (f) SEQ ID NOs: 362-367; (g) SEQ ID NOs: 372-377; and (h) SEQ ID NOs: 382-387.
[3]
3. PD-1 antigen-binding protein according to claim 2, characterized by the fact that it comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 358 and 359; (b) SEQ ID NOs: 328 and 329; (c) SEQ ID NOs: 338 and 339; (d) SEQ ID NOs: 348 and 349; (e) SEQ ID NOs: 318 and 319; (f) SEQ ID NOs: 368 and 369; (g) SEQ ID NOs: 378 and 379; and (h) SEQ ID NOs: 388 and 389.
[4]
4. PD-1 antigen-binding protein according to claim 3, characterized by the fact that it comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 360 and 361; (b) SEQ ID NOs: 330 and 331; (c) SEQ ID NOs: 340 and 341; (d) SEQ ID NOs: 350 and
351; (e) SEQ ID NOs: 320 and 321; (f) SEQ ID NOs: 370 and 371; (g) SEQ ID NOs: 380 and 381; and (h) SEQ ID NOs: 390 and 391.
[5]
PD-1 antigen-binding protein according to any one of claims 1, 2, 3 and 4, characterized in that it is an antibody.
[6]
6. PD-1 antigen-binding protein according to any one of claims 1, 2, 3 and 4, characterized in that it is an antigen-binding fragment of an antibody.
[7]
7. PD-1 antigen binding protein according to any one of claims 1, 2, 3 and 4, characterized in that it is an antibody protein product, optionally, a scFv.
[8]
8. Nucleic acid characterized by the fact that it comprises a nucleotide sequence encoding the PD-1 antigen binding protein, as defined in any one of claims 1, 2, 3, 4, 5, 6 and 7.
[9]
Nucleic acid according to claim 8, characterized in that it comprises the sequence of any one of SEQ ID NOs: 392-471.
[10]
10. Vector characterized by the fact that it comprises nucleic acid, as defined in any of claims 8 and 9.
[11]
11. Host cell characterized by the fact that it comprises the nucleic acid, as defined in any of claims 8 and 9, or the vector, as defined in claim 10.
[12]
12. Case characterized by the fact that it comprises a PD-1 antigen binding protein, as defined in any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, acid nucleic, as defined in any one of claims 8 and 9, the vector, as defined in claim 10, the host cell, as defined in claim 11, or a combination thereof, and a container.
[13]
13. Pharmaceutical composition characterized by the fact that it comprises a PD-1 antigen binding protein, as defined in any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, the nucleic acid as defined in any one of claims 8 and 9, the vector as defined in claim 10, the host cell as defined in claim 11, or a combination thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
[14]
14. Method of preparation of protein binding to the PD-1 antigen characterized by the fact that it comprises culture of the host cell, as defined in claim 13, in order to express the protein binding to the PD-1 antigen and collection of the binding protein to the expressed PD-1 antigen.
[15]
15. Method of treating a subject with his need characterized by the fact that it comprises administering to the subject with his need for a pharmaceutical composition, as defined in claim 13, in an amount effective to treat the subject.
[16]
16. Method according to claim 15, characterized in that the subject has a solid tumor and the pharmaceutical composition is administered to the subject in an amount effective to treat the solid tumor in the subject.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US20190270817A1|2019-09-05|Anti-PD-1 Antibodies and Methods of Treatment

---

ES2788979T3|2020-10-23|Antigen-binding molecules comprising a ligand trimer of the TNF family

---

US20210403589A1|2021-12-30|Combination therapies with anti cd40 antibodies

---

JP6931329B2|2021-09-01|Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function

---

JP2020515239A|2020-05-28|Anti-ICOS agonist antibodies and their use

---

WO2019080872A1|2019-05-02|Fusion protein for blocking pd-1/pd-l1 signaling pathway and activating t cells and use thereof

---

BR112019007714B1|2022-01-18|ANTI-4-1BB ANTIBODIES, USE THEREOF, PHARMACEUTICAL COMPOSITION, METHODS FOR DETERMINING A DOSE, FOR INCREASE IFN-GAMMA SECRETION BY A CELL IN VITRO AND FOR EX VIVO PROLIFERATION OR ISOLATION OF ACTIVATED T CELLS AND USE THEREOF

---

EP3661954B1|2022-02-09|Interleukin-21 muteins and methods of treatment

---

US20190367617A1|2019-12-05|Anti-pd-1 antibody and use thereof

---

TW201842937A|2018-12-16|Immunoconjugates

---

BR112019027211A2|2020-06-30|anti-human papillomavirus | antigen binding proteins and methods of use

---

BR112020018539A2|2020-12-29|ANTIBODIES AGAINST MICA AND / OR MICB AND USES OF THE SAME

---

CN112384534A|2021-02-19|Compositions and methods for enhancing killing of target cells by NK cells

---

JP2021528048A|2021-10-21|CD19 directional chimeric antigen receptor and its use in immunotherapy

---

KR20190117467A|2019-10-16|IFN- [gamma] -induced regulatory T cell switchable anticancer | antibodies and uses thereof

---

JP2022514179A|2022-02-10|New agonist anti-TNFR2 antibody molecule

---

TW202116811A|2021-05-01|Monospecific proteins with immune checkpoint regulation for cancer therapy, pharmaceutical composition, nucleic acid, and use thereof

---

AU2019394877A1|2021-06-17|Methods for selective in vivo expansion of gamma delta T-cell populations and compositions thereof

---

TW202003581A|2020-01-16|Antibodies specific for CD3 and uses thereof

---

JP2021524269A|2021-09-13|Mesoterin and CD137 binding molecules

---

KR20210030406A|2021-03-17|FC binding fragment comprising the CD137 antigen-binding site

---

TW202016149A|2020-05-01|Ox40 binding molecules

---

CN114026122A|2022-02-08|Multifunctional molecules that bind to T cell-associated cancer cells and uses thereof

同族专利:

---

公开号 | 公开日

---

MA51631A|2020-11-18|

---

CL2020001820A1|2020-10-02|

---

JOP20200172A1|2019-07-12|

---

CO2020009234A2|2020-10-30|

---

SG11202005605SA|2020-07-29|

---

WO2019140196A1|2019-07-18|

---

CN111727197A|2020-09-29|

---

PE20211270A1|2021-07-19|

---

IL275096D0|2020-07-30|

---

TW201930344A|2019-08-01|

---

KR20200110358A|2020-09-23|

---

AU2019207895A1|2020-06-18|

---

US20190270817A1|2019-09-05|

---

JP2019122373A|2019-07-25|

---

PH12020550967A1|2021-03-22|

---

CR20210319A|2021-07-27|

---

EP3737694A1|2020-11-18|

---

UY38049A|2019-07-31|

---

CA3087273A1|2019-07-18|

---

CR20200330A|2020-12-23|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4450150A|1973-05-17|1984-05-22|Arthur D. Little, Inc.|Biodegradable, implantable drug delivery depots, and method for preparing and using the same|

---

AU597574B2|1986-03-07|1990-06-07|Massachusetts Institute Of Technology|Method for enhancing glycoprotein stability|

---

EP0623679B1|1987-05-21|2003-06-25|Micromet AG|Targeted multifunctional proteins|

---

US4946778A|1987-09-21|1990-08-07|Genex Corporation|Single polypeptide chain binding molecules|

---

US6673986B1|1990-01-12|2004-01-06|Abgenix, Inc.|Generation of xenogeneic antibodies|

---

AU633698B2|1990-01-12|1993-02-04|Amgen Fremont Inc.|Generation of xenogeneic antibodies|

---

US6770274B1|1990-09-14|2004-08-03|The General Hospital Corporation|Viral mutant HSV mediated destruction of neoplastic cells|

---

JP3266311B2|1991-05-02|2002-03-18|生化学工業株式会社|Novel polypeptide and anti-HIV agent using the same|

---

GB9206422D0|1992-03-24|1992-05-06|Bolt Sarah L|Antibody preparation|

---

US7381803B1|1992-03-27|2008-06-03|Pdl Biopharma, Inc.|Humanized antibodies against CD3|

---

US5585096A|1994-06-23|1996-12-17|Georgetown University|Replication-competent herpes simplex virus mediates destruction of neoplastic cells|

---

US5728379A|1994-06-23|1998-03-17|Georgetown University|Tumor- or cell-specific herpes simplex virus replication|

---

US6699468B1|1994-06-23|2004-03-02|Georgetown University|Replication-competent herpes simplex virus mediates destruction of neoplastic cells|

---

US5824318A|1996-07-24|1998-10-20|American Cyanamid Company|Avirulent herpetic viruses useful as tumoricidal agents and vaccines|

---

EP2305027B1|1996-12-03|2014-07-02|Amgen Fremont Inc.|Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom|

---

US6379674B1|1997-08-12|2002-04-30|Georgetown University|Use of herpes vectors for tumor therapy|

---

AU2546399A|1998-02-10|1999-08-30|Yoshitomi Pharmaceutical Industries, Ltd.|Preparations with controlled release|

---

ID27512A|1998-04-21|2001-04-12|Microment Ges Fur Biomedizinis|PRIVATE POLIPEPTIDES CD19XCD3 AND ITS USES|

---

GB9815909D0|1998-07-21|1998-09-16|Btg Int Ltd|Antibody preparation|

---

GB2344287A|1998-12-03|2000-06-07|Ferring Bv|Controlled release pharmaceutical formulation|

---

CA2356937A1|1998-12-31|2000-07-13|Richard J. Whitley|Recombinant herpes simplex virus useful for treating neoplastic disease|

---

WO2000054795A1|1999-03-15|2000-09-21|The Trustees Of The University Of Pennsylvania|Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject|

---

US6764675B1|1999-06-08|2004-07-20|The Uab Research Foundation|Herpes simplex virus expressing foreign genes and method for treating cancers therewith|

---

US6833268B1|1999-06-10|2004-12-21|Abgenix, Inc.|Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions|

---

WO2001053505A2|2000-01-21|2001-07-26|Biovex Limited|Herpes virus strains for gene therapy|

---

US20020197266A1|2000-02-08|2002-12-26|Waldemar Debinski|Immunotherapy using interleukin 13 receptor subunit alpha 2|

---

WO2002076216A1|2001-03-27|2002-10-03|Medigene, Inc.|Viral vectors and their use in therapeutic methods|

---

AR036993A1|2001-04-02|2004-10-20|Wyeth Corp|USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS|

---

AT395413T|2001-12-03|2008-05-15|Amgen Fremont Inc|ANTIBODY CATEGORIZATION BASED ON BINDING CHARACTERISTICS|

---

DE60331455D1|2002-10-04|2010-04-08|Microchips Inc|MEDICAL DEVICE FOR THE CONTROLLED MEDICAMENTAL ADMINISTRATION AND HEART CONTROL AND / OR HEART STIMULATION|

---

WO2004106381A1|2003-05-31|2004-12-09|Micromet Ag|Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders|

---

NZ546173A|2003-10-16|2009-04-30|Micromet Ag|Multispecific deimmunized CD3-binders|

---

EP1753783B1|2004-06-03|2014-08-06|Novimmune SA|Anti-cd3 antibodies and methods of use thereof|

---

US7731952B2|2004-06-24|2010-06-08|New York University|Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response|

---

EP3530736A3|2005-05-09|2019-11-06|ONO Pharmaceutical Co., Ltd.|Human monoclonal antibodies to programmed death 1 and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics|

---

TW200745163A|2006-02-17|2007-12-16|Syntonix Pharmaceuticals Inc|Peptides that block the binding of IgG to FcRn|

---

CN101230334B|2007-01-22|2011-06-01|北京奥源和力生物技术有限公司|Herpes simplex virus and recombinant virus as well as host cell and medicinal combination thereof|

---

CN101230335B|2007-01-22|2010-08-11|北京奥源和力生物技术有限公司|Herpes simplex virus and recombinant virus as well as host cell, and medicinal combination thereof|

---

NZ580755A|2007-04-03|2012-05-25|Micromet Ag|Cross-species-specific cd3-epsilon binding domain|

---

TR201816277T4|2007-04-03|2018-11-21|Amgen Res Munich Gmbh|Cross-species-specific binding domain.|

---

KR101034888B1|2007-04-19|2011-05-17|동아제약주식회사|A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof|

---

WO2009114335A2|2008-03-12|2009-09-17|Merck & Co., Inc.|Pd-1 binding proteins|

---

CA2721202A1|2008-04-17|2009-10-22|Hilde Adi Pierrette Revets|Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same|

---

CN102171248B|2008-10-01|2015-07-15|安进研发（慕尼黑）股份有限公司|Cross-species-specific PSMAxCD3 bispecific single chain antibody|

---

EP2406282A1|2009-03-11|2012-01-18|Novo Nordisk A/S|Interleukin-21 variants having antagonistic binding to the il-21 receptor|

---

KR101904065B1|2009-06-26|2018-10-04|리제너론 파마슈티칼스 인코포레이티드|Readily isolated bispecific antibodies with native immunoglobulin format|

---

WO2012059486A1|2010-11-01|2012-05-10|Novozymes Biopharma Dk A/S|Albumin variants|

---

US8748380B2|2009-10-30|2014-06-10|Novozymes Biopharma Dk A/S|Albumin variants|

---

US9944691B2|2012-03-16|2018-04-17|Albumedix A/S|Albumin variants|

---

US8822417B2|2011-05-05|2014-09-02|Novozymes Biopharma DIC A/S|Albumin variants|

---

WO2013006795A2|2011-07-07|2013-01-10|Humanitas International Foundation|Antiviral compositions and methods of their use|

---

EP2753355B1|2011-09-08|2018-10-24|New York University|Oncolytic herpes simplex virus and therapeutic uses thereof|

---

TWI679212B|2011-11-15|2019-12-11|美商安進股份有限公司|Binding molecules for e3 of bcma and cd3|

---

EP2780364A2|2011-11-18|2014-09-24|Eleven Biotherapeutics, Inc.|Proteins with improved half-life and other properties|

---

WO2013169734A1|2012-05-07|2013-11-14|Amgen Inc.|Anti-erythropoietin antibodies|

---

WO2013169693A1|2012-05-09|2013-11-14|Bristol-Myers Squibb Company|Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody|

---

US20140128326A1|2012-11-08|2014-05-08|Novozymes Biopharma Dk A/S|Albumin variants|

---

WO2015000585A1|2013-07-02|2015-01-08|Walter Sebald|Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group|

---

TW201708261A|2015-07-31|2017-03-01|安美基研究（慕尼黑）公司|Antibody constructs for DLL3 and CD3|

---

JO3788B1|2015-07-31|2021-01-31|Amgen Res Munich Gmbh|Antibody constructs for egfrviii and cd3|

---

TW201708257A|2015-07-31|2017-03-01|安美基研究（慕尼黑）公司|Antibody constructs for FLT3 and CD3|

---

MA44146A|2015-12-22|2018-10-31|Regeneron Pharma|COMBINATION OF ANTI-PD-1 AND BISPECIFIC ANTI-CD20 / ANTI-CD3 ANTIBODIES TO TREAT CANCER|

---

EP3805376A1|2016-01-08|2021-04-14|Replimune Limited|Engineered virus|

---

AR107520A1|2016-02-03|2018-05-09|Amgen Res Munich Gmbh|BIESPECTIFIC ANTIBODY CONSTRUCTS THAT ARE LINKED TO T-CELLS|

---

AU2017216230A1|2016-02-03|2018-07-19|Amgen Inc.|BCMA and CD3 bispecific T cell engaging antibody constructs|

---

EA201891753A1|2016-02-03|2019-01-31|Эмджен Рисерч Гмбх|BISPECIFIC CONSTRUCTIONS OF ANTIBODIES TO PSMA AND CD3, INVOLVING T-CELLS|

---

SG11201808622SA|2016-04-01|2018-10-30|Amgen Inc|Chimeric receptors to flt3 and methods of use thereof|

---

EP3380621A4|2016-04-22|2019-05-08|Immvira Co., Limited|CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY|

---

EP3478321A4|2016-06-30|2020-04-22|Oncorus, Inc.|Pseudotyped oncolytic viral delivery of therapeutic polypeptides|

---

WO2018026872A1|2016-08-01|2018-02-08|Virogin Biotech Canada Ltd|Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules|

---

GB201700350D0|2017-01-09|2017-02-22|Replimune Ltd|Altered virus|CN110121352B|2016-09-01|2020-12-11|嵌合体生物工程公司|GOLD-optimized CAR T-cells|

---

WO2019160815A1|2018-02-13|2019-08-22|Chimera Bioengineering, Inc.|Coordinating gene expression using rna destabilizing elements|

---

CA3140904A1|2019-06-24|2020-12-30|Amgen Inc.|Inhibition of sirp-gamma for cancer treatment|

---

WO2021078219A1|2019-10-25|2021-04-29|Wuxi BiologicsCo., Ltd.|Novel anti-cd47 antibodies and uses thereof|

---

WO2021092355A1|2019-11-08|2021-05-14|Amgen Inc.|Engineering charge pair mutations for pairing of hetero-igg molecules|

---

WO2021113853A1|2019-12-05|2021-06-10|Vycellix, Inc.|Modulators of the immune escape mechanism for universal cell therapy|

---

WO2021173307A1|2020-02-25|2021-09-02|Gensun Biopharma Inc.|Trispecific t cell engagers|

---

WO2021247892A1|2020-06-04|2021-12-09|Amgen Inc.|Assessment of cleaning procedures of a biotherapeutic manufacturing process|

---

WO2021263167A2|2020-06-26|2021-12-30|Amgen Inc.|Il-10 muteins and fusion proteins thereof|

---

WO2022015853A2|2020-07-15|2022-01-20|Amgen Inc.|Tigit and cd112r blockade|

---

CN112516319A|2020-12-08|2021-03-19|华中农业大学|Combination medicament for treating breast cancer|

法律状态:
2021-12-07| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201862616733P| true| 2018-01-12|2018-01-12|

---

US62/616,733|2018-01-12|

---

US201862770029P| true| 2018-11-20|2018-11-20|

---

US62/770,029|2018-11-20|

---

PCT/US2019/013205|WO2019140196A1|2018-01-12|2019-01-11|Anti-pd-1 antibodies and methods of treatment|

---